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ABSTRACT 
This exploratory study described levels of personal growth and examined 
relationships among personal growth, demographic, clinical, and cognitive factors in a 
convenience sample (N = 103) of community-residing adults with New York Heart 
Association (NYHA) functional class II-IV heart failure (HF). The study was guided by 
Mishel’s reconceptualized uncertainty in illness theory and Tedeschi and Calhoun’s post-
traumatic growth model. The following research questions were addressed: (1) Do adults 
living with NYHA class II-IV HF report personal growth following their diagnosis of 
HF? (2) To what extent are age, sex, ethnicity, disease severity, time since diagnosis, 
symptom status, and uncertainty levels associated with personal growth in individuals 
with HF? and (3) Which variables (age, sex, ethnicity, disease severity, time since 
diagnosis, symptom status, or uncertainty levels) make independent contributions to 
personal growth in individuals living with NYHA class II-IV HF? Participants completed 
a demographic and clinical survey, the Posttraumatic Growth Inventory (PTGI), the 
Mishel Uncertainty in Illness Scale-Community Version, and the Memorial Symptom 
Assessment Scale–Heart Failure. Participants reported moderate levels of personal 
growth (M = 48.6, SD = 28.6). There were no significant differences in personal growth 
vii 
by sex, ethnicity, or disease severity. Personal growth had a weak, negative correlation 
with age (r = –.20, p < .05) and a weak, positive correlation with symptom burden (r = 
.20, p < .05). Uncertainty was positively correlated with symptom burden (r = .49, p < 
.01) and disease severity (r = .28, p < .01), but was not significantly correlated with PTGI 
scores. A hierarchical regression model that included age, sex, ethnicity, NYHA 
classification, years since diagnosis, uncertainty, and symptom burden did not account for 
significant variance in PTGI scores. Findings provide foundational knowledge to guide 
future study of personal growth in HF and add to the overall literature on personal growth 
in relation to uncertainty and symptoms within chronic illness.  
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CHAPTER 1 
INTRODUCTION 
 
Currently, more than 5 million Americans are living with a diagnosis of heart 
failure (HF), and by 2030, this population is expected to increase by 3 million (Go et al., 
2013). HF is a chronic, progressive disease that is associated with an unpredictable 
disease trajectory, significant symptom burden, increased rates of anxiety and depression, 
poor quality of life, decreased life expectancy, and increased health-care costs (Adler, 
Goldfinger, Kalman, Park, & Meier, 2009). National guidelines that address the diagnosis 
and treatment of HF largely focus on disease-modifying interventions based on a 
biomedical model of care (Heart Failure Society of America, 2010a, 2010b; Jessup et al., 
2009). To date, the majority of research conducted with this population has focused on 
the adverse physical and psychosocial effects of living with a diagnosis of HF. A growing 
body of research suggests that people living with serious illness may also report personal 
growth and positive outcomes (Barskova & Oesterreich, 2009). Major gaps in the 
literature exploring personal growth in patients with HF exist. A better understanding of 
personal growth and factors that contribute to it may help to supplement traditional HF 
management programs and inform models, such as palliative approaches, that are being 
investigated to provide more holistic, supportive care to this population (Bekelman, 
Nowels, Allen et al., 2011; Bekelman, Nowels, Retrum et al., 2011; Goodlin, 2009; 
Hupcey, Penrod, & Fenstermacher, 2009). The purpose of this exploratory study was to 
describe levels of personal growth in HF and to examine the relationship between 
relevant demographic, clinical, and cognitive variables and personal growth.  
2 
HF: Epidemiology, Pathophysiology, and Demographics 
HF is a complex condition resulting from structural cardiac changes that impact 
the ability of the heart to pump or fill, limiting its ability to provide adequate cardiac 
output and/or to support venous return, ultimately reducing the heart’s ability to meet the 
basic metabolic demands of the body (Kemp & Conte, 2012). An insult to the 
myocardium arising from any of the following cardiac pathologies can lead to the loss of 
functioning myocardial cells and trigger the development of HF: coronary artery disease 
(CAD), myocardial infarction (MI) or chronic ischemia, hypertension (HTN), valvular 
heart disease, cardiomyopathies, or, less commonly, myocardial injury due to infection, 
toxins, or sustained dysrhythmias (Kemp & Conte, 2012; Ramani, Uber, & Mehra, 2010). 
Modifiable risk factors for HF include those that are associated with the development of 
CAD, HTN, and/or cardiomyopathies and include factors such as diabetes, dyslipidemia, 
obesity, smoking, and alcohol or drug abuse. Advancing age is the primary 
nonmodifiable risk factor for HF (Jessup et al., 2009).  
By age 40, both men and women have a 20% lifetime risk of developing HF (Go 
et al., 2013). The incidence of HF increases for both sexes after the age of 65 (Go et al., 
2013). According to the U.S. Department of Health and Human Services (2014), the 
number of people aged 65 years and older is expected to reach 72.1 million by the year 
2030, contributing to a growing prevalence of HF. With advances in cardiac care, such as 
the use of better drugs, stents, and cardiac devices, people who might have died from an 
MI in the past are now living longer and may eventually be diagnosed with HF. Thus, 
increases in life expectancy generally, as well as improvements in cardiac care and 
improvements in diagnostic capabilities, have all contributed to increasing the number of 
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people living with HF. Despite improvements in survival after an HF diagnosis, 50% of 
people diagnosed with this disease die within 5 years (Go et al., 2013). Over time, many 
with the diagnosis will progress to advanced stages of HF (Jessup et al., 2009; Stuart, 
2007). In the United States, the risk of developing HF is highest in African Americans, 
followed by Hispanics, non-Hispanic Whites, and persons of Chinese heritage; in general, 
HF events are higher in men than in women until age 65 (Go et al., 2013).   
Providers diagnose HF as systolic, diastolic, or mixed systolic and diastolic, 
according to the primary pathology of the left ventricle underlying the development of 
HF. Systolic dysfunction describes the inability of the left ventricle to effectively contract 
or pump and is present when the left ventricular ejection fraction (the percentage of blood 
volume ejected from the left ventricle per heartbeat) is less than 40%; diastolic 
dysfunction describes the inability of the ventricles to relax or fill adequately during 
diastole (Kemp & Conte, 2012). Changes in myocardial fiber function lead to dilation or 
hypertrophy of the cardiac chambers and stimulate a neurohormonal reaction involving 
the release of catecholamines (norepinephrine and epinephrine) and vasopressin, as well 
as activation of the renin-angiotensin-aldosterone axis. This response initially serves as a 
compensatory mechanism to support cardiac output and perfusion, but over time, results 
in cardiac cell death and further hypertrophy, leading to ventricular remodeling (a change 
in the size, shape, composition, or function of the ventricle) and worsening contractile 
dysfunction (Ramani et al., 2010). Other neurohormones that are elevated in HF include 
the natriuretic peptides and endothelium-derived vasoactive agents (which promote 
compensatory vasodilation), and various cytokines (Kemp & Conte, 2012).  
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Left ventricular HF is primarily associated with pulmonary signs and symptoms. 
Worsening left ventricular HF can lead to right ventricular HF, resulting in venous 
congestion in the systemic circulation and corresponding signs and symptoms, which 
include peripheral edema and jugular venous distention, and abdominal pain and nausea 
(Kemp & Conte, 2012). As a result of ventricular dysfunction, individuals living with HF 
experience a significant symptom burden. Studies indicate that dyspnea and fatigue are 
the two most common and distressful symptoms, but also report that patients experience 
insomnia, pain, depression, anxiety, cough, anorexia, dry mouth, nausea, palpitations, 
dizziness, and difficulty concentrating, among others (Janssen, Spruit, Wouters, & 
Schols, 2008; Zambroski, Moser, Bhat, & Ziegler, 2005).   
HF Classification Systems and Models of Care 
The NYHA classification system for HF is based on the occurrence of fatigue, 
palpitations, dyspnea, and angina with various degrees of activity. Clinicians use this 
system to assess functional abilities and mortality risk in the context of HF (Kemp & 
Conte, 2012). Class I patients are asymptomatic with usual activity; class II patients are 
asymptomatic at rest, but have slight limitations with usual activity due to symptoms; 
class III patients have more moderate limitations that occur with less than usual activity; 
and class IV patients have significant symptoms even at rest, limiting their ability to 
participate in any activity (Hunt et al., 2009).   
The American College of Cardiology/American Heart Association (ACC/AHA; 
Hunt et al., 2001) developed a second classification system to supplement the NYHA 
system. The ACC/AHA classification incorporates markers of the development and 
progression of HF and outlines goals of therapy based on disease staging. This staging 
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system highlights disease prevention strategies for patients at high risk for HF and 
recommends a continuum of treatment options for individuals with structural heart 
disease based on their symptom burden, functional limitations, and response to current 
therapies. Lifestyle modifications, such as diet and exercise, largely constitute risk 
reduction strategies for individuals at high risk for HF, whereas pharmacologic, device 
therapy (such as biventricular pacemakers and implantable defibrillators), and surgical 
options are accepted interventions for advancing HF. These guidelines recommend end-
of-life care when individuals meet criteria for stage D, class IV HF and are no longer 
responsive to evidence-based medical or surgical therapies.  
Advocates for palliative care have suggested that practitioners initiate palliative 
care earlier in the trajectory of HF rather than at the end stage (Adler et al., 2009; 
Bekelman, Nowels, Allen et al., 2011; Bekelman, Nowels, Retrum et al., 2011; Goodlin, 
2009; Hupcey et al., 2009). More contemporary conceptualizations of palliative care 
characterize it as a supportive approach that should be initiated for individuals impacted 
by chronic or life-limiting illnesses, such as HF, at the time of diagnosis to improve 
symptom management, quality of life, communication, decision making, and 
psychosocial support for the patient and family (Adler et al., 2009; Goodlin, 2009; 
Hupcey et al., 2009). Unlike traditional disease management programs, models 
integrating palliative care incorporate goals of psychosocial and spiritual well-being and 
aim to facilitate personal growth (National Consensus Project for Quality Palliative Care, 
2009). Research examining whether individuals with HF report positive psychosocial 
consequences or personal growth as a result of their illness experience is needed to 
support the development of these supportive care models.    
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Personal Growth 
Over the last 20 years, researchers in the behavioral, psychological, social, and 
health sciences have examined the concept of personal growth more extensively. 
Researchers have conceptualized personal growth as positive psychosocial adjustment or 
adaptation to some form of adversity, such as a serious illness. This kind of growth has 
been referred to in the literature as post-traumatic growth (PTG), stress-related growth, 
thriving, adversarial growth, benefit finding, and positive disease adjustment (Barskova 
& Oesterreich, 2009). Corresponding assessment tools measure growth as an individual’s 
ability to achieve a positive change in relationships, a greater appreciation for life, a 
change in life priorities, personal strength, new opportunities, and enhanced spirituality 
(Calhoun & Tedeschi, 2006; Pakenham, 2007). The literature on personal growth 
suggests that growth is dependent on coping with a difficult experience (Barskova & 
Oesterreich, 2009). Similarly, Tedeschi and Calhoun (2004) assert within their work on 
PTG that the adverse event or stimulus should be serious enough to incite stress that is 
sufficient to challenge or threaten existing personal worldviews and to provoke reframing 
of life goals and priorities.  
Medical researchers have most frequently studied growth in cancer (Stanton, 
Bower, & Low, 2006) and HIV (Milam, 2006a) populations; other research has been 
conducted with individuals living with multiple sclerosis, arthritis, lupus erythematosus, 
neurological disorders, and heart disease (Barskova & Oesterreich, 2009). In a review of 
studies exploring growth in individuals living with a variety of medical illnesses, 
Barskova and Oesterreich (2009) concluded that demographic factors (e.g., age, gender, 
and ethnicity), as well as social support, coping styles, and mental and physical health, 
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correlated with measures of growth. They suggested that growth may be an important and 
relevant indicator of positive disease outcomes. Subsequent positive outcomes 
significantly associated with growth included improved morbidity and mortality, higher 
CD4 T-lymphocyte levels, better health-related quality of life (HRQOL), and decreased 
levels of cortisol, pain, fatigue, disability, depression, and anxiety (Barskova & 
Oesterreich, 2009).  
Another approach to growth in response to serious health conditions has been to 
consider it an adaptive response to uncertainty (Mishel, 1990). Growth through 
uncertainty has been studied less frequently than has PTG and mostly in cancer 
populations (Mishel & Clayton, 2008). Mishel (1990) describes growth through 
uncertainty, experienced by individuals living with ongoing uncertainty due to persistent 
illness, as a potential outcome within her reconceptualized uncertainty in illness theory 
(RUIT). In the RUIT, growth is defined as a new life perspective, that is, “a new ability 
to focus on multiple alternatives, choices and possibilities; re-evaluate what is important 
in life; consider variations in personal investment; and appreciate the impermanence and 
fragility of life” (Mishel & Clayton, 2008, p. 60). The RUIT proposes that individuals 
who achieve growth through uncertainty move beyond basic adaptation and experience a 
process of favorable psychological adjustment (Mishel, 1990). 
In general, studies explicitly examining either PTG or growth through uncertainty 
in an HF population are lacking. The following well-documented factors characterize HF 
as a challenging illness to live with: (a) an unpredictable illness course, (b) uncertainty in 
prognosis, (c) significant symptom burden, and (d) impact on psychosocial well-being. 
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Efforts to improve the holistic management of HF would also benefit from a greater 
understanding of how these factors relate to personal growth. 
Uncertainty in HF 
Individuals living with HF, their caregivers, and their health care providers 
frequently experience uncertainty related to knowledge deficits, an unpredictable disease 
trajectory, inadequate social support, and varying frequency, duration, and severity of 
symptoms and distress over time (Brännström, Forssell, & Pettersson, 2011; Falk, 
Swedberg, Gaston-Johansson, & Ekman, 2007; Hopp, Thornton, & Martin, 2010; 
Hupcey, Fenstermacher, Kitko, & Penrod, 2010; Jurgens, 2006). In a qualitative review 
of individuals’ experiences of living with HF, Yu, Lee, Kwong, Thompson, and Woo 
(2007) reported that 
patients used the terms “a roller coaster life” and “knocking on death’s door” to 
describe their meanings of living with CHF [congestive heart failure]. The former, 
a symbolic representation of the life situation characterized by the ongoing 
oscillations between ups and downs, the latter of being threatened by the 
unpredictable condition and uncertain future. (p. 478) 
Thus, uncertainty contributes to the challenges of coping with HF. Overcoming or 
adapting to uncertainty is likely to be a prerequisite for growth following a diagnosis of 
HF. Therefore, in this study, the RUIT served as an overall conceptual framework for the 
exploration of personal growth in individuals living with HF.  
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Conceptual Frameworks 
Mishel’s (1990) RUIT served as the primary guiding framework for this study. In 
addition to the RUIT, Tedeschi and Calhoun’s (2004) conceptualization of PTG and 
assumptions related to PTG also informed the development of this study. 
Reconceptualized Uncertainty in Illness Theory  
The RUIT describes how individuals living with chronic illness or disease 
reoccurrence can reappraise ongoing uncertainty and move beyond adaptation to achieve 
growth through the discovery of new life meaning and the acceptance of change (Mishel, 
1990; see Appendix A). Uncertainty is among the challenges experienced by individuals 
living with HF. The RUIT provides a broad lens to examine whether individuals can 
potentially achieve growth through attempts to cope with this type of adversity. It was 
developed in response to clinical cases and qualitative studies of uncertainty in chronic 
illness in which Mishel’s (1988) original uncertainty in illness theory (UIT) did not 
account adequately for the experiences of some individuals living with enduring 
uncertainty.  
Mishel’s (1990) reconceptualization of the UIT was influenced by critical social 
theory and a desire to situate uncertainty in the context of culture. Critical social theory 
illuminated Western biases that tend to value order, balance, and predictability over 
uncertainty and disequilibrium, potentially limiting growth and change (Mishel, 1990). 
Furthermore, UIT was mechanistic in nature, focusing more on uncertainty as a state than 
as a process. In addition, the UIT did not address how time and culture could influence 
one’s experience of uncertainty over the course of chronic illness (Mishel, 1990). The 
RUIT has the following new assumptions (Mishel, 1990):  
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• Uncertainty in chronic illness is an ongoing experience. 
• Appraisal of uncertainty evolves over time. 
• Embracing complexity and change alters existing personal realities and may   
help individuals to adapt and grow in the face of uncertainty. 
Mishel (1990) retained the original antecedents of UIT (stimuli frame, cognitive 
capacity, and structure providers), which classify the factors that can contribute to 
uncertainty (see Appendix B). Stimuli frame includes symptom pattern, event familiarity, 
and event congruence. The stimuli frame can, in turn, be influenced by the other two 
antecedents, cognitive capacity and structure providers. Structure providers consist of 
credible authority, social support, and education.  
The RUIT builds upon uncertainty, originally defined as “the inability to 
determine the meaning of illness-related events occurring when the decision maker is 
unable to assign definite value to objects or events and/or is unable to accurately predict 
outcomes” (Mishel & Clayton, 2008, p. 59), by suggesting that individuals can integrate 
ongoing uncertainty into a novel worldview not characterized by predictability and 
control and, as a result, achieve growth. Reframing one’s view of uncertainty begins at 
the appraisal stage and is influenced by two new concepts, self-organization and 
probabilistic thinking (Mishel & Clayton, 2008).  
Self-organization is defined as the ability of an individual to recreate a new 
version of order from enduring uncertainty that is built on probabilistic or conditional 
thinking (Mishel, 1990). Probabilistic thinking implies that uncertainty becomes an 
accepted part of one’s reality, generating new possibilities and is conceptualized in the 
RUIT as an opportunity for growth (Mishel, 1990). Additionally, prior life experiences, 
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physiologic status, social resources, and interactions with health care providers can 
influence this process. Social support and health care providers that promote probabilistic 
thinking can help facilitate growth (Mishel, 1990). Therefore, appraisal of uncertainty in 
the RUIT is based on one’s ability to cognitively reframe an event in a positive yet 
realistic way.  
Post-Traumatic Growth 
Tedeschi and Calhoun (2004) conceptualize PTG as a process and/or an outcome 
that results from grappling with a life-altering event, commonly characterized as a 
trauma, major crisis, threat, or significant challenge. The following assumptions guide 
Tedeschi and Calhoun’s (2004) work on PTG: 
• PTG occurs in circumstances in which an individual’s fundamental worldviews 
are substantially disrupted as a result of an extremely adverse event that may be 
discrete or ongoing. 
• Growth occurs concurrently with serious psychological distress and does not 
necessarily minimize the suffering associated with a traumatic event or imply that 
an individual, if given the option, would choose to experience the challenging 
circumstances.  
• Growth does not simply reflect a coping mechanism, but rather, an outcome or 
process that enables an individual to move beyond pre-trauma levels of 
adaptation, which is characterized by some degree of personal transformation. 
• Growth is dependent on an individual’s struggle to come to terms with a reality 
that has been significantly altered by the challenging circumstances. 
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• The struggle primarily represents a process of cognitive restructuring, but it also 
encompasses an affective component. 
Specific Aims 
 The specific aims of this study were: 
1. To describe the levels of personal growth in adults living with NYHA class II-
IV HF and explore the relationship of personal growth with age, sex, 
ethnicity, disease severity, time since diagnosis, symptom status, and 
uncertainty levels. 
2. To determine the extent to which variance in personal growth in individuals 
living with NYHA class II-IV is accounted for by age, sex, ethnicity, disease 
severity, time since diagnosis, symptom status, and uncertainty. 
The following research questions address these specific aims: 
1. Do adults living with NYHA class II-IV HF report personal growth following 
their diagnosis of HF?  
2. To what extent are age, sex, ethnicity, disease severity, time since diagnosis, 
symptom status, and uncertainty levels associated with personal growth in 
individuals with HF?  
3. Which variables (age, sex, ethnicity, disease severity, time since diagnosis, 
symptom status, and uncertainty levels) make independent contributions to 
personal growth in individuals living with NYHA class II-IV HF? 
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Limitations 
 The following limitations of this study were anticipated: 
1. Convenience sampling was used to recruit participants, reducing the external 
validity of findings and decreasing generalizability. 
2. Participants living near San Antonio, TX, were recruited, limiting the 
generalizability of findings to individuals with HF with similar socioeconomic 
and demographic characteristics. 
3. Participants were limited to those who could speak and understand English, 
most likely limiting conclusions related to ethnic differences in personal 
growth. 
4. The descriptive, exploratory nature of the study design did not allow for the 
testing of causal hypotheses between select variables and personal growth. 
5. Cross-sectional data did not support inferences related to growth as an 
evolving temporal process.  
Significance of the Study 
Results from this study addressed significant gaps in the literature by first 
revealing the extent to which personal growth is present in persons with HF and by 
identifying factors that are associated with growth. Findings add to the body of literature 
exploring growth in chronic illness and enhance the theoretical understanding of growth 
through uncertainty. Findings may also help inform the supportive care models being 
developed to supplement traditional medical management of HF.   
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CHAPTER 2 
REVIEW OF THE LITERATURE 
 
In this chapter, a summary of the literature on personal and post-traumatic growth 
in cardiac populations and how these findings compare with findings of personal and 
post-traumatic growth in other illnesses is provided. Next, uncertainty in HF, which is 
postulated under the RUIT as a stimulus for growth, is presented, and the literature that 
explores the concept of growth through uncertainty is described. The chapter concludes 
with a summary of symptom status and burden in HF.  
Personal Growth: An Overview 
In recent years, there has been increasing interest in the potential positive 
psychosocial consequences of illness rather than focusing exclusively on negative 
outcomes (Barskova & Oesterreich, 2009). This trend has been particularly evident in 
health psychology (Affleck, Tennen, Croog, & Levine, 1987; Barskova & Oesterreich, 
2009; Chan, Lai, & Wong, 2006; Leung et al., 2010; Luszczynska, Sarkar, & Knoll, 
2007; Petrie, Buick, Weinman, & Booth, 1999; Senol-Durak & Ayvasik, 2010a, 2010b; 
Sheikh, 2004) and nursing (Benetato, 2011; Black & Sandelowski, 2010; Chiba, 
Kawakami, & Miyamoto, 2011; Kahana, Kahana, Deimling, Sterns, & VanGunten, 2011; 
Kamibeppu et al., 2010; Mosher, Danoff-Burg, & Brunker, 2006; Panagopoulou, 
Triantafyllou, Mitziori, & Benos, 2009; Rahmani et al., 2012; Sato, Yamazaki, & Sakita, 
& Bryce, 2008; Steel, Gamblin, & Carr, 2008; Turner & Cox, 2004; Turner-Sack, Menna, 
& Setchell, 2012).  
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Researchers focusing on personal growth have attempted to identify its 
antecedents, understand relationships among factors that contribute to or impede growth, 
and evaluate the influence of growth on other clinically important outcomes, such as 
mortality, depression, and health behaviors, in a variety of populations with chronic or 
acute health problems. Personal growth has been most extensively studied in cancer 
populations. Researchers have also studied personal growth in individuals living with 
HIV, multiple sclerosis, arthritis, lupus, neurological disorders, and heart disease 
(Barskova & Oesterreich, 2009). In addition to illness, researchers have studied growth in 
a variety of traumatic contexts, including grief, infertility, sexual abuse, domestic 
violence, traumatic injuries, homicides, war, natural disasters, and airline crashes (Antoni 
et al., 2001; Tedeschi & Calhoun, 2004).  
The growth literature encompasses seminal research in psychology that explored 
individuals’ abilities to successfully adapt, positively perceive difficult circumstances, or 
find meaning during times of significant stress, loss, or suffering. It has been largely 
influenced by well-known scholars, such as Maslow, Caplan, Dohrenwend, Frankl, and 
Yalom, who have generated foundational research and theory pertaining to stress, coping, 
and positive psychology (Tedeschi & Calhoun, 2004). Beginning in the 1980s, 
researchers began studying growth as a distinct phenomenon that was conceptualized as a 
process or outcome characterized by positive changes in psychosocial perceptions 
resulting from significant adversity (Tedeschi & Calhoun, 2004). To support this inquiry, 
researchers have used a variety of psychometric instruments to measure personal or post-
traumatic growth, including the Stress-Related Growth Scale (SRGS; Park, Cohen, & 
Murch, 1996), the Benefit Finding Scale (BFS; Mohr et al., 1999), the Posttraumatic 
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Growth Inventory (PTGI; Tedeschi & Calhoun, 1996), and the Growth Through 
Uncertainty Scale (GTUS; Mishel & Fleury, 1994).  
Tedeschi and Calhoun’s (2004) work on PTG and studies using the PTGI have 
informed much of the research on personal growth. Tedeschi and Calhoun (2004) define 
trauma as more or less synonymous with highly stressful life events or crisis, including 
but not restricted to physical or psychological injury. They suggest that PTG can occur 
with “circumstances that represent significant challenges to the adaptive resources of the 
individual, and that represent significant challenges to individuals’ ways of understanding 
the world and their place in it” (Janoff-Bulman, as cited in Tedeschi & Calhoun, 2004, p. 
1). Tedeschi and Calhoun (2004) conceptualize PTG as encompassing processes of 
cognitive reappraisal as well as cognitive and behavioral outcomes of those processes. 
Personal or Post-Traumatic Growth in Cardiac Populations 
Relatively few studies explore personal growth in cardiac conditions. Most 
studies were exploratory. For purposes of this review, they are presented chronologically. 
Affleck et al. (1987) conducted a secondary analysis of data from the Boston Heart 
Patient Study, a longitudinal investigation of health, psychological outcomes, and social 
outcomes in healthy men who had experienced a first-time MI. They found that 
individuals who reported benefits 7 weeks after experiencing their first MI were less 
likely to have a subsequent MI and had experienced less morbidity over the following 8 
years than those who reported no benefits. Both 7 weeks and 8 years following the initial 
MI, a majority (58% and 59%, respectively) reported benefits or gains that they attributed 
to the event. Gains or benefits included learning the value of healthier behaviors and 
positive changes in life, values, overall outlook, or relationships.   
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Participants in the original study (N = 345) were recruited from 26 hospitals in 
Massachusetts. Interviews were conducted after discharge home, 7 weeks following a 
first MI. Approximately 60% (n = 205) were reinterviewed 8 years later. In the original 
and follow-up interviews, causal attributions (categorized as personal behavior, stress 
responses, other people, bad luck, and hereditary) and perceived benefits (in response to 
open-ended questioning) were among the topics assessed. The most frequently reported 
benefits involved changes in (a) life philosophy/values/religion, (b) family life and 
relationships, (c) stress and conflict reduction, (d) life enjoyment, (e) health behaviors, 
and (f) longevity expectations. 
The secondary analysis (N = 287) included a sample of 82 participants who died 
before the 8-year follow-up plus all 205 who were interviewed again at 8 years. Among 
those interviewed for the 8-year follow-up, 111 had suffered at least one additional MI 
(Affleck et al., 1987). After controlling for age, prognostic severity of the initial MI, and 
socioeconomic status, the inability to identify benefits and blaming others (e.g., family 
problems) 7 weeks after the initial MI were independent predictors of a second MI over 
the subsequent 8 years. Among the 205 survivors interviewed 8 years after the initial MI, 
after controlling for age, statistically significant independent predictors of greater 
morbidity 8 years later included the prognostic severity of the initial MI, socioeconomic 
status, inability to identify benefits and causal attributions of stress 7 weeks after the 
initial MI. Affleck et al. (1987) also found that participants who experienced a second MI 
prior to the 8-year follow-up reported greater benefit at 8 years than did those who had 
not. Affleck et al. (1987) acknowledged that the identification of benefits by the sample 
studied may not generalize to sicker populations for which clinical outcomes may not be 
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as responsive to lifestyle changes or emotional reframing. This study was the first to 
explore associations between perceiving benefits, a key component within the personal 
growth literature, and health outcomes in a cardiac population. A major limitation was 
the all-male sample.  
Petrie et al. (1999) examined the positive changes reported by individuals 3 
months after either their first MI or a diagnosis of breast cancer. The MI sample consisted 
of 143 participants (87% men), aged 65 years or younger (mean age ≈ 53 years). The 
breast cancer sample consisted of 52 women with primary breast cancer (and no prior 
breast cancer diagnosis), who were scheduled to begin radiation therapy (mean age ≈ 54 
years). Both samples were recruited from university hospitals in New Zealand. At 3 
months, 58% of both samples completed a questionnaire that asked “What positive 
effects do you feel may have occurred in your life due to your heart attack/cancer?” 
(Petrie et al., 1999, p. 539) There were no significant differences in illness severity 
between participants who reported positive changes from their illness and those who did 
not in either the MI or breast cancer group. However, patients who experienced an MI 
were significantly more likely to report positive outcomes than were participants in the 
breast cancer group.  
Three independent researchers reviewed and categorized the written responses 
detailing the participants’ positive effects of illness. Positive outcomes reported by the 
MI participants included (a) healthy lifestyle changes (68%), (b) greater appreciation of 
health and life (28%), (c) improved close relationships (23%), and (d) changes in 
personal life priorities (17%); followed by smaller percentages of participants reporting 
perceiving second chances, greater knowledge about health, and improved empathy. 
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Breast cancer participants reported improved close relationships (33%), greater 
appreciation of life (27%), changes in personal priorities (20%), and improved empathy 
(20%). No significant differences related to gender were shown in the MI group, and no 
significant relationships among positive outcomes and age, education, self-rated health, 
and life satisfaction were shown in either group (Petrie et al., 1999).    
Sheikh (2004) examined the degree to which personality traits, coping styles, and 
social support contributed to positive outcomes in survivors of cardiac arrest. The sample 
consisted of 28 participants recruited from a cardiac rehabilitation program in the United 
States and 82 participants recruited from a cardiac support group in the United Kingdom. 
Positive outcomes were measured using the PTGI total score. In addition to assessing 
demographics, time since diagnosis, treatments, and perception of control, participants 
completed measures of personality traits, social support, stressful life events, and coping. 
No significant differences between the samples were shown in any of the main 
study variables. PTG was positively correlated with measures of problem-focused and 
emotion-focused coping to a moderate degree and more weakly with extraversion and 
satisfaction with social support. No significant association was found between time since 
diagnosis and PTG, suggesting that time alone is not a sufficient condition for growth. 
There was a significant association between PTG and perceived control. Extraversion 
was the only personality trait independently predicting PTG. Controlling for previous 
traumatic experiences and perceived control, extraversion was the strongest predictor of 
PTG; problem-focused coping partially mediated that association (Sheikh, 2004). Social 
support satisfaction was not found to be a significant independent predictor of PTG. 
Sheikh (2004) hypothesized that resources that facilitate the cognitive processing of an 
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event may be more important to achieving growth than the overall satisfaction with social 
support or the number of people available to help.  
Chan et al. (2006) studied the effects of personal resilience and cardiac 
rehabilitation on PTG in 67 Chinese patients with single-vessel CAD following 
percutaneous transluminal coronary angioplasty (PTCA). They found that resilience and 
attributions of growth to the rehabilitation program were significant predictors of PTG. A 
path model showed strong direct effects of both resilience and attributions of growth to 
participation in cardiac rehabilitation. In addition, there was a weaker, although still 
significant, indirect path whereby the attributions of growth to participation in 
rehabilitation partially mediated the relationship between resilience and PTG.   
Resilience in this study was evaluated using a composite score from measures of 
optimism, perceived control, and self-esteem. PTG was measured using a composite of 
items from the SRGS and the PTGI. Most of the participants reported not having a 
religion. Participants reported higher levels of PTG in the area of family appreciation and 
lower levels of PTG related to spirituality. The authors suggested that study findings 
imply that certain personal attributes, such as resilience, may help facilitate an 
individual’s ability to perceive gain in other areas of his or her life, in the face of serious 
stress or suffering that result from illness.  
Panagopoulou et al. (2009) conducted semistructured interviews with 11 married 
couples in Greece to explore dyadic benefit finding. One partner in each couple had 
experienced an MI. Interview questions focused on general concerns and the 
consequences and positive outcomes of experiencing an MI. Specifically, participants 
were asked the following question, which has been utilized in other studies exploring 
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benefit finding: “Sometimes people who are faced with a sudden health threat find some 
positive aspect in the experience. For example, some people feel they learn something 
about themselves or others. Have you found anything positive in this experience?” 
(Panagopoulou et al., 2009, p. 293)? Three researchers analyzed the interview transcripts 
using an interpretative phenomenologic approach. Participants perceived the MI as a 
stimulus for change, particularly in terms of health behaviors and as a chance to help 
others. Spouses were more purposeful in their efforts to recognize benefits, but had a 
more difficult time perceiving positive consequences from their partners’ MI. In most 
cases, spouses acknowledged benefits only in terms of having avoided more serious 
outcomes. Patients and spouses reported that benefit finding was generally a deliberate 
effort.  
Leung et al. (2010) investigated PTG in patients with CAD (N = 1,237) enrolled 
in outpatient rehabilitation in Canada. This study was the only one found that included 
participants with a diagnosis of HF (N = 178). This secondary analysis of data from a 
prospective cohort study (Grace et al., 2008) explored the relationships among 
sociodemographic, clinical, and behavioral factors and PTGI scores. Leung et al. 
examined which factors contributed most significantly to PTG and they compared scores 
of PTG from their cardiac sample with PTGI scores reported in the literature for other 
chronic illnesses.  
Significant correlates of PTG included younger age, non-White race, less income, 
reduced functional abilities, less depression, and better social support. In addition, 
participants who perceived their CAD as an acute illness associated with serious 
outcomes and as a condition that was responsive to treatment, rather than a chronic 
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cyclical disease in which they had less control over outcomes, reported higher levels of 
PTG. In general, compared with results of earlier studies in patients with various 
diagnoses, PTG scores in this large heterogeneous sample of cardiology outpatients were 
equivalent to previously reported scores in patients with MI or CABG, HIV/AIDS, and 
colorectal or prostate cancers, but substantially lower than previously reported in patients 
with multiple sclerosis, breast cancer, stage IV liver cancer, or bone marrow transplant.  
Senol-Durak and Ayvasik (2010a, 2010b) explored factors associated with PTG 
among patients with MI and spouses of patients with MI. The MI sample consisted of 148 
individuals (mean age = 56 years; 87% male) following an MI, recruited from four 
different Turkish hospitals (Senol-Durak & Ayvasik, 2010a). Senol-Durak and Ayvasik 
(2010a) investigated the influence of perceived social support, event perception, and 
coping on PTG in this sample. Turkish translations of the PTGI and measures of coping 
and social support were used. Overall, women had significantly higher PTG scores than 
did men. PTG scores were significantly and positively correlated with measures of social 
support, emotion-focused coping, and problem-focused coping. 
In a structural equation model, perceived social support was significantly and 
directly associated with event perception and coping. Coping (problem-focused, emotion-
focused, and indirect) was significantly related to PTG; perceived social support showed 
significant indirect effects via coping on PTG (Senol-Durak & Ayvasik, 2010a). 
However, event perception was not significantly related to PTG. The authors suggested 
that variations in the nature of an illness (disease stage, symptom burden, illness duration, 
and probability of reoccurrence) may impact results related to event perception and 
therefore its impact on PTG.   
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Synthesis of Findings 
In summary, researchers examining personal growth in cardiac populations have 
included individuals who experienced an MI (Affleck et al., 1987; Leung et al., 2010; 
Panagopoulou et al., 2009; Petrie et al., 1999; Senol-Durak & Ayvasik, 2010a), with a 
history of heart disease, specifically cardiac arrest (Sheikh, 2004), with single-vessel 
CAD undergoing PTCA (Chan et al., 2006), and with either a diagnosis of HF or history 
of CABG (Leung et al., 2010). Variations in population characteristics and measurement 
approaches limit the ability to draw solid conclusions related to personal growth in 
cardiac populations.   
All of the quantitative studies were observational; only two included participants 
from the United States (Affleck et al., 1987; Sheikh, 2004). Only one study included 
patients with a diagnosis of HF (Leung et al., 2010). Most studies involved cross-
sectional data collection; only two studies evaluated the trajectory of growth over time, 
but with samples that were exclusively (Affleck et al., 1987) or predominantly (Petrie et 
al., 1999) male.  
Growth was explored in relation to MI reoccurrence and morbidity (Affleck, et 
al., 1987); disease severity (Petrie et al., 1999); time since diagnosis (Sheikh, 2004); 
gender, age, and other illness populations (Leung et al., 2010; Petrie et al., 1999); 
ethnicity, income, functional abilities, and depression (Leung et al., 2010); personality 
traits (Sheikh, 2004); event perceptions (Leung et al., 2010; Senol-Durak & Ayvasik, 
2010a; Sheikh, 2004); social support (Leung et al., 2010; Sheikh, 2004); coping (Senol-
Durak & Ayvasik, 2010a; Sheikh, 2004); resilience (Chan et al., 2006); and causal 
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attributions or perceived benefits (Affleck et al., 1987; Chan et al., 2006; Panagopoulou 
et al., 2009; Petrie et al., 1999).  
In general, benefits or positive outcomes reported by the participants fit into the 
following categories: (a) health promotion knowledge/strategies (Affleck et al., 1987; 
Panagopoulou et al., 2009; Petrie et al., 1999); (b) reevaluation of values, priorities, and 
interpersonal relationships (Affleck et al., 1987; Chan et al., 2006; Panagopoulou et al., 
2009; Petrie et al., 1999); (c) greater appreciation for life (Affleck et al., 1987; Petrie et 
al., 1999); and enhanced religious or spiritual views (Affleck et al., 1987; Chan et al., 
2006; Panagopoulou et al., 2009).  
Personal or Post-Traumatic Growth in Other Illness Populations 
 Barskova and Oesterreich (2009) conducted a systematic review of 68 studies 
published between 1985 and 2009 that focused on growth in patients with or survivors of 
a variety of medical illnesses, including cancer (36 studies), HIV/AIDS (eight studies); 
brain and spinal cord injuries (six studies); heart disease (five studies); multiple sclerosis 
(four studies); rheumatoid arthritis (four studies); multiple chronic conditions or 
disabilities (two studies); burns (one study); orthopedic injuries (one study); and lupus 
erythematosus (one study). A majority of these studies measured personal growth using 
either the PTGI or the Benefit Finding Scale (BFS).  
In two studies that used the PTGI, higher levels of growth were found in 
participants who were younger in age or female (Bellizzi, 2004; Morris, Shakespeare-
Finch, & Scott, 2007). In contrast, studies using the BFS either did not detect 
relationships with age or sex (Katz, Flasher, Cacciapaglia, & Nelson, 2001; Schulz & 
Mohamed, 2004; Siegel & Schrimshaw, 2007) or found greater growth in older compared 
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with younger participants (Carver & Antoni, 2004; Luszczynska et al., 2007). 
Correlations between growth and education or income level examined in studies included 
in Barskova and Oesterreich’s (2009) review were predominantly nonsignificant. Five 
studies that examined growth in relation to ethnicity demonstrated that compared with 
non-Hispanic White participants, minority groups, specifically African Americans and 
Hispanics, reported more personal growth (Milam, 2004, 2006b; Siegel, Schrimshaw, & 
Pretter, 2005; Tomich & Helgeson, 2004; Urcuyo, Boyers, Carver, & Antonio, 2005). 
Two studies that did not show a significant association between growth and ethnicity 
(Thornton & Perez, 2006; Widows, Jacobsen, Booth-Jones, & Fields, 2005) included a 
small number of ethnically diverse participants, possibly diminishing the statistical power 
to detect significant relationships. 
Six studies cited by Barskova and Oesterreich (2009) showed that growth was 
significantly higher in individuals who had lived longer with their diagnosis (Cordova, 
Cunningham, Carlson, & Andrykowsky, 2001; Evers et al., 2001; McGrath & Linley, 
2006; Pakenham, 2005; Powell, Ekin-Wood, & Collin, 2007; Sears, Stanton, & Danoff-
Burg, 2003), whereas only one (Milam, 2004) found a negative association between time 
since diagnosis and PTG in individuals living with HIV. Nine studies cited by Barskova 
and Oesterreich did not detect a significant relationship between time and growth.  
Illness severity (based on established criteria for specific diseases) was related to 
growth in some studies cited by Barskova and Oesterreich (2009), but not others. In three 
studies of cancer, greater personal growth was found in individuals with more advanced 
disease (Carver & Antoni, 2004; Tomich & Hegelson, 2004; Urcuyo et al., 2005), but 
Lechner et al. (2003) found higher levels of PTG in people with stage II cancer compared 
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with either stage I or stage IV. One study of multiple sclerosis showed higher growth in 
participants in a relapse-remitting phase than among those living with a chronic, 
progressive form of the disease (Pakenham, 2005). Six studies cited by Barskova and 
Oesterreich did not demonstrate significant associations between growth and illness 
severity.  
Uncertainty in HF 
 Uncertainty is a common challenge for persons living with HF (Hopp et al., 2010; 
Jurgens, 2006; Waterworth & Jorgensen, 2010; Winters, 1999; Yu et al., 2007). Winters 
(1999) conducted one of the first studies to examine uncertainty in community-residing 
patients with HF. The sample in this mixed-methods study included 15 men and 7 women 
classified as NYHA class I to IV who were recruited from outpatient cardiology clinics. 
The mean number of years that participants had been living with HF was 7 (range, 1 to 21 
years). Participants most frequently described uncertainty related to (a) changing 
symptoms and therapies, (b) insufficient patient education, (c) decreased perceived 
control, (e) thoughts of the future, and (f) the impact of aging. In addition, participants 
reported higher uncertainty at the time of initial diagnosis and during diagnostic testing 
and treatment adjustments. Themes characterizing uncertainty in the qualitative portion 
of this study included recognition and response to symptoms and treatment, trying to stay 
well: a shared responsibility, and looking forward: quality of life and death (Winters, 
1999). Participants’ perceptions of uncertainty changed over time and were influenced by 
the adequacy of information, communication, trusting relationships with providers, 
spirituality, hope, social support, and self-care capabilities. Uncertainty scores (possible 
range, 23-115) were moderate (mean score = 54.9, SD = 7.7). Scores were highest for the 
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items that addressed uncertainty related to the progression of symptoms, expectations 
related to the future, and the likelihood of additional health problems (Winters, 1999).  
Qualitative Studies 
Several exclusively qualitative studies have identified uncertainty as a common 
theme among individuals living with HF (Aldred, Gott, & Gariballa, 2005; Brännström, 
Ekman, Boman, & Strandberg, 2007; Brännström, Ekman, Norberg, Boman, & 
Strandberg, 2006; Dougherty, Pyper, Au, Levy, & Sullivan, 2007; Nordgren, Asp, & 
Fagerberg, 2007; Russell, Geraci, Hooper, Shull, & Gregroy, 1998; Waterworth & 
Jorgensen, 2010).  
Russell et al. (1998) explored how individuals living with HF or chronic 
obstructive pulmonary disease (COPD) understood or explained the etiology, cause, 
effects, and treatments of an acute exacerbation. Participants were recruited from a 
Veterans Affairs Medical Center. The HF subsample consisted of 30 adult men (mean 
age = 69 years; mean ejection fraction = 35%) admitted to noncritical care units. The 
participants’ mean subjective disease severity was 3.2 on a 1-to-4 scale, with 4 indicating 
more severe disease. Participants reported uncertainty related to the cause of their 
hospitalization. In particular, one third of the HF participants could not describe the 
factors that had triggered an acute change in their HF stability, precipitating the need for 
hospitalization. 
Brännström et al. (2006) conducted a phenomenological study to better 
understand the experience of living with severe HF. Participants included 1 woman 
(NYHA class III) and 3 men (NYHA class IV) receiving palliative advanced home care 
in Sweden, with a median age of 79 years. One-time interviews were conducted in the 
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individuals’ homes. Using a hermeneutic interpretative approach to analysis, Brännström 
et al. identified four major themes, two of which were related to uncertainty: “being 
aware that one’s life hangs by a fine thread” and “struggling to cope with one’s 
unpredictable deteriorated body” (Brännström et al., 2006, p. 297). Uncertainty was 
described in relation to symptoms, periods of instability, and expected death. Two other 
themes pertained to isolation and the reactions to receiving HF care at home. Brännström 
et al. (2006) characterized the overall experience of living with severe HF as “being 
forced to ride a ‘roller coaster’ with an ongoing oscillation between ups and downs” (p. 
301). To further elucidate the meaning of living with the ups and downs, Brännström et 
al. (2007) subsequently recruited 1 of those participants with severe HF(NYHA class IV) 
and his wife, who were living at home, to participate in longitudinal interviews every 3 to 
5 months over a 4.5-year period, for a total of 26 interviews. Using a phenomenological–
hermeneutic approach, Brännström et al. (2007) characterized the participants’ overall 
experience of ups and downs as “integrating the unpredictable illness into life, enduring 
suffering, and enjoying life.” Subthemes included “Living life as it has become; Adapting 
to versus struggling against fatigue; Learning to take the good with the bad—striving to 
keep a check on the failing heart; [and] Finding meaning in togetherness with the spouse, 
others and God” (Brännström et al. 2007, p. 14). These themes characterized the couple’s 
daily attempts to balance the uncertainty associated with living with a diagnosis of HF, 
while embracing opportunities to live more fully.  
Aldred et al. (2005) studied the impact of advanced HF on 7 men and 3 women, 
recruited from a U.K. hospital, aged 60 years or older, categorized as NYHA class II to 
IV, and their primary informal caregivers. Interviews addressed the participants’ 
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understanding of HF, its impact of their daily lives, their educational needs, their feelings 
on available support services, and their general concerns. The patients and their 
respective caregivers were interviewed together in their homes. They identified four 
major themes: impact of HF on daily life, impact of HF on relationships, professional 
support, and future concerns. Uncertainty per se was not identified as a theme in this 
study, but participants expressed concerns about the unpredictability of symptoms 
making it difficult to plan daily activities. Participants also had concerns about prognosis, 
changes in condition, and availability of support services.   
Dougherty et al. (2007) conducted semistructured interviews with 24 participants 
(21 male) meeting criteria for stage C or D HF (Heart Failure Society of America, 2010a, 
2010b) to explore how individuals living with advanced HF perceive and plan for their 
future. This qualitative study was part of a larger study that aimed to explore end-of-life 
decision making in people living with advanced HF or COPD. Using grounded theory 
content analysis procedures, the authors identified Living with HF as the central theme 
and the following subthemes: my experience of HF, help with HF, and my future with HF. 
Uncertainty was implicit in the participants’ characterizations of daily life, their ability to 
make plans, end-of-life discussions with family, and life expectancy: “people with HF 
described their future in terms of an uncertain shortened life” (Dougherty et al., 2007, p. 
483, emphasis original).     
Nordgren et al. (2007) conducted a phenomenological study with 4 men and 3 
women, 38 to 66 years of age, to explore their experiences of living with HF. Participants 
were recruited from a hospital in Sweden. All reported at least one hospital admission for 
HF within the past year and met criteria for NYHA class III or IV. The major themes 
30 
included ambiguity of the body, losing track of life, and balancing life.  Uncertainty was 
implicit in these themes; overall, Nordgren et al. concluded that living with HF was 
experienced “as living with an unpredictable and failing body, an altered self-image, a 
rapidly changing health condition, and a life under constant and immediate threat” (p. 6). 
However, over time, individuals adjusted to living within their limitations, participated in 
activities that were meaningful to them, and achieved a sense of balance and contentment 
in their lives.  
Waterworth and Jorgensen (2010) conducted a longitudinal, qualitative study of 
25 older individuals (70 to 90 years of age) living in New Zealand who were transitioning 
toward greater dependence due to their HF diagnosis. Interviews were conducted every 3 
months for up to 1 year; 19 participants completed all interviews. Uncertainty emerged as 
a major theme in this study. Participants expressed uncertainty about daily happenings, 
future expectations, their ability to recognize changes in their health status, and death. 
Information-seeking, relying on religious and community support services, following 
medical instructions (e.g., regarding diet, activity, and stress management), and 
participating in advanced care planning discussions with family were among the ways 
participants managed uncertainty.  
Bekelman, Nowels, Retrum et al. (2011) conducted interviews with 33 individuals 
diagnosed with NYHA class II-IV HF and 20 informal caregivers to gain a better 
understanding of palliative care needs. Participants were recruited through providers at a 
university hospital in Colorado. They found that the patients’ daily and longer-term 
experiences were characterized by uncertainty related to symptoms, functioning, acute 
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exacerbations, and impending death. They concluded that research exploring palliative 
models for this population should address the management of illness uncertainty.  
Quantitative Studies 
As part of a larger Swedish study, Ekman, Norberg, and Lundman (2000) 
conducted an intervention study that consisted of scheduled visits to a nurse-managed 
outpatient HF clinic and regular follow-up phone consultations with a group of 158 
individuals diagnosed with moderate to severe HF (NYHA class III-IV). The intervention 
aimed to educate participants and, when present, their caregivers on identifying and 
managing HF signs, symptoms, and treatments and to provide them with tools to achieve 
these goals. The nurses individualized care based on each patient’s unique illness 
experience and cultural preferences. Seventy-nine participants were randomly assigned to 
either the control group (conventional care) or the intervention group. A validated 
Swedish version of the Cardiac Population Scale (CPS; Mishel, 1983), a modified version 
of the Mishel Uncertainty in Illness Scale (MUIS), also developed by Mishel to assess 
perceptions related specifically to illness ambiguity and complexity of treatments in 
people with heart disease, was used to measure uncertainty. Data were collected at 
baseline (during hospitalization) and 6 months later. At the 6-month follow-up, 21 
participants had died, leaving 58 participants in the intervention group and 62 in the 
control group. Follow-up questionnaires assessing uncertainty were completed by 45 
participants in the intervention group and 47 participants in the control group.  
There were no significant differences in uncertainty scores between the groups at 
baseline or at follow-up. Uncertainty scores at follow-up were significantly lower for 
both groups compared with baseline scores. In particular, no differences in participants’ 
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abilities to identify signs or symptoms of worsening HF were detected between groups at 
6 months. Ekman et al. (2000) offered two possible explanations for these findings: the 
CPS may not be sensitive enough to capture changes in uncertainty scores and/or the 
uncertainty associated with a life-threatening illness, such as HF, might not be responsive 
to cognitive strategies alone. They also suggested that measuring the participants’ 
knowledge post-intervention may have been a more suitable outcome for assessing the 
effectiveness of the intervention (Ekman et al., 2000).  
Thompson (2006) tested a model of self-care in 100 men and women with class I 
or II HF to better understand the relationships among social support, spiritual well-being, 
uncertainty, and self-care in this population. Path analyses were conducted to examine 
social support and spiritual well-being as predictors of self-care and uncertainty, and 
social support, spiritual well-being, and uncertainty as predictors of self-care, while 
controlling for comorbidities. In addition, Thompson examined whether uncertainty 
mediated relationships between social support and self-care and between spiritual well-
being and self-care. Spiritual well-being was found to be the main predictor of self-care. 
Thompson found strong relationships between spirituality and self-care and between 
spirituality and uncertainty. Although spirituality accounted for 22% of the variance in 
uncertainty, uncertainty did not significantly contribute to self-care and it weakened the 
relationship between social support and self-care.  
Jurgens (2006) investigated relationships among uncertainty, somatic awareness, 
symptom severity, symptom pattern (sudden vs. gradual onset), age, sex, HF history, and 
delay in care-seeking patterns in a sample of 201 adult patients admitted with a diagnosis 
of acute HF to either an urban or suburban tertiary or community hospital in the eastern 
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United States. The majority of the participants were White (95%) and male (56%), and 
the mean age of the sample was 70 years. Uncertainty was measured using the MUIS–
Community Version (MUIS-C). The Heart Failure Somatic Awareness Scale (HFSAS) 
was used to measure somatic awareness and symptom severity. Symptom duration was 
used to measure delay in care-seeking and was assessed during a researcher interview. 
Uncertainty scores (possible range, 23-115) were moderate (mean score = 71.4, SD = 
9.6). Jurgens reported that the majority of the participants indicated that they still had 
many questions and were not sure what was wrong with them (cf. Winters, 1999). 
Uncertainty scores did not differ based on symptom onset (gradual or acute), age, sex, or 
prior HF admissions. Uncertainty scores were not related to age, symptom pattern or 
duration, or delay in care seeking. Uncertainty scores were positively associated HFSAS 
scores (r = .36, p < .01), suggesting that greater somatic awareness and symptom severity 
were associated with greater uncertainty. 
Falk et al. (2007) examined the impact of uncertainty and sense of coherence on 
fatigue in 93 individuals with HF (52% male; mean age = 74 years; NYHA class I-IV 
HF) admitted to a university hospital in Sweden for worsening HF. To measure 
uncertainty, they used a Swedish version of the CPS. To measure fatigue, they used a 
Swedish version of the Multidimensional Fatigue Inventory, which measures general 
fatigue, physical fatigue/tiredness, functional/activity status, motivation, and mental 
fatigue. Uncertainty was positively associated with tiredness and reduced 
functional/activity status. When modeled with sense of coherence and NYHA class, 
uncertainty made a significant, but small (4%), independent contribution to physical 
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fatigue, but did not account for significant variance in any of the other domains of 
fatigue.  
Synthesis of Findings 
In summary, qualitative investigations have highlighted uncertainty as a highly 
challenging but common component of the HF illness experience. Consistent with the 
aims of qualitative research, these studies used convenience, purposive, or theoretical 
sampling procedures and included small sample sizes (2 to 33 participants). Two studies 
(Bekelman, Nowels, Retrum et al., 2011; Brännström et al., 2007) included caregivers in 
addition to individuals living with HF. Quantitative studies used larger sample sizes (93 
to 201 participants), but also used convenience sampling. The majority of samples 
included a greater percentage of men, individuals older than age 65, and participants with 
NYHA class II-IV HF. Nordgren et al.’s (2007) study was the only one to specifically 
examine the HF experience in a middle-aged population, but their sample only included 7 
people. Only one study included African American participants (Russell et al., 1998). 
Studies addressing uncertainty in HF were conducted in the United States (Bekelman, 
Nowels, Retrum et al., 2011; Dougherty et al., 2007; Jurgens, 2006; Russell et al., 1998, 
Thompson, 2006; Winters, 1999), the United Kingdom (Aldred et al., 2005), New 
Zealand (Waterworth & Jorgensen, 2010) and Sweden (Brännström et al., 2006; 
Brännström et al., 2007; Ekman et al., 2000; Falk et al., 2007; Nordgren et al., 2007).  
Uncertainty was described in relation to symptoms (Aldred et al., 2005; 
Bekelman, Nowels, Retrum et al., 2011; Brännström et al., 2006; Brännström et al., 2007; 
Falk et al., 2007; Jurgens, 2006; Russell et al., 1998; Winters, 1999) and planning for the 
future or anticipation of death (Aldred et al., 2005; Bekelman, Nowels, Retrum et al., 
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2011; Brännström et al., 2006; Brännström et al., 2007; Nordgren et al., 2007, 
Waterworth & Jorgensen, 2010; Winters, 1999). Participants suggested that information, 
supportive communication, trusting relationships, health care provider support, religion 
or spirituality, and self-care behaviors helped them to deal with uncertainty (Brännström 
et al., 2006; Brännström et al., 2007; Waterworth & Jorgensen, 2010; Winters, 1999). 
Participants in a few studies expressed the ability to perceive positive outcomes from 
their HF diagnosis, such as reframing their expectations, finding joy and meaning in their 
lives, and focusing on new possibilities (Brännström et al., 2006, Nordgren et al., 2007, 
Winters, 1999).  
Quantitative assessments of uncertainty levels were obtained via the MUIS-C or a 
Swedish-translated version of the CPS. For the most part, moderate levels of uncertainty 
were reported (Ekman et al., 2000; Jurgens, 2006; Winters, 1999) Positive associations 
were reported between uncertainty and spirituality (Thompson, 2006), HF-specific 
somatic awareness (symptom severity; Jurgens, 2006), and tiredness and reduced 
functional abilities (Falk et al., 2007). One nurse-directed education interventional, which 
randomly assigned participants to groups, did not demonstrate significant differences in 
uncertainty scores between the intervention and control groups (Ekman et al., 2000).   
Growth Through Uncertainty 
Results of both qualitative and quantitative studies indicate that uncertainty is 
common in HF. As proposed within the RUIT, positive reappraisal of uncertainty may be 
a stimulus for growth. 
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Qualitative Studies 
The Winters (1999) study reviewed above was the only investigation to provide 
some qualitative support for the RUIT within an HF population. Winters suggested that 
“In response to uncertainty, participants looked to the future, maintained a positive 
outlook, and identified a positive outcome resulting from their illness” (p. 89). Mishel 
and Murdaugh’s (1987) study of family adjustment to heart transplantation provided 
preliminary qualitative support for how family members of patients with major cardiac 
conditions process unpredictability and adopt a new life perspective in relation to three 
phases of transplantation: (a) waiting for a heart, (b) hospitalization (transplant surgery 
and the post-operative period), and (c) recovery and life after the transplant. Participants 
were 20 family members (14 wives, 5 mothers, and 1 sister) of heart transplant recipients 
or of individuals awaiting transplant who were willing to participate in support groups 
focused broadly on their experiences. Support sessions were conducted over 12 weeks. 
Data collection and analysis were concurrent using a grounded theory approach.  
The major theme was redesigning the dream, which summarized the cognitive 
and behavioral changes experienced by the family members through the phases of 
waiting, hospitalization, and recovery. Those phases were characterized by the subthemes 
of immersion, passage, and negotiation, respectively. Immersion and passage described 
the cognitive and psychosocial changes experienced almost exclusively by the family 
members, whereas the negotiation phase described how the family member and patient 
integrated ongoing uncertainty into their future together. Throughout this process, the 
family members restructured their views of reality to create a new normal. Mishel and 
Murdaugh (1987) described how living with ongoing uncertainty resulted in a new view 
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of reality in which family members redefined their expectations and integrated 
uncertainty in their worldview. They did not, however, provide substantial support that 
this process resulted in the positive appraisal of uncertainty or growth.   
Fleury, Kimbrell, and Kruszewski (1995) explored the experiences of women 
after an acute coronary event to better understand the psychosocial processes that support 
their recovery. The sample consisted of 13 women in the United States: 4 had been 
diagnosed with an acute MI, 5 had undergone CABG surgery, 2 had undergone PTCA, 
and 2 had been diagnosed with myocardial ischemia. Data were collected from weekly 
support group meetings over 9 months. Sessions were initiated with open-ended 
questions about how participants were doing in general. Sessions were not recorded; 
rather, the researchers took detailed notes after each session describing the content 
discussed, observations, and group interactions.  
The major theme that evolved from this study was healing, which was defined as 
“an individual patterning that evolved over time and incorporated a struggle through the 
uncertainty that surrounded the cardiac event to a way of creating a new and positive 
health behavior change” (Fleury et al., 1995, p. 477). Fleury et al. (1995) characterized 
this process as involving three nonsequential stages, surviving, originating, and 
patterning balance. Surviving was characterized by instability that initiated changes in 
personal worldviews. Originating involved developing new ways of living to reduce 
cardiac risk in the face of uncertainties. Patterning balance was characterized by 
reprioritizing life goals and values and redefining personal worldviews to effect positive 
lifestyle changes. The authors argued that the process was congruent with the RUIT. 
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Baier (1995) conducted a qualitative study exploring how individuals living with 
schizophrenia and their family members experienced uncertainty to specifically assess the 
applicability of Mishel’s (1990) RUIT to this population. She interviewed 6 individuals 
with schizophrenia (4 females and 2 males) who were well controlled on antipsychotic 
medications and 5 family members. Participants were recruited through a mental health 
support group. Baier reported that all participants described uncertainty as part of their 
illness experience and used probabilistic thinking defined as the ability to accept illness 
uncertainty and perceive alternative ways of living to varying degrees. Uncertainty was 
related to the effectiveness of drug therapy, symptom patterns, timing of relapses, 
mortality, and managing family responsibilities. Some participants suggested that 
uncertainty contributed to thoughts of fear, doubt, concerns, and obstacles, while one 
participant and the four family members of the same relative were able to perceive hope 
and optimism through their uncertainty.  
Brashers et al. (1999) conducted a qualitative study exploring uncertainty in 
people living with HIV who initially thought that they would die from their disease but, 
due to successful treatment, were surviving. They recruited 33 individuals from an Adult 
AIDS Clinical Trials Unit in the midwestern United States to participate in focus group 
discussions. The interview guide focused on four main areas: (a) general experiences of 
being HIV positive, (b) sources of uncertainty related to HIV status, (c) how uncertainty 
impacted participants’ lives, and (d) strategies used to manage uncertainty. Latent content 
analysis and constant comparative procedures guided data analysis. Participants described 
uncertainty related to ambiguous symptoms, complicated treatment regimens, inadequate 
education about diagnosis and prognosis, and the unpredictable disease trajectory. These 
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findings were congruent with Mishel’s (1988) original UIT. Participants also discussed 
the need to restructure certain facets of their lives (life priorities, financial support, 
employment, interpersonal relationships, and long-term plans) to come to terms with a 
new reality. The authors described this as a process of renegotiation that prompted new 
uncertainties related to the future, social roles and identities, interpersonal relationships, 
and quality of life. These accounts lent some support for growth as an outcome of 
uncertainty as conceptualized within the RUIT.  
Bailey, Wallace, and Mishel (2007) conducted a qualitative study with 10 men 
diagnosed with localized prostate cancer within the previous year who had opted for a 
watchful waiting approach. Time since diagnosis ranged from 4 months to 1 year. 
Participants were interviewed once by the primary investigator, who asked broad 
questions that addressed living with prostate cancer, treatment decision-making 
processes, sources of uncertainty, and strategies to cope with uncertainties and other 
illness challenges. Mishel’s (1990) RUIT served as the guiding theoretical framework for 
this study and helped to organize findings into the following three categories: uncertainty, 
appraisal of danger, and appraisal of opportunity. Uncertainty resulted from the limited 
number of symptoms and ambiguous nature of symptoms, vague diagnostic and 
prognostic indicators, and multiple treatment choices. Participants most commonly 
appraised their illness and its uncertainty as danger as a result of unclear treatment 
guidelines (need to obtain a second opinion, and watchful waiting vs. more aggressive 
therapies), and treatment choices. Some participants did perceive their experience as 
positive and viewed their future optimistically. Bailey et al. reported that several 
participants “viewed their decision to watch and wait as an opportunity to successfully 
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manage their uncertainty through work, self-care, keeping options open, and the use of 
alternative medications and prayers” (p. 738).  
Quantitative Studies 
Mast (1998) examined correlates of illness uncertainty and emotional distress in 
breast cancer survivors. The sample included 109 women, originally diagnosed with 
nonmetastatic breast cancer (stage I-III), who were 1 to 6 years post-treatment. Length of 
time since treatment ranged from 12 to 68 months, with a mean of 35 months. Mast 
hypothesized that positive appraisal was associated with greater time since completion of 
treatment and less emotional distress. They also hypothesized that time since treatment 
completion was negatively correlated with emotional distress among those reporting 
positive reappraisal. Positive reappraisal was measured using the GTUS. Emotional 
distress was measured using the Profile of Mood States-Short Form (POMS-SF). Scores 
on the GTUS (possible range, 39-234) ranged from 87 to 220 (mean 166; SD 28.1). 
Women who reported higher unpredictability on the MUIS did reported less personal 
growth. As hypothesized, GTUS scores were significantly and negatively correlated with 
distress. Using hierarchical regression, GTUS scores made a significant independent 
contribution to emotional distress controlling for coexisting illnesses, uncertainty, fear of 
reoccurrence, and symptom distress; this model predicted 51% of the variance in 
emotional distress. Mast (1998) did not find a significant association between length of 
time since treatment and positive reappraisal or between length of time since treatment 
and emotional distress. Furthermore, length of time since treatment did not predict higher 
GTUS scores, contradicting a key premise of the RUIT, that perceiving uncertainty as 
part of a new life view requires cognitive reframing over time.   
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Mishel et al. (2005) and Gil et al. (2006) reported 10-month and 20-month 
outcomes, respectively, from a randomized trial of a home-based uncertainty 
management intervention for African-American (n = 149) and White (n = 360) breast 
cancer survivors 5 to 9 years after treatment. Approximately 95% of the sample was 
surveyed at the 20-month follow-up (Gil et al., 2006). The intervention materials 
consisted of audiotapes of various cognitive strategies to promote emotion-focused 
coping (relaxation, imagery, calming self-talk, and distraction) and a self-help manual 
that reviewed information on symptoms and side effects of treatment, cancer resources, 
and other content individualized to each participant’s needs. A trained nurse reinforced 
this information and allowed the participants to practice one of the four cognitive 
strategies during four weekly phone calls that lasted approximately 30 minutes. During 
the phone call, the researcher also discussed managing uncertainty in general. The 
women in the control group received usual care (Gil et al., 2006; Mishel et al., 2005).  
At baseline, participants were initially blocked by race and then randomly 
assigned to the experimental or control group. Data collected at baseline, 10 months, and 
20 months included assessments of uncertainty, uncertainty management (cancer 
knowledge, communication, social support, and cognitive reframing), coping, personal 
growth, and negative mood state. Measures included a survivor version of the MUIS to 
measure uncertainty, the Cancer Survivor Knowledge Scale to measure cancer 
knowledge, the satisfaction subscale of the Social Support Questionnaire to measure 
social support satisfaction, a patient–provider communication rating scale to measure 
communication, the problem-solving and cognitive reframing subscale of the Self-
Control Schedule to measure cognitive reframing, a modified version of the Coping 
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Strategies Questionnaire to measure cognitive coping styles, a researcher-developed 
questionnaire to measure adequacy and helpfulness of information as a facet of coping, 
the POMS-SF to measure negative mood state, and the GTUS to measure personal 
growth. A detailed overview of instrument selection that included a description of each 
scale’s psychometric properties was provided (Gil et al., 2006; Mishel et al., 2005). A 
research nurse not involved with baseline data collection or the intervention called each 
participant monthly for 8 months to collect data on the uncertainty triggers and symptoms 
that the women had experienced, the strategies used to deal with them, and the 
effectiveness of each strategy (Mishel et al., 2005). 
Descriptive statistics at 10 months indicated that the women used the audiotapes 
to help manage their uncertainty between zero to nine times a month, with a mean of 2.24 
(SD = 1.63); calming self-talk was used the most frequently (75%), followed by 
distraction and relaxation (53%), and imagery was used the least (Mishel et al., 2005). 
The women reported that all strategies except imagery were helpful. In addition, the 
majority of women thought the manual was helpful in managing symptoms and referred 
to it between zero and seven times a month, with a mean of 2.45 times per month (SD = 
1.88; Mishel et al., 2005).  
Results indicated that women in the treatment group reported significant 
reductions in uncertainty, increased use of cognitive reframing, improved cancer 
knowledge, greater use of distraction as a coping method, increased perceptions of the 
amount and helpfulness of information, and consistent levels of personal growth at 20 
months compared with baseline. In addition to significant improvements in total personal 
growth scores, women in the treatment group also reported increases in the GTUS 
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subscales, flexibility and a new view of life. In the control group, total personal growth 
scores and flexibility and new view of life subscale scores decreased from baseline to 10 
months and then decreased further from 10 months to 20 months. These findings were 
more pronounced in African American women. Mishel et al. (2005) and Gil et al. (2006) 
suggested that the results demonstrated preliminary evidence of effectiveness of a nurse-
directed cognitive behavioral intervention in reducing uncertainty and facilitating 
personal growth through enhancing positive reappraisal skills in breast cancer survivors.  
Porter et al. (2006) conducted a secondary analysis of the data from the 
intervention trial (Gil et al., 2006; Mishel et al., 2005). The secondary sample included 
524 long-term breast cancer survivors (all female; 369 Whites, 155 African Americans; 
mean time since diagnosis = 81 [SD = 14] months; 85% stage I or II at diagnosis). The 
purpose of this secondary analysis was to test a conceptual model (based in part on 
concepts from the UIT and RUIT) of mood state and personal growth using structural 
equation modeling. Predictors of mood state and growth included demographic variables 
(age and education), disease factors (number of symptoms, symptom distress, and other 
health problems), social factors (social support satisfaction and religious involvement), 
negative cognitive factors (uncertainty, troublesome thoughts, and catastrophizing), and 
cognitive reframing. The POMS-SF was used to measure negative mood state, and the 
GTUS was used to measure personal growth.  
Religious involvement and social support satisfaction directly strengthened 
cognitive reframing in both White and African American participants. In both racial 
groups, a greater number of symptoms, more religious participation, more education, and 
younger age were directly correlated with greater personal growth. Although cognitive 
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reframing was significant in predicting personal growth for both groups, there was a 
larger effect in African American participants. Cognitive reframing also mediated the 
influence of social support and partially mediated the influence of religious involvement 
on growth. Negative cognitive state was directly correlated with less growth and 
mediated the influence of symptom distress and social support satisfaction on growth in 
both groups. In the final model for both ethnic groups, negative cognitive state explained 
35% of the variance in negative mood state and 25% of the variance in growth, making 
the largest contributions to the model. Cognitive reframing explained 21% of the variance 
in growth for White women and 40% of the variance in growth for African American 
women, providing support for the relationship between positive reappraisal and growth 
proposed in the RUIT.   
Bailey, Mishel, Belyea, Stewart, and Mohler (2004) tested the effectiveness of a 
watchful waiting intervention for men with prostate cancer. The intervention incorporated 
principles based on the RUIT, including cognitive reframing and positive reappraisal of 
uncertainty. The sample consisted of 39 men diagnosed with prostate cancer (nearly all 
Stage 1 or 2) who had opted for watchful waiting in place of more aggressive therapy. 
The average duration of watchful waiting was 52 months. Participants were randomly 
assigned to usual care or the intervention, which consisted of five weekly phone calls 
from a study nurse that were focused generally on providing factual information while 
encouraging probabilistic thinking to incorporate uncertainty into participants’ 
worldviews. In addition, the calls emphasized maintaining an optimistic outlook, 
participation in activities, and ongoing awareness and monitoring of symptoms. 
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Findings post-intervention did not demonstrate a statistically significant difference 
between the intervention and control groups in total growth scores, although the increase 
in GTUS scores for the intervention group (approximately 15 points) was substantially 
greater than in the control group (approximately 5 points).  
Santacroce and Lee (2006) examined relationships among post-traumatic stress 
symptoms, uncertainty, and health promotion behaviors in young adult cancer survivors 
(N = 45). They hypothesized that symptoms of post-traumatic stress mediated the 
relationship between uncertainty and health promotion behaviors. As expected, 
uncertainty was positively and significantly associated with post-traumatic stress 
symptoms and inversely associated with health-promoting behaviors. Uncertainty and 
post-traumatic stress had statistically significant negative bivariate correlations with 
health-promoting behaviors. However, the hypothesized mediating role of post-traumatic 
stress was not supported. When modeled together with uncertainty, the relationship 
between post-traumatic stress and health-promoting behaviors was no longer statistically 
significant, whereas the negative association between uncertainty and health-promoting 
behaviors remained statistically significant and was similar in magnitude to the 
relationship before the hypothesized mediator was added to the model. A respecified 
model in which uncertainty mediated the relationship between post-traumatic stress and 
health-promoting behaviors was better supported. 
 Y. L. Lee, Gau, Hsu, and Chang (2009) subsequently developed a conceptual 
model of uncertainty, post-traumatic stress, and health behaviors in young adult and 
adolescent survivors of childhood cancer based on an integrative, narrative literature 
review. The model, based in part on the RUIT, proposed that reduced or time-limited 
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uncertainty was conducive to developing a new view of life and health-promoting 
behaviors (or decreases in risky health behaviors), whereas chronic, unresolved 
uncertainty was a risk factor for post-traumatic stress disorder and risky health behaviors 
(or decreases in health-promoting behaviors). However, the model posited post-traumatic 
stress as a potential mediator between uncertainty and health-promoting behavior, which 
was not supported in the earlier study by Santacroce and Lee (2006). The authors 
acknowledged that the model was in need of empirical validation before it could be 
claimed to support the RUIT.   
Synthesis of Findings 
In summary, a small number of qualitative and quantitative studies were either 
informed by the RUIT or generated tentative support for uncertainty as a stimulus for 
growth. These studies examined the illness experiences of people living with heart 
disease (Fleury et al., 1995; Winters, 1999), schizophrenia (Baier, 1995), HIV (Brashers 
et al., 1999), breast cancer (Gil et al., 2006; Mast 1998; Mishel et al. 2005; Porter et al., 
2006), prostate cancer (Bailey et al; 2004; Bailey et al., 2007), or childhood cancer 
(Santacroce & Lee, 2006). In addition, one study examined experiences of family 
members in the context of heart transplantation (Mishel & Murdaugh, 1987). Qualitative 
sample sizes ranged from 10 (Bailey et al., 2007) to 33 (Brashers et al., 1999), whereas 
quantitative sample sizes ranged from 39 (Bailey et al., 2004) to 524 (Porter et al., 2006). 
The majority of studies were conducted in the United States, seven of which were 
conducted by researchers affiliated with the University of North Carolina (Mishel’s 
academic home). The majority of participants were female, with the exception of 
participants in the HIV (Brashers et al., 1999) and prostate cancer (Bailey et al., 2004, 
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2007) investigations. Most studies included a greater percentage of older participants, 
with the exception of studies conducted by Baier (1995), Brashers et al. (1999), 
Santacroce and Lee (2006), and Mishel and Murdaugh (1987). Although the majority of 
participants were White, relevant ethnic differences between White and African 
American breast cancer survivors were reported by Mishel et al. (2005) and Gil et al. 
(2006).  
Qualitative studies generated data related to growth through uncertainty by 
broadly exploring general illness experiences (Fleury et al., 1995; Mishel & Murdaugh, 
1987) or illness knowledge and future concerns (Baier, 1995). In addition to examining 
the overall illness experience, two studies included an explicit focus on sources of 
uncertainty and approaches to managing uncertainty (Bailey et al., 2007; Brashers et al., 
1999), providing data more congruent with appraisals of uncertainty. In particular, Bailey 
et al. (2007) specifically used the RUIT to help organize findings during data analysis.  
Data were collected in either group sessions (Brashers et al., 1999; Fleury et al., 
1995, Mishel & Murdaugh, 1987) or via one-time interviews (Baier, 1995; Bailey et al., 
2007). The use of group sessions and the lack of audiotaping in two studies (Baier, 1995; 
Fleury et al., 1995) may have contributed to bias in study results. In two studies, 
longitudinal data collection provided better insights related to how uncertainty is 
processed over time (Fleury et al., 1995; Mishel & Murdaugh, 1987).  
All of the qualitative studies concluded that some participants described the 
ability to adopt a new life perspective through illness uncertainty via a process of 
negotiation, redefining expectations, or restructuring ways of thinking or living. Themes 
or findings characterizing this process included redesigning the dream (Mishel & 
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Murdaugh, 1987), healing (Fleury et al., 1995), renegotiating the future (Brashers et al., 
1999), and danger and opportunity appraisals (Baier, 1995; Bailey et al., 2007). Although 
a new view of reality was evident in all of these studies, this outcome was not 
consistently characterized favorably by participants. For example, Baier (1995), Brashers 
et al. (1999), and Mishel and Murdaugh (1987) reported, to a greater degree, new realities 
largely formed by adverse thoughts and emotions. Reports of positive perceptions arising 
from uncertainty in these studies were not as common, but when present, they described 
hope or optimism for the future, personal or spiritual growth, or finding joy. In one study, 
positive views reported by Baier (1995) were generated largely by members of the same 
family, suggesting another potential bias. Although qualitative evidence to support 
positive outcomes resulting from the appraisal of uncertainty is limited, this body of 
literature did reveal participants’ abilities to reconstruct new realities that were 
concurrently shaped by negative and positive perceptions.   
Fleury et al.’s (1995) study provided qualitative support for integrating 
uncertainty into positive cognitive changes, which is congruent with key propositions of 
the RUIT, despite the study not being explicitly based on the RUIT. Fleury et al. (1995) 
described this transition as an iterative process, which they characterized as being rooted 
initially in chaos and instability that evolved over time to create favorable cognitive and 
behavioral health changes. In conclusion, there is some qualitative, empirical support for 
Mishel’s (1990) claim that individuals living with chronic illness can integrate 
uncertainty into a new reality, but no conclusive evidence about whether that process 
routinely results in the positive reappraisal of uncertainty, opportunity, or growth. Rather 
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this qualitative synthesis suggests that some individuals are capable of perceiving 
positive outcomes in the face of uncertainty.  
In quantitative analyses, researchers discussed growth through uncertainty as a 
process or an outcome and characterized it as positive reappraisal (Mast, 1998) or 
personal growth (Bailey et al., 2004; Gil et al., 2006; Mishel et al., 2005; Porter et al., 
2006) and often referred to it interchangeably as a new view of life. Researchers either 
examined relationships between this concept and other relevant variables (e.g., 
uncertainty, emotional distress, cognitive reframing, symptoms, comorbidities, social 
support, religious participation, coping strategies, or time), or they examined differences 
in these variables among groups. Quantitative investigations were conducted only with 
cancer populations: one with prostate cancer patients (Bailey et al., 2004), one with 
survivors of childhood cancers (Santacroce & Lee, 2006), and four with breast cancer 
survivors (Gil et al., 2006; Mast, 1998; Mishel et al., 2005; Porter et al., 2006). Three of 
these studies reported data from one larger program of research (Gil et al., 2006; Mishel 
et al., 2005; Porter et al., 2006). The GTUS was used to measure positive reappraisal or 
personal growth in all of these studies. All but one of the quantitative studies (Santacroce 
& Lee) were conducted by investigators affiliated with the University of North Carolina.  
Significant negative correlations were found in breast cancer survivors between 
personal growth and unpredictability related to illness progression and prognosis (Mast, 
1998) and emotional distress (Mast, 1998; Porter et al., 2006). Significant positive 
correlations were found between personal growth and a greater number of symptoms, 
more religious involvement, more education, and younger age (Porter et al., 2006).   
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Studies that examined differences in personal growth were intervention studies 
that evaluated the effects of interventions informed, to varying degrees, by the RUIT 
(Bailey et al., 2004; Gil et al., 2006; Mishel et al., 2005). Whereas both interventions 
addressed cognitive strategies to address uncertainty, the watchful waiting intervention 
(Bailey et al., 2004) more fully incorporated key principles of the RUIT, such as 
probabilistic thinking, integrating uncertainty into life, and positive reappraisal, 
consistent with the study’s purpose, to help participants incorporate ongoing uncertainty 
into a new worldview via cognitive reframing. The uncertainty management intervention 
used in the other study, which aimed to help participants cope with uncertainty and 
manage symptoms, was based on more traditional cognitive–behavioral strategies, such 
as relaxation techniques and a more structured educational component. Significant 
differences in reports of total personal growth at 10 months and 20 months in both 
African American and White breast cancer survivors were found between the control and 
intervention groups, but not in men living with prostate cancer at follow-up. Both studies 
did report significant differences in the new view of life subscale of the GTUS at follow-
up between the control and intervention groups.    
Variations in findings most likely result from differences in population 
characteristics and in the interventions. In particular, although Bailey et al. (2004) 
provided a comprehensive description of key components of the watchful waiting 
intervention, the intervention nurse individualized content based on the unique concerns 
of each participant. It was not clear whether a structured template guided this intervention 
and the extent to which various components of the intervention (probabilistic thinking, 
incorporating uncertainty, optimism for the future, participation in activities, self-
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monitoring and vigilance) were emphasized. In contrast, the uncertainty management 
intervention implemented with breast cancer survivors was based on specific topics and a 
consistent and structured process, although some content could be tailored to individual 
needs. Results from these two studies provide preliminary evidence that cognitive 
strategies aimed to help process uncertainty can help facilitate aspects of personal growth 
in cancer populations.  
In addition to demonstrating whether uncertainty can serve as a stimulus for 
growth, qualitative and quantitative studies provided data related to the influence of time 
on the development of personal growth through uncertainty, a key premise within the 
RUIT. Time was considered in terms of time since diagnosis or treatment or in the 
context of phases of an illness (diagnosis, treatment, and recovery). Mishel and 
Murdaugh (1987) collected data weekly over 12 weeks, and Fleury et al. (1995) collected 
data weekly over 9 months, generating longitudinal qualitative insights that described 
how coping with illness uncertainty evolved over time through specific phases and 
resulted in a new reality in cardiac populations. Baier (1995) assessed the number of 
years participants had been diagnosed with schizophrenia and considered time since 
diagnosis in evaluating uncertainty as an opportunity; mixed responses limited the ability 
to draw definitive conclusions from this study related to time and growth through 
uncertainty.  
Mast (1998) measured length of time since treatment and did not find a significant 
correlation between time and positive reappraisal in breast cancer survivors. In contrast, 
Mishel et al. (2005) and Gil et al. (2006) reported significant improvements in personal 
growth over 10 months and 20 months, respectively, in an uncertainty management 
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intervention group, and decreases in personal growth over this period in the control 
group. Similarly, Bailey et al. (2004) reported significant improvements in the new view 
of life subscale of the GTUS and, although not significant, trends toward total growth in 
the intervention group at the 10-week follow-up. These findings suggest that time may 
play a role in the appraisal of illness uncertainty, but there are not enough data to 
conclude that time alone contributes to the positive appraisal of uncertainty as an 
opportunity. Rather, interventions that promote cognitive restructuring of uncertainty, at 
least in cancer populations, likely contribute to personal growth over time. The small 
number of studies and variations in sample characteristics limit judgments about the 
influence of time on growth through uncertainty.    
Nature of Illness 
 The nature of an illness is conceptualized within the RUIT in terms of disease 
pattern (acute vs. chronic vs. disease reoccurrence) and illness duration. As described in 
Chapter 1, HF is a chronic disease resulting from structural and functional abnormalities 
of the heart and is characterized by varying degrees of symptoms and activity limitations, 
which can improve or worsen based on a variety of factors. The ACC/AHA guidelines 
(Hunt et al., 2001) and NYHA classifications of HF, also described in Chapter 1, are used 
to categorize HF’s disease stage and activity limitations. Disease patterns in HF can best 
be understood in terms of disease stage (e.g., NYHA class), and changes in HF signs and 
symptoms that lead to acute exacerbations of HF. Acute or progressive worsening of 
chronic, stable HF results from increasing symptoms and/or deteriorating activity 
tolerance when individuals (a) are nonadherent with diet or drug therapy, (b) affected by 
a secondary physiological insult or concurrent illness, (c) experience adverse drug side 
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effects or interaction, or (d) are no longer responsive to existing treatments (Jessup et al., 
2009). Clinical manifestations of acute exacerbations, such as respiratory distress, are 
normally preceded by fluid overload, significant reductions in cardiac output, or a 
combination of both (Jessup et al., 2009). Acute exacerbations (also referred to as acute 
HF syndromes or acute decompensated HF) may be followed by extended periods of 
stability (Hupcey et al., 2009; Jessup et al., 2009).  
This unpredictable illness course complicates practitioners’ ability to determine 
the number of years that someone can survive with HF (Hupcey et al., 2009; Jessup et al., 
2009). Duration of illness in HF is often considered in terms of prognosis. Although the 
duration of time that an individual can live with HF has improved in recent years, the 
most current evidence still indicates that 50% of individuals diagnosed with HF will die 
within 5 years (Jessup et al., 2009; Levy et al., 2006). Sudden cardiac death from 
ventricular arrhythmias also contributes to mortality in HF. Although sudden cardiac 
death is more common in end-stage HF (stage D), individuals in less advanced stages can 
still succumb to sudden death (Jessup et al., 2009). In summary, although guidelines exist 
to categorize patterns in HF and guide prognosis, in general, the overall nature of HF 
remains unpredictable.  
Symptom Status 
Over the last several decades, researchers have conceptualized symptoms in a 
variety of ways. Leventhal and Johnson (1983) defined symptoms within their theory of 
self-regulation as the actual representations of illness experienced by an individual via 
cognitive processing, characterizing the symptom as an objective occurrence distinct 
from an individual’s emotional response to it. Rhodes and Watson (1987) emphasized the 
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subjective nature of symptoms, characterizing symptoms as a change perceived by an 
individual that is reflective of abnormalities in functioning, sensation, or appearance. 
Similarly, Lenz, Pugh, Milligan, Gift, & Suppe (1997) defined symptoms, within their 
middle-range theory of unpleasant symptoms, as perceived markers of alterations in 
normal functioning experienced by an individual. They also suggested that symptoms are 
multidimensional, they can be experienced individually or in combination, and symptom 
assessment should not only address the presence or absence of a symptom, but should 
also consider the frequency, severity, and distress associated with the symptom. Dodd et 
al. (2001) defined symptoms as subjective experiences that represent alterations in 
normal biopsychosocial abilities, cognition, or sensations; they are typically distressful 
and indicators of deteriorating health. 
Understanding how an individual interprets a symptom (the meaning a person 
attributes to a symptom) is another important facet of more recent conceptualizations of 
the symptom experience (Armstrong, 2003). Symptom experience has been characterized 
as “the perception of the frequency, intensity, distress, and meaning occurring as 
symptoms are produced and expressed,” in which the situational and existential meaning 
of symptoms and the collective influence of multiple symptoms are considered 
(Armstrong, 2003).  
Within the RUIT, symptoms are conceptualized in terms of pattern, that is, “the 
degree to which symptoms are present with sufficient consistency to be perceived as 
having a pattern or configuration,” and in terms of event congruence, that is, “the 
consistency between the expected and the experienced illness-related events,” in this 
case, symptoms (Mishel, 1990, p. 59). In the literature, researchers using this framework 
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have evaluated symptom pattern in terms of symptom ambiguity (inability to recognize a 
symptom as related to a particular illness) and severity of symptoms. The event 
congruence of symptoms has been evaluated via the predictability of the symptom 
(ability to predict the frequency, onset, duration, intensity, location, and meaning of a 
symptom) (Mishel & Clayton, 2008). For the purposes of this study, symptom status was 
conceptualized as an individual’s ability to perceive symptoms and components of a 
symptom pattern to include occurrence, frequency, severity, distress and overall burden.  
In HF, inadequate cardiac output and insufficient venous return contribute to the presence 
of symptoms, such as dyspnea or abdominal fullness (Kemp & Conte, 2012). As 
described in Chapter 1, select symptoms during activity (notably fatigue, dyspnea, 
palpitations, and angina) contribute to the NYHA classification system, which is used to 
stage HF and as an approximate indication of prognosis. Therefore, although symptoms 
are a key component of disease severity, they do not on their own capture the full scope 
of disease severity. By the same token, estimates of disease stage do not entirely account 
for symptom severity. Consequently, disease severity in this study will be operationally 
defined as NYHA stage, whereas symptom status cannot be equated to disease stage.   
Symptom Patterns in HF 
There is a large body of literature exploring symptoms in HF. Researchers have 
generated knowledge related to symptom status in HF through studies that explore the 
experience of HF broadly (Bekelman, Nowels, Retrum et al. 2011; Hopp et al., 2010; Yu 
et al., 2007); focus on specific symptoms, such as fatigue or dyspnea (Austin, Williams, 
& Hutchison, 2012; Falk et al., 2007; Jones, McDermott, Nowels, Matlock, & Bekelman, 
2012; Parshall et al., 2001); assess HF symptoms in general (Janssen, Spruit, Uszko-
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Lencer, Schols, & Wouters, 2011; Janssen et al., 2008; Walke et al., 2007); or evaluate 
symptom clusters (Jurgens, Moser et al., 2009; C. S. Lee et al., 2014; K. S. Lee et al., 
2010; Song, Moser, Rayens, & Lennie, 2010). Research questions include how HF 
symptoms are related to comorbidities (Austin et al., 2012; Janssen et al., 2011; Jurgens, 
Hoke, Byrnes, & Riegel, 2009; Jurgens, Moser et al., 2009; Walke et al., 2007), age 
(Janssen et al., 2011; Jurgens, Hoke et al., 2009; Jurgens, Moser et al., 2009; Riegel et al., 
2010; Zambroski, et al., 2005), gender (Austin et al., 2012; Jurgens, Hoke et al., 2009; K. 
S. Lee et al., 2010; Zambroski et al., 2005), HRQOL (Bekelman et al., 2007; Opasich et 
al., 2008; Zambroski et al., 2005), and overall morbidity or mortality (Ekman et al., 2005; 
Gallagher et al., 2012; C. S. Lee et al., 2014; Moser et al., 2011).  
Researchers have used terms such as detect, recognize, identify, appraise, and 
experience somewhat interchangeably to characterize cognitive processes whereby 
individuals perceive symptoms. Symptom perception is assessed primarily via patient 
self-reports (spontaneous or in response to questionnaires or clinical interview). Self-
reports may be real-time or retrospective based on patient recall, interviews, or medical 
record review (Lam & Smeltzer, 2012). Recall may involve questions about the usual 
pattern of the symptoms experienced over some recent time interval (e.g., past week or 2 
weeks), or a specific episode (Parshall et al., 2012). Symptom perception is often 
discussed in terms of symptom severity, but terms that are used to convey symptom 
severity in the HF literature (e.g., burden, distress) are often used imprecisely and 
inappropriately, as though they were synonymous, even when they refer to different 
constructs (Landrum, 2009). The use of multiple descriptors, diverse instruments, and 
variations in aims of existing studies make it difficult to compare studies or draw 
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definitive conclusions from findings related to symptom perception, intensity, and 
predictability in HF (Landrum, 2009). For that reason, studies of symptoms in HF need to 
be examined closely to determine what was measured, as well as how and when it was 
measured. In this chapter, the focus is on studies that address symptom perception or 
reporting in HF in terms of patterns of occurrence, severity, or distress as relevant to 
evaluating HF or patient decisions to seek care.  
Comorbidities 
Comorbidities are common in individuals living with HF (Janssen et al. 2011). In 
a large cross-sectional study drawn from a random sample of all Medicare recipients in 
the United States (N = 122,630; aged 65 years or older), Braunstein et al. (2003) reported 
that more than 40% of participants had five or more comorbid conditions, of which the 
most common were HTN (55%), diabetes mellitus (31%), COPD (26%), eye conditions 
(24%), and high cholesterol levels (21%).  
Walke et al. (2007) conducted an observational cohort study that examined the 
impact of comorbidities on the range and severity of symptoms reported by individuals 
living with either COPD (n = 74) or HF (n = 59; NYHA class III or IV). Participants 
were interviewed every 4 months for up to 24 months; 93 participants completed all 
phases of follow-up. Symptoms evaluated during data analysis included physical 
discomfort, pain, fatigue, lack of appetite, depression, anxiety, and shortness of breath. 
Symptom burden, which characterized a total symptom severity score, was calculated by 
totaling the individual symptom scores. Symptoms reported by the HF cohort in order of 
frequency included physical discomfort, fatigue, lack of appetite, shortness of breath, 
pain, depression, and anxiety. Symptoms present at baseline were not associated with 
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survival. The frequency of reports of shortness of breath, fatigue, pain, and depression 
increased significantly over time. The number of participants assessing symptoms as 
moderate to severe increased from baseline to follow-up for all symptoms. Using linear 
mixed-effects models, Walke et al. (2007) explored the relationships among symptom 
burden, length of time in the study, number of comorbidities, and survival. Symptom 
burden increased over time and in relation to an increased number of comorbidities, but 
not to a statistically significant degree.    
Age, Gender, and Quality of Life 
In some HF studies, age and gender have been explored in relation to symptom 
perception and quality of life. In a sample of 77 men and women, aged 65 years and 
older, Jurgens, Hoke et al. (2009) explored factors associated with symptom recognition 
and response in an elderly cohort receiving care for worsening HF in the emergency 
center or in an inpatient unit of a tertiary care facility in the northeastern United States. 
The sample consisted of 40 men and 37 women; 66% were White, 48% were married, 
and the majority had at least a high school education. Approximately 80% of the 
participants met criteria for functional performance consistent with NYHA class III or 
IV. 
Perception of symptom distress was measured using a researcher-modified 
version of The Heart Failure Somatic Perception Scale (HFSPS). The Response to 
Symptoms Questionnaire was used to measure cognitive, emotional, and social factors 
impacting symptom response. Researchers also collected data on HF history, symptom 
duration, onset, and care-seeking decisions. In addition, they conducted interviews with 
participants to better understand contextual factors that influenced decision-making and 
59 
care-seeking. Jurgens, Hoke et al. (2009) found that 56% of their participants were unable 
to identify HF symptoms or recognize their significance. Age, comorbidities, and gender 
did not contribute to significant differences in symptom distress scores. Almost half of 
the sample reported experiencing shortness of breath for more than 3 days prior to 
seeking medical care, but a majority of participants did not know that their symptoms 
were related to their HF diagnosis. Among participants who had been hospitalized for HF 
previously (n = 53), approximately 20% did not know the etiology of their symptoms and 
were inclined to attribute HF symptoms to other causes, such as colds or strenuous 
activity.  
Riegel et al. (2010) examined differences in symptom identification and 
interpretation between two age groups of individuals with NYHA class II-III: younger 
than 73 years of age (n = 13) and 73 years of age or older (n = 16). Most participants 
were male, were married, were born in Australia, had a high school education, and met 
criteria for NYHA class II. The only significant difference between age groups was a 
higher percentage of retired individuals in the older group. To assess symptom detection, 
the participants and a researcher rated shortness of breath and perceived exertion before, 
immediately after, and 5 minutes after a 6-minute walk test (6MWT) using a visual 
analog scale and the Borg scale of perceived exertion. Ratings between the participants 
and the researcher were compared for differences in scores (the ability to detect 
symptoms) and then compared by age groups. Inter-rater reliability was established 
between two researchers employing the 6MWT on patients not enrolled in this study. 
Inter-rater reliability was highest for the Borg scale (0.91). Results showed that, at each 
time point, there were greater discrepancies between the older participants’ ratings of 
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their shortness of breath and the researcher’s assessments, compared with the younger 
participants’ and researcher’s ratings. Significant differences between age groups in 
symptom detection were only found in ratings collected immediately after the 6MWT.  
In addition, qualitative semistructured interviews were conducted to better 
understand the participants’ ability to detect and interpret their symptoms. Riegel et al. 
(2010) found that older individuals with HF had greater difficulty in identifying and 
interpreting shortness of breath and fatigue as relevant to their HF management compared 
with younger persons; older participants attributed shortness of breath to being out of 
shape, fatigue to poor sleep or excessive daytime activity, and ankle edema to arthritis. 
Younger participants reported the ability to independently recognize symptoms earlier 
and therefore act on them. Younger participants also perceived symptoms as having an 
adverse impact on their daily lives, which increased their self-monitoring, whereas older 
participants perceived their health more favorably and, as a result, were less attentive to 
the effects of their HF. Consistent with Winters’ (1999) study, Riegel et al. (2010) found 
that older participants experienced greater uncertainty related to symptom identification.  
Zambroski et al. (2005) evaluated the impact of age and gender on symptom 
prevalence, severity, distress, and burden, and the influence of these factors on HRQOL 
in a sample consisting of 53 participants recruited from an outpatient HF clinic in the 
midwestern United States. Participants were predominantly male (66%), with a mean age 
of 55 years (SD = 9.6), 89% were non-Hispanic White, 64% were married, and the 
majority met criteria for NYHA class III (57%). Participants completed a symptom 
assessment using the Memorial Symptom Assessment Scale–Heart Failure (MSAS-HF), 
a 32-item scale that asks the participants to rate the frequency, severity, and distress of 
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physical, psychological and HF-specific symptoms experienced during the last week, 
using a Likert scale. Symptom burden scores were the mean of the frequency, severity, 
and distress scores for each symptom. Results related to symptom prevalence, severity, 
distress, and burden, and relationships with age and gender were reviewed.  
More than 60% of the sample reported the following symptoms in order of 
decreasing prevalence: shortness of breath (85.2%), lack of energy (84.9%), dry mouth 
(74.1%), feeling drowsy (67.9%), difficulty sleeping (64.2%), and worrying (61.5%). 
Symptoms reported as having the greatest frequency (at least occasionally or more 
frequently as reported by > 85% of participants), in ascending order, included feeling 
bloated, worrying, shortness of breath, diarrhea, numbness/tingling in hands and feet, 
difficulty concentrating, other (non-chest) pain, lack of energy, poor appetite, and 
difficulty sleeping. The most severe symptoms (at least moderately severe) reported by 
this sample included change in the way food tastes (100%), difficulty sleeping (96.8%), 
other pain (90%), lack of energy (88.6%), shortness of breath (88.6%), numbness and 
tingling in the hands and feet (87%), and feeling drowsy (87%). Participants reported that 
lack of energy (63.6%), difficulty sleeping (60.6%) and shortness of breath (60.5%) were 
the most distressful and that shortness of breath, other pain, feeling bloated, poor 
appetite, change in the way food tastes, numbness/tingling in hands and feet, problems 
with sexual interest/activity, and lack of energy were the most burdensome (Zambroski et 
al., 2005).  
Significant differences by gender in baseline characteristics included that men 
were more likely to be married and have a high school education compared with women. 
Significant gender differences related to prevalence, severity, distress, and burden 
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included the following: significantly more women than men reported feeling nervous and 
sweating, and men reported a significantly higher frequency of sexual problems that were 
significantly more distressing and burdensome (after controlling for marital status), 
compared with reports by women (Zambroski et al., 2005).  
Significant differences related to age included the following: nausea was 
significantly more prevalent in older participants (patients 55 years and older) compared 
with younger participants (54 years or younger), and shortness of breath and waking up 
breathless at night were significantly more distressing and burdensome in younger 
participants. The only significant difference in baseline characteristics between the older 
and younger groups was that older participants were more likely to be taking 
antiarrhythmic medications. Using hierarchical stepwise regression, the authors found 
that after controlling for age and NYHA class, symptom prevalence and symptom burden 
made independent contributions to explained variance in HRQOL. Younger age, worse 
functional status, and greater symptom prevalence and burden predicted decreased 
HRQOL in this sample.     
Opasich et al. (2008) assessed symptom severity in a study designed to test the 
appropriateness of the Edmonton Symptom Assessment Scale (ESAS) in a cardiac 
population and to assess the relationship between symptoms and global health status or 
quality of life. The sample consisted of 46 inpatients admitted to an Italian medical 
facility with late-stage HF (NYHA class III or IV). The sample was mostly male (57%), 
with a mean age of 71 years (SD = 11) living with HF for a mean duration of 42 months 
(SD = 36). Symptom intensity was measured using the original 10-point ESAS. The 
ESAS was administered two times a day (morning and afternoon) for 5 days. A total 
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daily score for each symptom was calculated by adding the morning and afternoon scores 
and generating a mean score. An overall symptom distress score was calculated by 
adding mean scores of the total daily symptom scores from the 5 days. Global health 
status was measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ) 
summary score. 
Although shortness of breath was reported as the most frequent symptom (100%), 
generalized discomfort, tiredness, and anorexia were found to be more distressing than 
shortness of breath. The authors suggested that participants may have become 
accustomed to ongoing shortness of breath and therefore did not rate it as distressing. In 
addition, total symptom distress scores were correlated with the KCCQ summary score  
(r = –0.78; p = .0001), but none of the individual symptoms independently predicted 
quality of life. 
Symptom Variability and Clinical Outcomes 
Other researchers have also focused explicitly on the variability of symptom 
occurrence and severity. Webel, Frazier, Moser, and Lennie (2007) evaluated daily 
changes in patients’ reports of dyspnea, edema, and weight gain for 1 month. A 
secondary aim of this study was to explore the relationships among dyspnea, edema, and 
body weight. Forty-eight individuals diagnosed with HF participated in this study. The 
mean age was 48 years (SD = 15), 55% were male, 54% were married, and the majority 
met criteria for NYHA class III (54%). Each day for 30 days, participants rated their 
shortness of breath and edema on a 0-to-10 scale, with 0 indicating the absence of the 
symptom and 10 indicating maximal symptom severity. To measure body weight, 
participants weighed themselves on the same scale, at the same time, each day. The 
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sample, as a whole, reported consistent and moderate levels of daily dyspnea, but 
individual participants differed in the variability of symptom intensity from day to day. 
The sample was divided into a stable group (n = 26; 62%) and an unstable group (n = 16; 
38%), based on conventional criteria for clinical stability/instability. The unstable group 
demonstrated greater variability in symptom intensity over the 30-day period compared 
with the stable group. Moderate changes in edema were also reported for the group as 
whole, with minor to moderate fluctuations over time. A subset of participants, who 
typically reported consistent levels of edema for extended periods, at certain time points, 
reported drastic increases in the extent of their edema. Webel et al. suggested that sudden 
changes in HF stability (exacerbations) or the inability of participants to accurately assess 
more subtle alterations in edema could account for this finding. A positive and a 
significant association was present between dyspnea and edema daily reports every day 
for 30 days, whereas dyspnea and edema were not significantly correlated with body 
weight for the majority of study days. The authors recognized that individual assessments 
of symptom severity may not be interpreted consistently among participants, making it 
difficult to objectively compare reports, and that the addition of a functional assessment 
would most likely improve the ability to detect symptom variability. 
 Moser et al. (2011) examined symptom variability as a predictor of event-free 
survival in 71 individuals living with HF (NYHA class I/II 45%; class III/IV 49%; not 
documented 6%). Participants had a mean age of 62 years (SD = 14), 59% were male, 
87% were White, and 63% were married or lived with a significant other. Comorbidities 
were reported as follows: HTN (63%), previous MI, CABG or coronary intervention 
(58%), diabetes (37%), reduced kidney function (20%), stroke (13%), and peripheral 
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vascular disease (PVD; 14%). Participants rated shortness of breath, swelling, fatigue, 
and difficulty sleeping every day for 30 days using the Daily Symptom Scale. This 
instrument assesses symptom severity on a 0-to-10 scale, with 0 indicating the absence of 
the symptom and 10 indicating the highest symptom severity. The researchers conducted 
monthly phone follow-ups to assess outcomes of event-free survival, specifically 
hospitalizations and/or death, and then verified verbal reports with hospital records. 
Ten nurses with HF expertise used consensus procedures to organize symptom 
patterns using graphic representations of daily reports into the following categories: mild, 
moderate, or severe symptoms and high or low symptom variability. In addition, for each 
participant, 30-day symptom scores were totaled to derive a mean symptom score as a 
measure of symptom severity. Symptom variability for each participant was determined 
using standard deviations of the symptom scores over the 30-day period. The median of 
the standard deviations was used to categorize scores into a high variability and a low 
variability group. More than 95% of the participants reported experiencing each of the 
four symptoms during the 30 days. Approximately 94% of participants reported shortness 
of breath, 90% reported difficulty sleeping, 89 % reported fatigue, and 82% reported 
edema, to varying degrees, every day. On the whole, symptom ratings were low to 
moderate in severity.  
Associations between symptom severity scores were assessed for each 
combination of symptoms and found to be both positive and significant, indicating that as 
the severity of one symptom increased, so did the severity of the others. Correlations 
between symptom variability scores were positive and significant for all symptom 
combinations, with the exception of fatigue and edema. Furthermore, an inverse 
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relationship was found between severity of shortness of breath and variability of 
shortness of breath, indicating that as variability increased, severity decreased.  
Participants who reported more variability in their shortness of breath and/or 
edema were more likely to be hospitalized compared with those who reported less 
symptom variability. Using Cox proportional hazards models, the authors found that 
symptom variability related to shortness of breath and edema predicted event-free 
survival independent of age, gender, symptom severity, ejection fraction, and 
comorbidities. Symptom severity did not predict event-free survival.  
Ekman et al. (2005) examined the predictive ability of self-reported severity of 
symptoms (breathlessness, fatigue, angina, orthopnea, and edema) on worsening HF, 
hospitalization, and mortality in a sample of 3,029 individuals. This study was a 
secondary analysis of a large, multicenter, randomized controlled trial which was 
conducted in 15 European countries to evaluate the effectiveness of beta-blocker therapy 
on HF outcomes. Participants were mostly men (79%), with a mean age of 62 years and 
designated as NYHA class II (48%), NYHA class III (48%), or NYHA class IV (4%). 
Breathlessness, fatigue, and angina were evaluated using a 5-point scale that assessed the 
presence of symptoms with different degrees of activity; orthopnea was measured as 
present or absent, and edema was measured as present or absent and by location. Data 
were collected at baseline and every 4 months for a mean of 58 months.  
Univariate analysis revealed that breathlessness, orthopnea, and fatigue were 
significantly associated with mortality and deteriorating HF and that angina was 
significantly associated with mortality and all-cause hospitalization. The influence of 
symptom severity on selected outcomes was assessed using Cox proportional hazards 
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models controlling for multiple baseline characteristics (age, gender, NYHA 
classification, duration of illness, cause of HF, comorbidities, and drug therapy). 
Breathlessness significantly predicted increased mortality and all-cause hospitalization, 
and fatigue significantly predicted worsening HF, after controlling for baseline 
characteristics.  
Gallagher et al. (2012) examined patterns and duration of symptoms prior to a 
first-time hospitalization for HF. Participants were recruited from an Australian HF 
registry (N = 242, 54% male; mean age = 79 years). A majority of participants met 
criteria for NYHA class II (38%) or III (24%). Participants were asked about the 
occurrence and duration of 10 HF-specific symptoms prior to their admission. The 
researchers used this information to construct two variables: duration of acute symptom 
onset and symptom pattern (gradual onset vs. multiple symptoms occurring 
simultaneously and more rapidly).  
Participants reported having experienced up to seven symptoms (mean = 2.7) for 
a median of 4.5 (range, 1-7) days prior to hospitalization. The most frequently reported 
symptoms were worsening dyspnea on exertion (88%), swelling (49%), and cough 
(27%). Approximately one third of participants reported multiple simultaneous symptoms 
rather than a gradual onset of symptoms. Participants sought hospitalization more quickly 
for chest pain, worsening dyspnea with exertion, and nocturnal dyspnea, indicating that 
these symptoms were perceived as more intense or concerning. Symptom duration prior 
to hospitalization increased if symptoms occurred during the hours of 8:30 am to 
midnight versus in the middle of the night and if symptoms changed. Symptom duration 
decreased prior to hospitalization if participants experienced chest pain or were older.   
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Parshall et al. (2001) examined the impact of dyspnea duration, distress, and 
intensity on individuals’ decisions to go to the emergency department (ED) and on 
admission status. The sample consisted of patients with an established diagnosis of HF (N 
= 57, 54% female) treated in a university hospital ED. The researchers collected data 
retrospectively via phone, in-person interviews, and/or medical record review. Prior to 
asking questions specifically about dyspnea, the researchers asked broad questions about 
the general nature of the symptoms that prompted the participant to seek emergency care. 
Data were also collected on demographic and clinical factors, daily activities, quality of 
life, and the participants’ comprehension of and compliance with HF management. The 
Specific Activity Scale (Goldman et al., as cited in Parshall et al., 2001) was used to 
measure functional status. To measure dyspnea distress, participants were asked to rate 
how much their breathing bothered them using a 5 point scale, with responses ranging 
from 0 (not at all) to 4 (very much), at two recalled time points: the time that they 
decided to go to the ED (Decision) and 1 week prior to this decision (Week Before). 
Duration was the number of days that the participants experienced dyspnea at the severity 
level reported at Decision. Participants were also asked what terms they would use to 
describe the breathing distress they experienced at the time they decided to go to the ED. 
Dyspnea intensity was measured using two versions of a researcher-developed dyspnea 
descriptor checklist (Elliot et al., 1991, and Simon et al., 1990, as cited in Parshall et al., 
2001), which asked participants to select the descriptors that best characterized how their 
breathing felt prior to seeking emergency care and then to rate their intensity on a 0-to-10 
scale, with 10 indicating the highest severity. Eleven items from this checklist were used 
to evaluate dyspnea intensity.   
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The majority of participants indicated that their HF symptoms routinely limited 
their ability to perform meaningful activities. Twenty three percent indicated that a 
primary concern at the time that they decided to go to the ED was related to functional 
limitations, with most (~70%) reporting an increase in dyspnea severity at this time, 
followed by reports of chest pain (~30%, cf. Gallagher et al., 2012; Parshall, 1999). At 
the Week Before time point, dyspnea distress was categorized by 39% as minimal or 
absent, by 15% as somewhat distressful, and by 46% as very distressful. At the Decision 
point, 12% reported dyspnea distress as minimal or absent, 8% reported it as somewhat 
distressful, and 80% reported it as very distressful, indicating an overall increase in 
distress over the week preceding the visit. Nearly half of the participants used distress-
laden words, such as couldn’t breathe, couldn’t get air, smothering, or choking in 
response to open-ended questioning. More than one third added emotional descriptors, 
such as awful or terrible, to further emphasize their distress.  
Approximately two thirds of participants recalled 3 days or less of dyspnea, 
whereas one third reported a duration of 6 days or more. Distress reports were not 
significantly different at the Decision point for participants reporting different durations 
of dyspnea (3 days or less vs. 6 days or more), and dyspnea duration prior to the ED visit 
was not associated with admission to the hospital. For the sample as a whole, the mean 
intensity rating was 6.7 (SD = 2.7) points at Decision and 4.4 (SD = 3.3) points 1 week 
prior. Those who experienced dyspnea for 6 or more days reported high levels of distress 
and intensity at both Week Before and Decision time points, whereas the participants 
experiencing dyspnea for 3 days or less had lower reports of distress and intensity 1 week 
before the visit that increased substantially over a few days prior to the visit.    
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Symptom Clusters and Clinical Outcomes 
Researchers have also studied the combined occurrence of multiple symptoms in 
HF populations to identify symptom clusters that may help individuals living with HF 
perceive their symptoms earlier and identify symptoms that are significant to their HF 
management. In a secondary analysis, Jurgens, Moser et al. (2009) retrieved data from 
the Heart Failure Quality of Life Trialist Collaborators registry to identify symptom 
clusters in hospitalized HF patients. The secondary sample consisted of 687 participants 
with a mean age of 71 years; 51% were female, 61% were White, and most participants 
were classified as either NYHA class III (45%) or class IV (38%). Participants assessed 
symptoms using nine items from the Minnesota Living with Heart Failure Questionnaire 
(MLHFQ): six physical symptoms and three emotional symptoms. The researchers used 
principal components analysis with oblique rotation to determine the following symptom 
clusters: (a) acute volume overload (shortness of breath, fatigue, and sleeping problems), 
(b) chronic volume overload (swelling, increased need to rest, and dyspnea on exertion), 
and (c) emotional (depression, memory problems, and worry). The authors found that, in 
general, older participants more frequently reported symptom clusters, but participants 75 
years and older reported less overall symptom impact. Diabetes was the only comorbidity 
that was a significant independent predictor of a symptom cluster (emotional).  
Using an agglomerative hierarchical clustering method, Song et al. (2010) 
identified a dyspnea cluster (shortness of breath, orthopnea, and awakening breathless 
from sleep) and a weary cluster (lack of energy and appetite, and problems sleeping) in a 
sample of 421 patients hospitalized with HF in Korea. In this study, the mean age was 62 
years; 40% were female, and most were classified as either NYHA class II (38.2%) or 
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class III (34.2%). Participants reported symptom occurrence and severity over the 
previous 2 weeks using a modified version of the MSAS-HF, which addressed the 
following symptoms: shortness of breath, lack of energy, difficulty sleeping, orthopnea, 
waking up breathless at night, lower extremity or ankle edema, dizziness, chest pain, 
palpitations, and poor appetite. Using hierarchal Cox proportional hazards regression 
analysis, Song et al. (2010) found that increased severity related to the weary cluster 
independently predicted hospital readmission for a cardiac-related problem and that 
increased severity associated with the dyspnea cluster independently predicted cardiac 
death.  
Finally, K. S. Lee et al. (2010) used data from 3 prospective longitudinal studies 
that included HF participants recruited from three outpatient settings in different states to 
better understand the influence of individual characteristics on symptom clusters and the 
effect of symptom clusters on morbidity and mortality. Sample characteristics included a 
mean age of 61 years; 65% were male, 81% were White, and 44% were classified as 
NYHA class III. Symptoms were assessed using eight items from the MLHFQ (edema, 
dyspnea, fatigue/increased need to rest, fatigue/low energy, sleep problems, worrying, 
feeling depressed, and cognitive problems). Using cluster analysis, the authors identified 
the following symptom clusters for both men and women: the physical cluster (dyspnea, 
fatigue/increased need to rest, fatigue/low energy, sleeping problems) and the 
emotional/cognitive cluster (worrying, depression, and cognitive disturbances). Edema 
constituted a third, single-symptom cluster. Total symptom distress scores from the 
physical and emotional/cognitive clusters were correlated (r = .64, p < .01). The 
emotional/cognitive distress cluster was associated with younger age, and women were 
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significantly more likely than men to report greater physical distress. After controlling for 
age, gender, comorbidities, body mass index, NYHA class, and interaction between 
emotional/cognitive and physical clusters, total distress from the emotional/cognitive 
cluster was a significant independent predictor of cardiac events (a composite of death, 
hospitalization, or HF-related ED visit). Compared with participants categorized as low 
distress on both the physical and emotional/cognitive clusters, participants categorized as 
high distress on both clusters or on just the emotional/cognitive cluster were more than 
twice as likely to experience a cardiac event. The likelihood of a cardiac event was not 
increased among participants categorized as high physical distress only compared with 
those categorized as low distress on both the physical and emotional/cognitive clusters.  
C. S. Lee et al. (2014) recently examined physical and psychological HF 
symptom profiles in relation to 1-year event-free survival (a composite of all-cause 
mortality, cardiac-related ED visit or hospitalization, cardiac transplant or ventricular 
assist device implantation). This prospective cohort study included 202 individuals 
recruited from an outpatient HF setting in the Pacific northwest. The mean age was 56.9 
years, 50% of participants were male, 85.6% were White, and most met criteria for 
NYHA class III (55.9%) or class II (40.1%). To evaluate physical symptoms, participants 
completed the HFSPS, an 18-item scale that asks participants to rate how much they have 
been bothered by HF-specific physical symptoms on a 6-point scale (0 = did not have 
symptom; 5 = extremely bothersome). Researchers also collected data on daytime 
sleepiness using the Epworth Sleepiness Scale (ESS), depression using the 9-item Patient 
Health Questionnaire (PHQ9), anxiety and hostility using the Brief Symptom Inventory 
(BSI), and clinical event outcomes via electronic medical record review or patient report. 
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The researchers used latent class mixture modeling to distinguish symptom profiles using 
continuous HFSPS, ESS, and BSI anxiety and hostility scores and a binary PHQ9 score 
cut point (depressed, not depressed). Significant positive linear associations (range, .27-
.66) existed among the four symptom measures. The researchers used symptom severity 
categories to create three distinct profiles of increasing symptom burden/severity: mild 
(41.7% of sample), moderate (30.2% of sample), and severe (28.1% of sample). None of 
the individual symptom measures independently predicted 1-year event-free survival, but 
the severity profiles did. After controlling for the Seattle Heart Failure Score (a proxy for 
disease severity), compared with the mild symptom profile (reference category), 
participants in the moderate (hazard ratio [HR] = 1.8, 95% CI: 1.1-3.1) and severe (HR = 
2.1, 95% CI: 1.2-3.5) symptom classes were significantly more likely to experience at 
least one of the composite endpoint events within 1 year. 
Synthesis of Findings 
In summary, researchers have examined symptoms in relation to occurrence, 
severity, and variability. They have also explored the influence of comorbidities, age, and 
gender on symptom patterns and the influence of symptom patterns on clinically 
important outcomes. Findings suggest that individuals living with HF experience a 
multitude of symptoms, of which shortness of breath and fatigue are the most frequent 
and distressing (Janssen, et al., 2011; Janssen et al., 2008; Jurgens, Hoke, et al., 2009; 
Parshall et al., 2001; Song et al., 2010). Other common HF symptoms include insomnia, 
pain, generalized discomfort, muscle weakness, edema, depression, anxiety, cough, 
anorexia, dry mouth, nausea, palpitations, dizziness, and difficulty concentrating and 
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urinating (Gallagher et al., 2012; Janssen et al., 2011; Janssen et al., 2008; Jurgens, 2006; 
Opasich et al., 2008; Walke et al., 2007; Zambroski et al., 2005).  
Studies of symptom clusters are limited and somewhat idiosyncratic (i.e., 
primarily descriptive of specific samples with little agreement across studies). Symptom 
clusters have been characterized as pertaining to acute versus chronic volume overload 
and emotional symptoms (Jurgens, Moser et al., 2009); physical versus 
emotional/cognitive symptoms (K. S. Lee et al., 2010); and dyspnea versus weary 
clusters (Song et al., 2010). An alternate approach, creating composite severity classes 
based on multiple symptom indices (C. S. Lee et al., 2014), has also been used. 
Although these studies indicate that individuals living with HF report a wide array 
of symptoms, variations in sample characteristics and design contribute to differences 
related to symptom perception, severity, and predictability. Mixed results related to 
symptom perception, severity, and predictability and the influence of comorbidities, age, 
and gender on these characteristics need to be considered in relation to variations in 
sample sizes and geographical regions. Primary studies in this review used sample sizes 
ranging from 29 (Riegel et al., 2010) to 421 (Song et al. 2010), whereas secondary 
analyses were conducted with data obtained from sample sizes ranging from 26 (Jones et 
al., 2012) to 3,029 (Ekman et al., 2005). Researchers recruited participants from diverse 
locations, including the Netherlands (Janssen et al., 2011), the United States (Jones et al., 
2012; Jurgens, Hoke et al., 2009; Jurgens, Moser et al., 2009; C. S. Lee et al., 2014; K. S. 
Lee et al., 2010; Moser et al., 2011; Parshall et al., 2001; Walke et al., 2007; Webel et al., 
2007; Zambroski et al., 2005), Korea (Song et al., 2010), Italy (Opasich et al., 2008), the 
United Kingdom (Austin et al., 2012), and throughout Europe (Ekman, et al. 2005). 
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Researchers assessed symptom patterns using the MLHFQ (or a subset of items) 
(Austin et al., 2012; Jurgens, Moser et al., 2009; K. S. Lee et al., 2010), the ESAS 
(Opasich et al., 2008; Walke et al., 2007), the MSAS-HF (Song et al., 2010; Zambroski et 
al., 2005), the HFSPS (Jurgens, Hoke et al., 2009; C. S. Lee et al., 2014), the Borg scale 
of perceived exertion (Riegel et al., 2010), the Daily Symptom Scale (Moser et al., 2011), 
and visual analog or numeric rating scales for various symptoms (Janssen et al., 2011; 
Parshall et al., 2001; Riegel et al., 2010; Webel et al., 2007), or researcher-developed 
rating scales (Ekman et al., 2005; Gallagher et al., 2012; Parshall et al., 2001). The 
variety of instruments and approaches to measuring symptom severity or distress 
complicates comparisons across studies. 
Even when the same instrument was used, researchers varied time frames. For 
example, Zambroski et al. (2005) and Song et al. (2010) both used the MSAS-HF, but 
Song et al. (2010) used a modified version and asked participants to evaluate their 
symptoms over the last 2 weeks, whereas Zambroski et al. (2005) used the original 
version and asked participants to assess their symptoms over the last week.  
The ability to assess variations in symptom perceptions or severity over time was 
limited by the use of cross-sectional study designs (Gallagher et al., 2012; Janssen et al., 
2011; Jurgens, Hoke et al., 2009; C. S. Lee et al., 2014; Opasich et al., 2008; Parshall et 
al., 2001; Riegel et al., 2010; Song et al., 2010; Zambroski et al., 2005). Longitudinal 
data provided greater insights related to symptom variability over time. For example, 
Walke et al. (2007) demonstrated increases over 2 years in reports of and severity of HF-
specific symptoms, such as shortness of breath and fatigue, as well as in symptoms that 
are less specific for HF, such as pain and depression.   
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Although comorbidities are important in clinical management, their relevance to 
severity, frequency, or patterns of HF symptoms is less clear. In examining contributions 
of comorbidities (lung disease, diabetes, renal disease, and PVD) to symptom clusters, 
Jurgens, Moser et al. (2009) found that diabetes mellitus was the only comorbidity to 
predict a symptom cluster (the emotional cluster) in patients with HF. Participants 
reporting high physical and emotional/cognitive distress in K. S. Lee et al.’s (2010) study 
had more comorbidities. Finally, Walke et al. (2007) found that symptom burden 
increased over time in relation to a higher number of coexisting illnesses, but this 
relationship was not statistically significant. 
Findings that described the relationship between age and symptom pattern 
characteristics in HF also varied, in part because of widely variable criteria for age group 
comparisons across studies. Janssen et al. (2011) did not find a significant relationship 
between the number of symptoms and age in an HF group with a mean age 76.2 years. 
Alternatively, Jurgens, Moser et al. (2009) found that older age (75 years or older) made 
significant contributions to three symptom clusters. Also within this study, although older 
participants reported more symptoms, the impact of symptoms on their lives was less 
distressful compared with the younger group. This finding is consistent with findings of 
K. S. Lee et al. (2010) that participants who reported less emotional/cognitive distress 
were older. Jurgens, Hoke et al. (2009) found that age did not make significant 
contributions to differences in symptom distress scores, but that the majority of 
participants in this elderly cohort (65 years and older) were unable to identify HF 
symptoms or recognize their significance. 
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In Riegel et al.’s (2010) study, significant differences in symptom identification 
between the younger group (younger than 73 years) and the older group (age 73 years or 
older) were only found immediately after a 6MWT, not before or 5 minutes after the 
6MWT. Similar to findings from Jurgens, Hoke et al.’s (2009) study, qualitative data also 
indicated that the older group had more difficulty in identifying and interpreting shortness 
of breath and fatigue as relevant to their HF management compared with the younger 
group. Older participants attributed shortness of breath to being out of shape, fatigue to 
poor sleep or excessive daytime activity, and ankle edema to arthritis (Riegel et al., 
2010). Zambroski et al. (2005) found that nausea was significantly more common in 
older participants (patients 55 years and older) compared with younger participants (54 
years or younger), and shortness of breath and waking up breathless at night were 
significantly more distressing and burdensome in younger participants. 
 Only a few studies found significant differences in symptom patterns by gender. 
Zambroski et al. (2005) found that a greater number of women reported feeling nervous 
and sweating compared with men. Men reported significantly greater reoccurrence of 
sexual problems and significantly more distress associated with sexual problems. 
Although K. S. Lee et al. (2010) found that women reported significantly greater distress 
from select symptoms (fatigue/increased need to rest, sleep problems, and depression) 
compared with men, the authors did not detect significant differences by gender in 
symptom clusters. In addition, Jurgens, Hoke et al. (2009) did not find significant 
differences in symptom distress scores by gender.  
In conclusion, HF is characterized by a wide array of symptoms that may occur in 
isolation or together with varying degrees of frequency, severity, and patterns of onset or 
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relief. Some individuals living with HF may not recognize that certain symptoms are 
likely due to their HF. Ambiguity in symptom patterns and the unpredictability of these 
patterns contribute to uncertainty in HF and create challenges for individuals living with 
HF over time. Researchers’ ongoing attention to a better understanding of symptom 
patterns and how these patterns can impact clinically important outcomes and patient-
centered care highlights the significance of symptom management as a key component of 
improving the experience of living with HF.  
79 
CHAPTER 3 
METHODS 
 
 This chapter addresses: (1) study design; (2) specific aims and research questions; 
(3) site and setting; (4) sample; (5) study procedures, including recruitment, enrollment, 
consent, data collection, and handling; (6) variables and measurements; (7) data analysis; 
and (8) human protection issues.  
Study Design 
A descriptive, exploratory design with cross-sectional data collection was used to 
examine reports of personal growth and to explore potential relationships between 
personal growth and relevant demographic, clinical, and cognitive factors in community-
residing adults living with class II-IV HF. This research was guided by Tedeschi and 
Calhoun’s (2004) work on PTG and Mishel’s (1990) RUIT. A convenience sample of 
participants meeting study criteria was recruited from an outpatient cardiology clinic. 
Once informed consent was obtained, participants were asked to complete questionnaires 
assessing personal growth, uncertainty, and symptoms. In addition, demographic and 
clinical data were collected either via participant self-report, provider report, or through a 
medical record review.    
Specific Aims and Research Questions 
 The specific aims of this exploratory study were to: (1) describe levels of personal 
growth in adults living with NYHA class II-IV HF; (2) explore the relationship of 
personal growth with age, sex, ethnicity, disease severity, time since diagnosis, symptom 
status, and uncertainty levels; and (3) determine the extent to which variance in personal 
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growth in individuals living with NYHA class II-IV was accounted for by age, sex, 
ethnicity, disease severity, time since diagnosis, symptom status, and uncertainty. The 
following research questions addressed these specific aims: 
1. Do adults living with NYHA class II-IV HF report personal growth following 
their diagnosis of HF?  
2. To what extent are age, sex, ethnicity, disease severity, time since diagnosis, 
symptom status, and uncertainty levels associated with personal growth in 
individuals with HF?  
3. Which variables (age, sex, ethnicity, disease severity, time since diagnosis, 
symptom status, or uncertainty levels) make independent contributions to personal 
growth in individuals living with NYHA class II-IV HF? 
Site and Setting 
 This study was conducted at an outpatient cardiology clinic located in San 
Antonio, Texas. San Antonio is the seventh largest city in the United States and the 
second largest city in the state of Texas (City of San Antonio, 2012). Approximately, 
1,785,704 individuals live in San Antonio and the surrounding area of Bexar County, 
which spans approximately 1,240 square miles (U.S. Department of Commerce, 2012). In 
Bexar County, more than 60% of the population is 18 years and older, with 10.4% of the 
population estimated to be 65 years and older. Approximately 50.9% of this population is 
female. People of Hispanic or Latin origins make up the majority (58.9%), whereas 
White persons of non-Hispanic origin make up 30.2% of the population (U.S. 
Department of Commerce, 2012).  
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The cardiology clinic serves a large local and referral HF population. The practice 
was established in 1975 and currently employs three physician providers and two 
advanced practice nurses (APNs). HF patients are primarily managed by one physician 
and one APN. Patients classified as NYHA class II are seen at least annually and NYHA 
class III-IV patients are seen weekly to monthly, based on their level of stability. The 
goal of the HF clinic is to optimize outpatient treatment to prevent hospital admissions 
(V. Paparelli, personal communication, September 13, 2014).  
Sample 
A convenience sample was recruited from this outpatient cardiology clinic. 
Inclusion criteria for the participants were (1) adults (≥ 18 years of age) with NYHA 
class II-IV HF, (2) community-residing, (3) able to speak and understand English, and (4) 
capable of providing informed consent. Exclusion criteria were (1) pregnant women, (2) 
children (< 18 years of age), and (3) prisoners. 
Sample size was estimated using G*Power (version 3.17; Heinrich Heine 
Universität Düsseldorf, 2013). The target sample established for this study was 120 to 
achieve 80% power to detect a medium standardized effect size (f
2
 = .15, equivalent to a 
model R
2
 = .13 against a null hypothesis that R
2
 = 0) at an alpha error level of .05 for a 
regression model with up to seven predictors, while allowing for up to 15% incomplete or 
nonreturned surveys. 
Recruitment, Enrollment, and Consent 
Prior to submitting the protocol to the Human Research Review Committee 
(HRRC) at the University of New Mexico (UNM) Health Sciences Center, I made initial 
contact with an APN, who had been working in a local cardiology clinic for several 
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years, helping to manage the clinic’s HF population. Over the next 3 months, the two of 
us communicated on a regular basis to assess the feasibility of conducting my study at 
this clinic. Subsequently, the clinic provided a letter of support to the HRRC, indicating 
that they were willing and eager to serve as the primary research site for the study, that 
the target sample size was realistic and achievable based on their current population, and 
that they were prepared to help ensure that study procedures met the requirements of the 
HRRC. 
After obtaining approval from the HRRC at UNM, recruitment commenced. 
Participants were recruited primarily through recruitment flyers (Appendix C), which 
were available in the office and given to HF patients by providers during scheduled 
appointments. The role of the clinical staff was limited to providing the flyer, verifying 
patients’ interest in learning more about the study, and referring potentially interested 
patients to me. If potentially eligible participants verbalized interest in the study and I 
was present in the clinic, I met with them in person before or after scheduled 
appointments. If I was not available in the clinic, initial contact occurred over the phone, 
at the request of the patient, and a time was scheduled to meet in person at the clinic. At 
this time, I provided interested participants with a verbal and written description of the 
study and screened them for eligibility. 
In addition to the use of flyers as a recruitment strategy, I also sent recruitment 
letters to potentially eligible patients (Appendix D), which indicated that the study was 
ongoing and had the endorsement of the clinic. A Health Insurance Portability and 
Accountability Act (HIPAA) Waiver of Authorization for recruitment only, obtained 
from the HRRC, permitted review of medical records using HF diagnostic criteria to 
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identify potentially eligible participants who may not have had scheduled appointments 
during the recruitment phase. A total of 180 recruitment letters were mailed. I received 16 
calls from individuals who had received letters. Three of these individuals chose not to 
participate, expressing concerns related to distance, a recent change in cardiology 
providers, and, in one case, a limited ability to understand English. Thirteen of the callers 
were interested in participating and most set up appointments to meet with me at the 
clinic during a scheduled appointment or at a time that was mutually convenient and were 
subsequently enrolled in the study. In a few cases, individuals were unable to meet me in 
person, so a modification request was obtained from HRRC to allow me to screen 
participants over the phone and obtain signed consent and HIPAA authorization through 
the mail.  
In all cases, after screening potential participants for eligibility, a signed informed 
consent and HIPAA Authorization for Use and Disclosure of Protected Health 
Information (Appendix E) was obtained from all who agreed to participate. Participants 
were given a copy of the combined informed consent/HIPAA document after a copy was 
scanned into their medical record.  
A total of 107 individuals were enrolled in the study. Two participants withdrew: 
1 female participant, who had a phone interview scheduled, called to indicate that she 
was too busy to participate, and 1 male participant called after completing the survey data 
to indicate that he no longer felt comfortable participating in the study. In addition, 2 
participants did not return the survey data, resulting in a final sample of 103, which was 
adequate to achieve 80% power based on the power analysis.  
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Data Collection and Handling 
Once informed consent and HIPAA authorization were obtained, each participant 
was assigned a unique study identification (ID) number. Participants were asked to 
complete the following questionnaires: (a) a demographic and clinical questionnaire, (b) 
the PTGI (Appendix F), (c), the MUIS-C (Appendix G), and (d) MSAS-HF (Appendix 
H). These questionnaires were combined into one survey that did not include any 
protected health information (Appendix I). Supplementary clinical data were obtained 
from the medical record or via provider report and stored in a separate data file that could 
be linked to the survey data by study ID number (Appendix J). Both the survey data file 
and the clinical data file were stored in REDCap
TM
 (Research Electronic Data Capture), 
an encrypted, web-based data collection system developed specifically to ensure 
confidentiality of study records. REDCap
TM
 is made available to UNM Health Sciences 
Center faculty by the UNM Clinical and Translational Science (CTSC). 
 Participants were given the option of completing the survey electronically or on 
paper. Electronic access was via a secure web portal to REDCap
TM
 from the electronic 
device of the participant’s choice. Participants who did not feel comfortable completing 
the surveys electronically or did not have Internet access completed paper copies of the 
survey either in person or via the mail. Participants were also given the option to 
complete the survey via a phone or in-person interview conducted by the researcher. All 
data that were documented on paper by either the participant or the researcher were 
entered into REDCap
TM 
by the researcher as soon as possible. Original copies of surveys 
were kept in a locked file cabinet, separate from any files that included identifiable 
information and were only accessible to the primary researcher.    
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Variables and Measures 
 Variables examined in this study included personal growth (the dependent 
variable included in the regression analysis) and the following independent or predictor 
variables: age, sex, ethnicity, disease severity, time since diagnosis, symptom status, and 
uncertainty.  
Demographic and Clinical Data 
Demographic and clinical data that were collected and examined as predictor 
variables in this investigation included age; sex; ethnicity; NYHA class, as a measure of 
disease severity; and time since diagnosis in years. In addition, to better assess significant 
differences in population characteristics and to support possible additional exploratory 
analyses, the following data were also collected: race, years of education, highest 
educational degree, marital/partner status, etiology of HF, number of hospitalizations 
within the last year for HF, ejection fraction (if documented within the last year) and how 
ejection fraction was established, comorbidities, and current cardiac medications. 
Demographic data were collected as part of the combined questionnaire (Appendix I). 
Clinical data were predominantly collected by the researcher through a medical record 
review or, in a few cases in which clinical data were not available in the medical record, 
via provider report (Appendix J).   
Growth 
Personal growth was measured using total growth scores from the PTGI 
(Tedeschi & Calhoun, 1996).  The PTGI is a 21-item instrument that measures an 
individual’s perceptions of favorable changes that occur as a result of dealing with a 
traumatic life event (see Appendix F). It consists of the following five domains: (a) new 
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possibilities (5 items); (b) relating to others (7 items); (c) personal strength (4 items); (d) 
appreciation of life (3 items); and (e) spiritual change (2 items). For items within each 
domain, participants are asked to rate the degree of change that occurred as a result of 
their adverse life event on a 6-point Likert scale, with zero indicating no change and five 
indicating the greatest degree of positive change. A total growth score is calculated by 
adding the individual items scores. The maximum total growth score that can be obtained 
is 105.  
Although the PTGI was originally developed and tested in a sample of healthy 
college students, it has been widely used in older individuals with medical illnesses, 
including populations with cancer, heart disease, HIV, and neurological, orthopedic, or 
burn injuries (Barskova & Oesterreich, 2009). Initial construct validity was established 
by comparing total PTG scores from a group of individuals who reported experiencing a 
major trauma in the last year with scores from a group of individuals who denied 
experiencing a major trauma in the last year. Participants who reported a major trauma 
reported greater growth and results were significant (Tedeschi & Calhoun, 1996). 
Concurrent validity was established by demonstrating significant, positive 
correlations between total PTG scores and scores of optimism, extraversion, openness to 
experience, agreeableness, conscientiousness, and religious involvement, personality 
factors and variables theoretically thought to be related to growth. Correlations between 
total PTG scores and scores of neuroticism were not associated, supporting discriminant 
validity (Tedeschi & Calhoun, 1996). In addition, to ensure that PTG scores did not 
simply reflect social desirability, correlations between PTG scores and scores from the 
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Marlowe-Crowne Social Desirability Scale were analyzed and found to be unrelated 
(Tedeschi & Calhoun, 1996).   
In a review of growth measurement scales, Park and Lechner (2006) reported 
scale intercorrelations ranging from r = 0.62 to r = 0.83, Cronbach’s alpha values ranging 
from 0.67 (appreciation of life subscale) to 0.90 (total growth score), and adequate test–
retest reliability values over 2 months for the total growth score (r = 0.71), but weaker 
test–retest reliability values for select subscales, such as the personal strength scale (r = 
0.37). Test–retest reliability assessments may not be the most appropriate measure of 
reliability because personal growth may not reflect a stable construct. Studies that used an 
English version of the PTGI in populations with heart disease demonstrated Cronbach’s 
alpha values for total growth scores of 0.96 (Leung et al., 2010; Sheikh, 2004). Leung et 
al. (2010) also reported Cronbach’s alpha values for the individual subscales as follows: 
new possibilities, 0.87; relating to others, 0.92; personal strength, 0.85; appreciation of 
life, 0.74; and spiritual change, 0.87.  
Symptom Status 
Symptom status was measured using the MSAS-HF, which is a 32 item 
instrument that assesses the presence, frequency, severity, and distress of symptoms 
experienced in HF (Zambroski et al., 2004; Appendix H). The MSAS-HF is a modified 
version of the original Memorial Symptom Assessment Scale (MSAS) which was 
designed for use in cancer populations (Portenoy et al., 1994). The MSAS-HF includes 
five additional HF-specific symptoms (chest pain, palpitations, waking up breathless at 
night, difficulty breathing while lying flat, and weight gain) and excludes five of the 
original cancer-related symptoms (don’t look like myself, mouth sores, hair loss, 
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difficulty swallowing, and changes in skin). The MSAS-HF consists of the following 
three subscales, physical symptoms, psychological symptoms, and HF-specific 
symptoms.  
Participants initially indicate the presence or absence of a variety of symptoms 
over the previous week. If a symptom is present, the participant is then asked to assess its 
frequency on a 1- to 4-point scale, with 1 indicating rarely and 4 indicating almost 
always, and to report both its severity on a 1- to 4-point scale, with 1 indicating mild 
severity and 4 indicating very severe, and its distress on a 0- to 4-point scale, with lower 
scores indicating no distress and 4 indicating very much distress. Higher scores indicate 
greater symptom frequency, severity, and distress. Consistent with guidelines established 
by Portenoy (1994) for the original MSAS and adopted by Zambroski et al., (2004), 
distress scores are calculated using the following scale: 0.8 for not at all, 1.6 for a little 
bit, 2.4 for somewhat, 3.2 for quite a bit, and 4 for very much. A total symptom 
prevalence score is calculated by adding the number of symptoms present. A symptom 
burden score is calculated by adding the symptom frequency, severity, and distress scores 
of individual symptoms, as applicable, and determining the mean. A total symptom 
burden score is determined by summing the symptom burden scores for each symptom 
and then determining the overall mean of all reported symptoms. In this study, the total 
symptom burden score was used to measure symptom status.   
Construct validity of the MSAS-HF was established by demonstrating greater 
symptom prevalence in an HF population compared with healthy adults not diagnosed 
with HF (Zambroski et al., 2004) and supported by findings that demonstrated significant 
associations between symptom presence and burden scores and HF HRQOL (Bekelman 
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et al. 2007; Zambroski et al., 2005) Preliminary reliability of the MSAS-HF has been 
established (Zambroski et al., 2004). Zambroski et al. (2005) reported Cronbach’s alpha 
coefficients of 0.92 for the total symptom score, 0.83 for the psychological subscale, 0.87 
for the physical subscale, and 0.73 for the HF-specific subscale. Song et al. (2010) used a 
modified version of the MSAS-HF to measure prevalence and distress of select physical 
symptoms and reported a Cronbach’s alpha coefficient of 0.81.  
Uncertainty 
Uncertainty was measured using the MUIS-C. The MUIS-C is a 23-item, one-
factor scale that was developed from the original MUIS-A (Mishel, 1981) to measure 
perceived uncertainty in illness in individuals not acutely ill or hospitalized (Mishel, 
1997). The MUIS-C contains the same items as the MUIS-A, with the exception of items 
related to treatment and communication in a hospital setting (Appendix G). Participants 
respond to questions using a 5-point Likert scale, with 1 indicating strongly disagree and 
5 indicating strongly agree. After reverse scoring select items according to established 
instructions, items are summed to provide a total uncertainty score. Composite 
uncertainty scores range from 23, reflective of low levels of uncertainty, to 115, 
indicative of very high levels of uncertainty.  
Construct validity and sensitivity have been established in studies primarily using 
the original MUIS-A (Mishel, 1997). Cronbach’s alpha values for the MUIS-C have been 
reported to be between 0.53 and 0.92, with the majority in the moderate-to-high range 
(Mishel, 1997). In an HF population, Jurgens (2006) reported a Cronbach’s alpha of 0.78. 
In other cardiac populations, a Cronbach’s alpha of 0.87 has been reported (Carroll, 
Hamilton, & McGovern, 1999).   
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Normative data synthesized from 20 studies using the MUIS-C in a variety of 
illness populations indicated no differences in mean uncertainty scores related to sex or 
age, but demonstrated a differences in mean uncertainty scores related to education, with 
mean uncertainty scores decreasing with greater education (Mishel, 1997). 
Data Analysis 
Statistical analysis was performed using IBM
®
 SPSS
® Statistics (version 22). 
Preliminary analyses using descriptive statistics and graphical displays were conducted to 
check for missing data or out-of-range values and to describe the sample. For 
demographic and clinical data and questionnaire scores, descriptive statistics included 
frequencies and percentages, means and standard deviations, or medians and percentages, 
as appropriate, based on measurement level and distributional characteristics. In addition, 
preliminary analyses were used to help assess assumptions for planned statistical 
procedures. 
Internal consistency of the measures of growth, uncertainty, and burden scores for 
each symptom were assessed using Cronbach’s alpha coefficients. Inter-item correlations, 
Cronbach’s alpha if the item was deleted, and corrected item total correlations were also 
reviewed. (Cronbach’s alpha cannot be estimated for the total burden score because 
individuals differ in the symptoms they report.) 
Bivariate correlations between continuous variables (age, time since diagnosis, 
total growth scores, total symptom burden scores, and total uncertainty scores) were 
analyzed using Pearson product-moment correlation coefficients. Hierarchical multiple 
regression with variables entered in three successive blocks was conducted to determine 
whether PTGI scores were predicted by a model consisting of the following independent 
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variables: age, sex, ethnicity, disease severity, time since diagnosis, symptom burden 
scores, and uncertainty scores. Demographic variables (age, sex, and ethnicity) were 
entered first, followed by clinical variables (disease severity and time since diagnosis) 
and then total symptom burden and uncertainty scores. 
Analysis to determine which predictors made significant independent 
contributions to the model, while controlling for the other predictors in the model, was 
planned. Supplemental analyses assessed whether assumptions of normality, linearity, 
homoscedasticity, multivariate outliers, and independence of residuals were satisfied and 
whether multicollinearity was problematic. 
 Two-sample t tests were conducted to determine whether personal growth scores 
differed by sex, ethnicity, and disease severity. For any significant differences, point-
biserial correlations were used as an effect size estimate. Additional exploratory analyses 
were performed to generate a better depiction of symptom prevalence and burden and 
reports of uncertainty in this sample.  
Human Protection 
 This study was approved by the HRRC at UNM. The study did not include any 
vulnerable populations. Each phase of the study, from recruitment to completion, was 
clearly outlined in the HRRC-approved protocol to ensure adherence to principles of 
responsible conduct of research with human subjects. Participants who were eligible and 
agreed to participate signed a combined informed consent and HIPAA Authorization for 
Use and Disclosure of Protected Health Information (Appendix E). The HIPAA 
authorization allowed the researcher to access the participants' medical record for clinical 
information relevant to the study; these data were clearly described within the informed 
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consent. The informed consent provided a detailed description of the study so that the 
participants had all the information they needed to make an informed choice about 
whether to participate given the study’s risks and benefits. Participants were reassured 
that their involvement was voluntary and that declining to participate would not impact 
their usual medical care. Participants were notified that they could withdraw from the 
study at any time without any adverse ramifications.  
 Because the study primarily involved questionnaire measures and did not involve 
sampling of blood or tissues, risks of participation were mainly fatigue or distress from 
answering several questionnaires. The questionnaires themselves did not involve 
questions about highly sensitive matters, but did focus on significant life events in 
relation to a diagnosis of HF. Participants were informed that they could skip any 
questions that made them uncomfortable, stop answering questions at any time, or 
withdraw if they preferred. Participants were also given the choice of how they preferred 
to complete the survey (on paper, electronically, or via a researcher-conducted interview) 
to minimize fatigue, distress, or any perceived inconvenience from completing multiple 
questionnaires. There were no direct benefits to participation, but participants were 
informed that the results of the study were expected to enhance understanding of 
psychosocial aspects of HF and could contribute to future improvements in care that may 
benefit others with the condition. Once the survey was completed and returned, 
participants were given a $20.00 gift card as a token of appreciation for their time and 
effort.  
As with all research, there was a risk of loss of confidentiality and/or privacy. A 
HIPAA Waiver of Authorization for recruitment only was approved by the HRRC to 
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facilitate recruitment of potentially eligible participants not seen in the clinic during the 
recruitment phase. In addition, the primary researcher signed a Medical Record Access 
Agreement, Confidentiality and Non-Disclosure Agreement, and HIPAA Confidentiality 
Agreement with the cardiology clinic. Names and addresses of potentially eligible 
participants were documented on a recruitment tracking form that was kept in a locked 
file cabinet in a secure office space, only accessible to the primary researcher. 
Recruitment letters were addressed by hand by the primary researcher while in the clinic 
and mailed as soon as possible, at which time, the recruitment tracking form was 
destroyed.  
Participants who agreed to take part in the study signed an informed consent and 
HIPAA authorization form that clearly outlined potential risks. Participants were also 
provided a copy of this document for their records. To minimize the risk of loss of 
confidentiality, participants’ names and other identifying information was maintained in a 
locked file cabinet, separate from the survey data, in a secure office space, only 
accessible to the primary researcher. At the completion of the study, any personal 
identifying information and any record linking that information to the study identification 
numbers were shredded and destroyed. For any survey data entered into REDCap
TM 
and 
subsequently exported to SPSS, the only identifiers were unique study identification 
numbers, which were assigned to each participant. Only members of the research team 
had access to these data. These data were stored and accessible to the research team for a 
period consistent with the policies and procedures of the UNM CTSC and HRRC.  
To protect participants’ privacy, participants were only approached if they 
verbalized interest in learning more about the study after receiving a recruitment letter or 
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a flyer. Recruitment materials clearly indicated that participation was voluntary and 
outlined how to contact the researcher if an individual was interested. Private space in the 
clinic was provided to the primary researcher to meet with interested patients to discuss 
the study, obtain informed consent, and complete the survey if participants chose to do so 
while in the clinic.  
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CHAPTER 4 
RESULTS 
 
 A sample of 103 participants completed the surveys. The majority (58%) 
completed the surveys via an in-person interview with the researcher, 40% completed the 
surveys on paper, and 2% completed the surveys electronically. Survey responses entered 
into REDCap
TM 
and exported to SPSS were reviewed for missing data. Participants 
responded to all clinical and demographic questions, with the exception of 3 participants 
who did not answer the question regarding the number of years of education; however, 
those individuals did respond to the item addressing highest educational (degree) level. 
Survey questionnaires had a minimal amount of missing data. Participants had been 
informed that they could skip questions that made them uncomfortable or that they 
preferred not to answer. Eight cases included missing data for only one or two items on 
the combined questionnaires. In one case, a participant did not respond to six items on the 
MUIS-C and one symptom on the MSAS-HF. This individual wrote “No answer fit” next 
to items that were skipped on the MUIS-C. The highest percentage (4%) of missing data 
on any one item addressed problems with sexual interest/activity on the MSAS-HF. Of 
the cases with missing data, six were completed on paper, two via in-person interview, 
and one electronically.  
Sample Description 
Sample demographic and clinical characteristics are shown in Tables 1 and 2. The 
sample was predominantly White, male, married or living with a partner, and educated at 
or above the high-school level, with ages ranging from 27 to more than 90 years.   
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Table 1 
Demographic Characteristics (N = 103, except as noted) 
Characteristic N (%) Mean (SD) 
Age, years  73.71 (12.58) 
Sex   
Male 78 (75.7)  
Female 25 (24.3)  
Married or living with a partner   
Yes 72 (69.9)  
No 31 (30.1)  
Race   
      Asian 1 (1.0)  
      African American 2 (1.9)  
      White 96 (93.2)  
      Other 2 (1.9)  
      Prefer not to answer 2 (1.9)  
Ethnicity   
      Hispanic 19 (18.4)  
      Not Hispanic 83 (80.6)  
      Prefer not to answer 1 (1.0)  
Highest number of years  
of education
a 
 14.82 (3.51) 
 
Highest educational level   
      < 12 years 5 (4.9)  
      High school graduate/GED 44 (42.7)  
      Associate’s degree 6 (5.8)  
      Bachelor’s degree 26 (25.2)  
      Graduate degree 22 (21.4)  
__________________________________________________________________ 
a
N = 100. 
 
In most cases, ischemic heart disease was documented as the cause of HF. The 
majority of participants met criteria for NYHA functional class II or III. Diabetes and 
pulmonary disease were the two most common noncardiac comorbidities, followed by 
peptic ulcer disease, cancer, chronic kidney disease, and peripheral vascular disease. 
More than half of the sample had lived with a diagnosis of HF for more than 10 years 
(range 1 to 30 years).  
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Table 2 
Clinical Characteristics (N = 103 except as noted) 
Characteristic n (%) 
Ejection fraction documented within last year
a 
 
             ≤ 40% 45 (49.5) 
              > 40% 46 (50.5) 
Etiology of heart failure
b 
 
              Ischemic heart disease 67 (65.0) 
              Hypertension 19 (18.4) 
              Cardiomyopathy 38 (36.9) 
              Other 7 (6.8) 
NYHA functional class  
              II 53 (51.5) 
              III 46 (44.7) 
              IV 4 (3.9) 
Hospitalized within last year for heart failure 40 (38.8) 
Significant medical history       
              Peripheral vascular disease 18 (17.5) 
              Stroke 9 (8.7) 
              Diabetes 35 (34.0) 
              Chronic pulmonary disease 34 (33.0) 
              Connective tissue disorder 4 (3.9) 
              Cancer 28 (27.2) 
              Peptic ulcer disease 29 (28.2) 
              Chronic kidney disease 26 (25.2) 
              Depression 17 (16.5) 
              Anxiety/mood disorder 11 (10.7) 
Medications  
              ACE inhibitor 53 (51.5) 
              Angiotensin receptor blocker 26 (25.2) 
              Beta blocker 92 (89.3) 
              Diuretic 82 (79.6) 
              Digoxin 28 (27.2) 
              Vasodilator 30 (29.1) 
              Milrinone 13 (12.6) 
Years since diagnosis  
              0-1 year 6 (5.8) 
              2-3 years 8 (7.8) 
              4-5 years 13 (12.6) 
              6-9 years 18 (17.5) 
              10-19 years 24 (23.3) 
              20-29 years 17 (16.5) 
              ≥ 30 years 17 (16.5) 
Note. NYHA = New York Heart Association; ACE = angiotensin converting enzyme. 
a
N = 91; 12 participants did not have an ejection fraction documented within the last year. 
b
Some 
participants had multiple etiologies documented. 
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Personal Growth in HF 
 Total growth scores from the PTGI were examined to answer the first research 
question, “Do adults living with NYHA class II-IV HF report personal growth following 
their diagnosis of HF?” Only one case had missing data for a single item that addressed 
improvements in religion. The PTGI total growth score demonstrated very good internal 
consistency (Cronbach’s α = .96); the deletion of any single item on the PTGI did not 
improve reliability. Inter-item correlations ranged from .23 to .75, with a mean of .52. 
The weakest correlation (r = .229) was between the items I discovered that I am stronger 
than I thought I was and I changed my priorities about what is important in life. The 
corrected item total correlations ranged from .59 to .78. 
 The mean for the total growth score was 48.6 (SD = 28.6), with a range of 
possible scores of 0 to 105, indicating that this sample reported experiencing a moderate 
degree of personal growth as a result of their HF diagnosis. Responses to individual items 
ranged from 0, if the participant did not experience any degree of change, to 5, indicating 
that the participant experienced a change to a very great degree as a result of his or her 
HF diagnosis. As shown in Figure 1, four items had modal categories greater than or 
equal to 4, indicating that participants experienced change in these areas either to a great 
or very great degree. Alternatively, as outlined in Table 3, 13 items had a mode of 0, 
indicating that participants did not report any change in these areas. A closer examination 
of responses to individual items demonstrated that in some areas in which greater change 
was reported by a high percentage of participants, a substantial number of individuals in 
these same areas reported no change and vice versa. 
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I have a greater appreciation for the value of my own life. 
 
 
I more clearly see that I can count on people in times of trouble.  
 
 
I can better appreciate each day. 
 
 
I learned a great deal about how wonderful people are.  
 
 
Figure 1. Percentages for PTGI items with modes ≥ 4.  
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Table 3  
Frequencies and Percentages for PTGI Items With Modes Equal to Zero
a
 
Item N (%) 
Change in priorities  
No change 35 (34.0) 
Very small 5 (4.9) 
Small 8 (7.8) 
Moderate 20 (19.4) 
Great 18 (17.5) 
Very great 17 (16.5) 
Developed new interests  
No change 54 (52.4) 
Very small 5 (4.9) 
Small 13 (12.6) 
Moderate 11 (10.7) 
Great 14 (13.6) 
Very great 6 (5.8) 
Greater feeling of self-reliance  
No change 54 (52.4) 
Very small 5 (4.9) 
Small 5 (4.9) 
Moderate 16 (15.5) 
Great 14 (13.6) 
Very great 9 (8.7) 
Better understanding of spiritual matters  
No change 45 (43.7) 
Very small 3 (2.9) 
Small 6 (5.8) 
Moderate 10 (9.7) 
Great 23 (22.3) 
Very great 16 (15.5) 
Established a new path for my life  
No change 48 (46.6) 
Very small 2 (1.9) 
Small 5 (4.9) 
Moderate 20 (19.4) 
Great 15 (14.6) 
Very great 13 (12.6) 
Greater sense of closeness with others  
No change 32 (31.1) 
Very small 3 (2.9) 
Small 9 (8.7) 
Moderate 20 (19.4) 
Great 24 (23.3) 
Very great 15 (14.6) 
More willing to express emotion  
No change 38 (36.9) 
Very small 3 (2.9) 
Small 7 (6.8) 
Moderate 31 (30.1) 
Great 20 (19.4) 
Very great 4 (3.9) 
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Table 3 (cont.) 
 
 
Item N (%) 
Know better that I can handle difficult situations 
No change 
 
33 (32.0) 
Very small 5 (4.9) 
Small 8 (7.8) 
Moderate 23 (22.3) 
Great 27 (26.2) 
Very great 7 (6.8) 
Able to do better things with my life  
No change 43 (41.7) 
Very small 7 (6.8) 
Small 8 (7.8) 
Moderate 23 (22.3) 
Great 11 (10.7) 
Very great 11 (10.7) 
Better able to accept the way things work out  
No change 33 (32.0) 
Very small 3 (2.9) 
Small 7 (6.8) 
Moderate 28 (27.2) 
Great 20 (19.4) 
Very great 12 (11.7) 
New opportunities are available  
No change 62 (60.2) 
Very small 6 (5.8) 
Small 7 (6.8) 
Moderate 9 (8.7) 
Great 12 (11.7) 
Very great 7 (6.8) 
Stronger religious faith
b  
No change 42 (40.8) 
Very small 2 (1.9) 
Small 7 (6.8) 
Moderate 10 (9.7) 
Great 23 (22.3) 
Very great 18 (17.5) 
Discovered I am stronger than I thought I was  
No change 37 (35.9) 
Very small 2 (1.9) 
Small 7 (6.8) 
Moderate 20 (19.4) 
Great 24 (23.3) 
Very great 13 (12.6) 
a
N = 103. 
b
N = 102. 
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For example, although more than 50% of participants reported that they learned a 
great deal about how wonderful people are to at least a great degree as a result of living 
with HF, 26% reported no change in this area. Alternatively, although 44% of individuals 
reported that they did not develop a better understanding of spiritual matters, more than 
37% reported experiencing enhanced spirituality to a great or very great degree as a result 
of their HF diagnosis. 
To generate a better understanding of the type of personal growth experienced in 
this population, descriptive statistics with Cronbach’s alpha coefficients were generated 
for the PTGI subscales and are outlined in Table 4. Participants in this study reported the 
greatest change in appreciation for life and the least amount of growth in new 
possibilities. All of the mean per-item scores except for new possibilities fall on average 
between a small (2) and moderate (3) degree of change.  
 
Table 4 
Characteristics of PTGI Subscales 
Subscale Mean (SD) 
Cronbach’s 
 
No. of 
Items 
 
Mean 
score 
per-item 
 
 
Percentage 
of 
maximum 
subscale 
score 
 
      
Appreciation for life 8.53 (4.82) .82 3 2.8 56.9 
Relating to others 18.32 (10.15) .91 7 2.6 52.3 
Spiritual change
a 
4.32 (3.85) .86 2 2.2 43.2 
Personal strength 8.50 (5.98) .82 4 2.1 42.5 
New possibilities 8.97 (7.38) .87 5 1.8 35.9 
      
Note. N = 103. 
a
N = 102 
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Demographic, Clinical, and Cognitive Factors Related to Personal Growth 
 Bivariate correlations were analyzed using Pearson product-moment correlation 
coefficients for all continuous variables and dichotomous categorical variables to answer 
the second research question, “To what extent are age, sex, ethnicity, disease severity, 
time since diagnosis, symptom status, and uncertainty levels associated with personal 
growth in individuals with HF?”  
Assumptions for Correlation Analysis 
Descriptive statistics and graphical displays were generated to assess for 
violations of assumptions. Total personal growth scores, uncertainty scores, and total 
symptom burden scores examined as part of the correlation analysis were at an interval 
level of measurement. Age and time since diagnosis in years were also continuous 
variables. Age was negatively skewed, with three outliers appearing to the far left of the 
distribution and a significant Kolmogorov–Smirnov (K-S) statistic (p = .001). Age was 
recoded to treat values ≤ to 50 years as a single, lowest age, leaving all other values as 
reported.  
Personal growth scores had a multimodal distribution and a significant K-S 
statistic (p = .037), but near-zero skewness. The K-S test was also significant for 
uncertainty scores (p = .026), but the histogram showed a fairly normal distribution, with 
only slightly positive skewness and no outliers. One outlier appeared on the boxplot for 
the total symptom burden score, but there was no significant difference between the mean 
(2.01339) and 5% trimmed mean (2.01066) for this variable, so the case was not 
excluded (Field, 2009). Given the sample size, departures from normality were within 
acceptable limits. Scatterplots examining personal growth scores, age, symptom burden, 
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and uncertainty did not show any obvious nonlinearity. (Field, 2009; Shadish, Cook, & 
Campbell, 2002).  
Sex and ethnicity (Hispanic or Latino vs. Not Hispanic or Latino) were 
dichotomous. One participant preferred not to answer the question assessing ethnicity so 
this case was excluded from the analysis. Only 4 participants met criteria for NYHA class 
IV HF. As a result, disease severity was recoded by combining NYHA class III and IV 
responses, resulting in a dichotomous variable with similar category frequencies. Time 
since diagnosis was recoded into ordinal categories: 1 = 0-1 year, 2 = 2-3 years, 3 = 4-5 
years, 4 = 6-9 years, 5 = 10-19 years, 6 = 20-29 years, and 7 = 30 or more years. Table 5 
shows the descriptive statistics for continuous variables. 
Correlation Results 
Pearson product-moment correlation coefficients are outlined in Table 6. Results 
showed that there was a small, negative correlation between age and total personal 
growth scores (r = –.204, p < .05), indicating that younger participants reported higher 
personal growth. Total symptom burden scores showed a small, positive correlation with 
personal growth (r = .204, p < .05) and a moderate, positive association with uncertainty 
scores (r = .492, p <.01), suggesting that a higher symptom burden is associated with 
greater personal growth and increased levels of uncertainty. Disease severity showed a 
small, positive correlation with age (r = .282, p < .01) and uncertainty scores (r = .279, p 
< .01), indicating that more severe HF was related to older age and greater reports of 
uncertainty. There were no significant associations between personal growth and sex, 
ethnicity, time since diagnosis, or uncertainty.  
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Table 5 
Descriptive Statistics for Continuous Variables 
Variable Min Max Mean SE SD Skewness (SE) Kurtosis (SE) 
Age 50 96 74.26 1.083 10.99 –.536 (.238) –.213 (.472) 
Time since 
   diagnosis
a
 
1 7 4.60 .171 1.734 –.376 (.238) –.684 (.472) 
Personal growth 0 105 48.64 2.820 28.616 –.061 (.238) –1.075 (.472) 
Uncertainty 27 92 52.85 1.430 14.241 .237 (.238) –.566 (.472) 
Symptom status .933 3.340 2.01 .0428 .434 .007 (.238) .133 (.472) 
Note. N = 103. SE = standard error; SD = standard deviation. 
a
1 = 0-1 years, 2 = 2-3 years, 3 = 4-5 years, 4 = 6-9 years, 5 = 10-19 years, 6 = 20-29 years, 7 = ≥ 30 years. 
 
 
 
Table 6 
Pearson Product-Moment Correlation Matrix Between Measures of Personal Growth 
and Age, Sex, Ethnicity, Disease Severity, Time Since Diagnosis, Symptom Status, and 
Uncertainty 
Variables Personal
Growth
a
 
1 2 3 4 5 6 
1. Age –.204*       
2. Sex .080 –.012      
3. Ethnicity –.120 .076 –.035     
4. Disease severity –.076 .282** .039 –.013    
5. Time since diagnosis .038 .088 –.184 –.100 .168   
6. Symptom status
b 
.204
* –.151 .060 –.054 .185 –.015  
7. Uncertainty
c
 .057 .152 .027 –.138 .279** –.054 .492** 
a
Personal growth as measured by the Posttraumatic Growth Inventory total growth score. 
b
Symptom status 
as measured by the Memorial Symptom Assessment Scale–Heart Failure total symptom burden score. 
c
Uncertainty as measured by the Mishel Uncertainty in Illness Scale-Community Version.  
*p < .05 (2-tailed). **p < .01 (2-tailed). 
 
 
Predictors of Personal Growth in HF 
Hierarchical multiple regression was conducted. Demographic variables (age, sex, 
and ethnicity) were entered first, followed by clinical variables (disease severity and time 
since diagnosis) and then total symptom burden scores and uncertainty scores, to answer 
the third research question, “Which variables (age, sex, ethnicity, disease severity, time 
since diagnosis, symptom status, or uncertainty levels) make independent contributions to 
personal growth in individuals living with NYHA class II-IV HF? 
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Assumptions for Multiple Regression 
The final sample of 103 was satisfactory for 80% power to detect a medium 
standardized effect size (f
2
 = .15, equivalent to a model R
2
 = .13 against a null hypothesis 
that R
2
 = 0) at an alpha error level of .05 for a regression model with up to seven 
predictors. Assumptions related to outliers, normality, linearity, homoscedasticity, and 
multicollinearity were assessed.   
As previously noted, there were no serious concerns about univariate normality 
for the continuous variables and no obvious curvilinear bivariate relationships among 
them. There were no significant multivariate outliers as determined by the maximum 
Mahalanobis distance for the continuous variables (df = 4) and for the full regression 
model (df = 7), based on chi-square critical values for p < .001 at the given degrees of 
freedom as the cutoff. 
The histogram of standardized residuals was approximately normally distributed 
in relation to personal growth scores, albeit with fewer cases at the far right. The 
scatterplot of standardized residuals by standardized predicted scores revealed scores 
widely but essentially equally distributed across the ranges for the x and y axes, 
consistent with the assumption of homoscedasticity. There was no indication of 
problematic multicollinearity (maximum variance inflation factor = 1.51 for the full 
model). 
Multiple Regression Results 
Hierarchical multiple regression was conducted. Demographic variables (age, sex, 
and ethnicity) were entered in Step 1, explaining 5.8% of the variance in personal growth. 
After entry of clinical variables (disease severity and time since diagnosis) in Step 2, the 
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total variance explained by the model was 6.3%. Finally, after adding uncertainty and 
symptom scores in Step 3, the total variance in personal growth explained by the model 
as a whole was 9.5%, F(7, 95) = 1.430, p = .202. The model as a whole was not 
statistically significant and individual regression coefficients in the model were also not 
significant. See Table 7 for a summary of the regression model and Table 8 for 
coefficients.  
 
Table 7 
Regression Model Summary
a 
Model R R
2 
R
2
 Change F Change df1 df2 p 
Step 1
b 
.241 .058 .058 2.033 3 99 .114 
Step 2
c 
.251 .063 .005 .254 2 97 .777 
Step 3
d 
.309 .095 .032 1.701 2 95 .188 
Note. N = 103. 
a
Dependent variable: personal growth scores. 
b
Predictors: age, sex, and ethnicity. 
c
Predictors: age, sex, 
ethnicity, disease severity, and time since diagnosis. 
d
Predictors: age, sex, ethnicity, disease severity, time 
since diagnosis, uncertainty, and symptom scores.  
 
 
 
Additional Exploratory Analyses 
Additional descriptive analyses were conducted to generate a better depiction of 
symptom prevalence and burden and reports of uncertainty in this sample. In addition, 
differences in personal growth scores were examined by sex, ethnicity, and disease 
severity.  
Symptom Prevalence and Burden 
 As outlined in Table 9, symptoms that were reported by at least 50% of the 
participants included lack of energy (73.8%), feeling drowsy (58.3%), dry mouth 
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Table 8 
Regression Model Coefficients
a 
Model  B SE(B) β t p 
Step 1  
Constant 
 
93.406 
 
23.715 
 
 
 
 
 
 
 Age –.508 .255 –.195 –1.994 .049 
 Sex 4.944 6.483 .074 .763 .448 
 Ethnicity –7.221 6.891 –.103 –1.048 .297 
Step 2       
 Constant 86.454 25.830  3.347 .001 
 Age –.496 .268 –.191 –1.852 .067 
 Sex 5.890 6.670 .089 .883 .379 
 Ethnicity –6.768 6.991 –.096 –.968 .335 
 Years since diagnosis 1.117 1.689 .068 .661 .510 
 Disease severity –2.163 5.921 –.038 –.365 .716 
Step 3       
 Constant 54.243 31.187  1.739 .085 
 Age –.391 .280 –.150 –1.400 .165 
 Sex 5.390 6.633 .081 .813 .418 
 Ethnicity –6.279 7.042 –.089 –.892 .375 
 Years since diagnosis 1.224 1.692 .074 .723 .471 
 Disease severity –4.832 6.139 –.085 –.787 .433 
 Symptom status 12.379 7.739 .188 1.600 .113 
 Uncertainty .000 .241 .000 .001 .999 
_______________________________________________________ 
Note. N = 103. SE = standard error.  
a
Dependent variable: personal growth scores. 
 
 
(55.3%), shortness of breath (52.4%), and worrying (50.5%). Individual symptom burden 
scores as shown in Table 9 demonstrated acceptable internal consistency with Cronbach 
alpha values > 0.8 for 16 symptoms, and > 0.7 for 12 symptoms. Symptoms with 
Cronbach’s alpha values > 0.6 but less than 0.7 included feeling nervous, problems with 
sexual interest or activity, weight loss, and waking up breathless at night. Symptoms that 
were most burdensome included problems with sexual interest or activity (M = 2.81, SD 
= 0.66), other pain (M = 2.51, SD = 0.7), lack of energy (M = 2.41, SD = 0.78), difficulty 
sleeping (M = 2.4, SD = 0.73), and shortness of breath (M = 2.35, SD = 0.77).  The mean 
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for the total symptom burden scale was 2 (SD = .43), indicating that on average 
participants reported symptoms occurring occasionally and as somewhat distressful and 
moderately severe.    
Uncertainty  
 In the current study, the Cronbach’s alpha coefficient for the MUIS-C was 0.92. 
The mean for the MUIS-C was 52.85 (SD = 14.24), indicating that participants reported 
moderate levels of uncertainty. Of the 23 items on the MUIS-C, 21 items had modal 
categories of 2, indicating that a higher number of participants either disagreed with 
statements that were indicative of greater uncertainty, such as, “I have a lot of questions 
without answers” or “I am unsure if my illness is getting better or worse,” or agreed with 
statements that were suggestive of greater certainty, such as “The purpose of each 
treatment is clear to me.” In this sample, more than 50% of participants reported that they 
strongly disagreed with the statement, “I don’t know what is wrong with me,” indicating 
that participants were aware of their HF diagnosis. 
Items that addressed the future had the highest percentage of individuals 
responding with some degree of uncertainty. The item that was reflective of the highest 
degree of uncertainty in this sample was “I am certain they will not find anything else 
wrong with me,” with 46% of participants indicating that they disagreed with this 
statement and 15% indicating that they strongly disagreed. The three other items that had 
the highest reports of uncertainty included “The course of my illness keeps changing. I 
have good days and bad days,” with 37% agreeing and 11% strongly agreeing with this 
statement and “It is not clear what is going to happen to me” and “Because of the 
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unpredictability of my illness, I cannot plan for the future,” with more than 30% of 
participants either agreeing or strongly agreeing with both of these items.  
Table 9 
Prevalence and Burden of Symptoms and Reliability of Burden Scores 
Symptom Prevalence Burden Alpha 
 
N % Mean SD 
 Lack of energy 76 73.8 2.41 0.78 .88 
Feeling drowsy 60 58.3 2.09 0.72 .80 
Dry mouth 57 55.3 2.20 0.67 .76 
Shortness of breath 54 52.4 2.35 0.77 .84 
Worrying 52 50.5 2.16 0.61 .78 
Dizziness 51 49.5 1.91 0.66 .82 
Numbness or tingling in hands or feet 49 48.0 2.32 0.74 .72 
Other pain 46 44.7 2.51 0.70 .74 
Cough 43 42.2 2.03 0.70 .79 
Difficulty sleeping 43 41.7 2.40 0.73 .82 
Feeling irritable 43 41.7 2.03 0.59 .76 
Feeling sad 33 32.0 2.06 0.69 .88 
Swelling of arms or legs 31 30.4 1.99 0.83 .71 
Itching 31 30.1 2.26 0.73 .81 
Problems with sexual interest or activity 28 28.3 2.81 0.66 .64 
Feeling nervous 29 28.2 2.15 0.54 .67 
Difficulty concentrating 28 27.2 2.30 0.67 .76 
Problem with urination 28 27.2 2.18 0.66 .72 
Weight loss 27 26.2 1.30 0.49 .62 
Weight gain 26 25.2 1.68 0.87 .77 
Constipation 24 23.5 2.21 0.71 .84 
Palpitations 24 23.3 1.82 0.58 .83 
Lack of appetite 24 23.3 2.01 0.63 .74 
Change in the way food tastes 23 22.3 2.00 0.71 .84 
Difficulty breathing when lying flat 22 21.8 2.12 0.72 .79 
Chest pain 21 20.4 1.95 0.72 .80 
Feeling bloated 20 19.4 2.32 0.75 .82 
Sweats 18 17.5 2.08 0.76 .82 
Waking up breathless at night 13 12.6 2.14 0.53 .60 
Diarrhea 12 11.7 1.87 0.74 .84 
Nausea 11 10.7 2.02 0.58 .89 
Vomiting 4 3.9 1.38 0.73 .93 
Note. N = 103. Burden scores only calculated for participants who report symptoms.   
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Differences in Personal Growth by Sex, Ethnicity, and Disease Severity 
To highlight differences in personal growth by sample characteristics, additional 
analysis was conducted. Differences in levels of personal growth by sex, ethnicity, and 
disease severity were examined to assess whether statistically significant differences 
existed in personal growth scores by groups using independent samples t tests.  
Assumptions of Independent Samples t Tests 
Each independent variable consisted of two groups; sex (male/female), ethnicity 
(Hispanic/not Hispanic), and disease severity (NYHA class II/NYHA class III or IV). 
The dependent variable, personal growth scores, was measured at an interval level. As 
previously noted, there were no serious departures from normality assumptions. Levene’s 
test for equality of variance by sex (F = .916, p = .34), by ethnicity (F = .489, p = .49), 
and by disease severity (F = .603, p = .44) indicated that equal variances between groups 
could be assumed (Pallant, 2007).  
Results of Independent Samples t Tests 
There was no significant difference in personal growth scores for males (M = 
47.35, SD = 29.38) and females (M = 52.68, SD = 26.24); t(df = 101) = –.810, p = .42 
(two-tailed). The magnitude of differences in the means (–5.334; 95% CI: –18.403 to 
6.735) was small (Cohen’s d = .19).  
Reports of personal growth also did not differ significantly by ethnicity, t(df = 
100) = 1.486, p = .14 (two-tailed). Hispanic persons reported, on average, slightly higher 
levels of personal growth (M = 57.21, SD = 26.28), compared with reports by individuals 
not Hispanic (M = 46.43, SD = 28.98). The mean difference (10.777; 95% CI: –3.611 to 
25.165) reflected a small-to-moderate effect size (Cohen’s d = .39).  
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Participants meeting criteria for NYHA class II HF reported higher levels of 
personal growth (M = 50.74, SD = 29.29) compared with those individuals with NYHA 
class III of IV HF (M = 46.42, SD = 28.00), but this difference was not statistically 
significant; t(df = 101) = .763, p = .44 (two-tailed). The mean difference (4.316; 95% CI: 
–6.899 to 15.530), again, only represented a small effect size (Cohen’s d = .15). In 
summary, there were no significant differences in reports of personal growth by sex, 
ethnicity, or disease severity in this sample.  
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CHAPTER 5 
DISCUSSION 
 
This study provided the first known examination of reports of personal growth in 
community-residing adults living in the United States with a diagnosis of HF. Findings 
highlighted the relevance of demographic and clinical factors to the development of 
personal growth in HF. In addition, findings enhanced the theoretical understanding of 
relationships among growth, uncertainty, and symptoms in chronic illness. This was the 
first known study to quantitatively explore personal growth with respect to uncertainty 
and symptoms in HF, providing empirical data that supported select relationships 
proposed by Mishel (1990) in the RUIT.  
Community-residing adults living with stable HF reported moderate levels of 
personal growth, suggesting that individuals living with HF can perceive some degree of 
favorable psychosocial change as a result of their illness experience. Personal growth 
showed a weak negative association with age and a weak positive association with 
symptom burden. Personal growth was not accounted for by disease severity, time since 
diagnosis, uncertainty, symptom burden, or demographic variables other than age. Study 
results are first reviewed in relation to past research examining personal growth in 
cardiac populations and other illness groups and then in relationship to conceptualizations 
and assumptions of personal growth belonging to Tedeschi and Calhoun’s (2004) model 
of PTG and the RUIT (Mishel, 1990). Lastly, results are discussed in light of study 
limitations.  
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Reports of Personal Growth 
 This is the first study to explore personal growth exclusively in an HF population. 
Personal growth has been studied previously in patients with cardiovascular disease, 
including Canadian patients with a diagnosis of HF (n = 178) or other major 
cardiovascular conditions (n = 1,090; Leung et al., 2010); U.S. (n = 28) and U.K. (n = 82) 
patients with a history of heart disease or cardiac arrest who were enrolled in cardiac 
rehabilitation or support group programs (Sheikh, 2004), and U.S. patients who had 
experienced an MI (n = 205; Affleck et al., 1987).  
PTGI scores in the current study (M = 48.6, SD = 28.6) were similar to those 
reported by Leung et al. (2010; M = 50.3, SD = 27.2) but lower than those reported by 
Sheikh (2004; M = 55.9, SD = 24.2). In the current study, participants reported the 
greatest degree of personal growth in appreciation for life and the least amount of 
personal growth in new possibilities. Leung et al. (2010) also found that participants 
more commonly endorsed items on the appreciation for life subscale and less commonly 
endorsed items related to new possibilities and spiritual change. Demographic 
characteristics of participants within these three studies were similar; however, 
participants in the current study were slightly older (M = 74.5, SD 10.99) compared with 
participants in the studies by Leung et al. (2010; M = 67.3, SD = 11.16) and Sheikh 
(2004; M = 63.5, SD = 9.7). In addition, although participants in the current study may 
have had a history of cardiac surgery or cardiac arrest, these events were not accounted 
for in the current study. By contrast, participants in the study by Sheikh (2004) had a 
history of cardiac arrest, which may have contributed to greater adversity and therefore 
higher reports of growth. The relationship between adversity and growth is discussed in 
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more detail in upcoming sections examining personal growth in relation to the RUIT and 
PTG model.  
Compared with studies cited by Leung et al. (2010) that used the PTGI in other 
patient populations, PTGI scores in the present study were higher than have been reported 
among patients with hepatobiliary cancer, prostate cancer survivors, and HIV/AIDS, but 
lower compared with those that have been reported for breast cancer, stage IV liver 
cancer, colorectal cancer, bone marrow transplant, and multiple sclerosis. However, 
variations in study design and sample characteristics make it difficult to generalize from 
such comparisons. That said, results of this study provide a preliminary baseline for 
future study of personal growth in HF and add to the overall literature on personal growth 
in chronic illness.   
Correlates of Personal Growth 
Age 
Personal growth showed a weak, negative correlation with age in this study, 
indicating that younger participants reported more growth. This finding is consistent with 
results reported by Leung et al. (2010) in cardiac patients, with studies in cancer 
survivors and HIV populations that measured growth with the PTGI (Barskova & 
Oesterreich, 2009), and with research in breast cancer survivors that used the GTUS to 
assess growth (Porter et al., 2006). 
Petrie et al. (1999) conducted the only other study that examined the relationship 
between growth (as measured by a single item question) and age in a cardiac sample 
(individuals 3 months post-MI) living in New Zealand and did not find a significant 
association between the two variables. Several studies conducted with other illness 
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populations demonstrated nonsignificant associations between age and growth, but only 
one of these studies used the PTGI (Barskova & Oesterreich, 2009).  
Sex 
In the current study, personal growth was not significantly associated with sex, 
consistent with findings demonstrated in other cardiac populations (Leung et al., 2010; 
Petrie et al., 1999; Sheikh, 2004) and in bone marrow transplant patients (Widows et al., 
2005). However, the current study had a small number of female participants (n = 25; 
24.3%) which may have limited the ability to detect differences in personal growth by 
sex. In contrast, Barskova and Oesterreich (2009) found that among cancer survivors and 
HIV patients women tended to report greater growth than men in their systematic review 
of PTG in serious illness.  
Ethnicity 
There was no significant relationship between personal growth and ethnicity or 
differences in growth scores by ethnicity in the current study. However, the majority of 
participants (n = 96; 93.2%) were White and were not Hispanic (n = 83; 80.6%). In 
contrast, Leung et al. (2010) reported significant differences in personal growth by race 
(their Canadian sample did not include Hispanic participants), with Asian participants 
reporting the highest growth, followed by African American participants, and then White 
participants. According to Barskova and Oesterreich (2009), studies that had only a small 
percentage of minority participants tended not to find significant associations between 
growth and race or ethnicity, whereas studies in cancer and HIV populations that found 
greater growth in African-Americans and Hispanics compared with Whites included 
larger numbers of ethnically/racially diverse participants.  
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Disease Severity 
Disease stage was not significantly associated with personal growth in the current 
study, congruent with results reported by Petrie et al. (1999), who did not find significant 
differences between reports of growth and illness severity in an MI population. Two 
studies using the PTGI in cancer groups demonstrated nonsignificant associations with 
disease stage (Thornton & Perez, 2006; Widows et al., 2005), whereas one study using 
the PTGI demonstrated greater growth in individuals with stage II cancer compared with 
stage I or stage IV cancer (Lechner et al., 2003). Overall, evidence that disease stage at 
the time of study participation impacted growth is equivocal at best. 
Time Since Diagnosis 
Time since diagnosis was not significantly associated with personal growth in HF, 
consistent with findings from earlier studies in cardiac and cancer populations, in which 
growth was measured using the PTGI (Lechner et al., 2003; Morris et al., 2007; Sheikh, 
2004). Alternatively, studies in breast cancer survivors 2 years post-diagnosis (Cordova 
et al., 2001) and 18 months after diagnosis (Sears et al., 2003), and in brain injury 
patients at 10 to 11 years post-insult (McGrath & Linley, 2006; Powell et al., 2007) have 
shown significant correlations between longer time since diagnosis and reports of greater 
growth. In the present study, a majority of participants (56.3%) had been living with HF 
for more than 10 years, and more than 30% of the sample had been living with HF for 
more than 20 years. The extended length of time that participants had to adjust to their 
HF diagnosis may have influenced the nonsignificant findings between time since 
diagnosis and personal growth in the current study. In addition, cross-sectional data 
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collection may have limited the ability to detect associations between time since 
diagnosis and personal growth.  
Symptom Status and Uncertainty 
No other studies were found that examined the relationship between personal 
growth and uncertainty or symptom status in HF. Studies investigated variables such as 
disease severity and morbidity (Affleck et al., 1987) and functional abilities (Leung et al., 
2010) that may be influenced by symptoms, but that influence cannot be teased out after 
the fact. Therefore, this is the only study that specifically examined the relationships 
among personal growth, uncertainty, and symptom status in HF.  Symptom status had a 
weak positive correlation with personal growth (r = .204, p < .05), but correlations 
between uncertainty and growth were not significant.  
Theoretical Implications of Study Results 
 The primary guiding framework for this study was Mishel’s (1990) RUIT. In 
addition to the RUIT, Tedeschi and Calhoun’s (2004) conceptualization of PTG and 
related assumptions also informed this study. In this section, study results are reviewed in 
relation to these concepts and other studies that have been informed by the RUIT. 
Theoretically derived variables included in this analysis were disease severity, time since 
diagnosis, symptom status, uncertainty, and personal growth. 
The first aim of this study was to determine whether individuals living with HF 
report personal growth, as characterized within the above conceptual frameworks. 
Tedeschi and Calhoun (1996, 2004) suggested that personal growth represents a process 
in which individuals move beyond traditional coping/adaptation to achieve positive 
psychosocial outcomes in response to significant adversity. Congruent with this 
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conceptualization of growth, Mishel (1990) argued that over time, individuals living with 
ongoing uncertainty in chronic illness may be able to perceive opportunities for growth 
through the discovery of new life meaning.  
Based on the literature, which suggests that HF is associated with significant 
mortality, symptom burden, uncertainty due to an unpredictable illness trajectory, high 
rates of depression, and poor quality of life (Adler et al., 2009), this study was rooted in 
the assumption that living with a diagnosis of HF could create significant challenges that 
subsequently disrupt an individual’s fundamental beliefs about his or her health and 
future, and encourage personal growth. Descriptive statistics of disease severity, 
symptom status, and uncertainty (variables that the literature suggests contribute to the 
challenges of HF) helped to depict the presence of these negative factors within this HF 
sample. 
Adversity in HF 
In terms of disease severity, approximately 52% of the sample met criteria for 
NYHA class II HF, indicating that they had slight limitations with usual activity due to 
symptoms, whereas the other half met criteria for either NYHA class III or IV HF, 
indicating that they had at least moderate limitations with less than usual activity due to 
their symptoms.  
As shown in Table 9, participants reported a variety of symptoms. The symptoms 
reported most commonly (lack of energy, feeling drowsy, dry mouth, shortness of breath, 
and worrying) were consistent with symptom prevalence findings reported by Zambroski 
et al. (2005), who also used the MSAS-HF to assess symptoms in an outpatient HF 
population. The most burdensome symptoms in the current study were problems with 
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sexual interest/activity, pain, lack of energy, difficulty sleeping, and shortness of breath. 
Zambroski et al. (2005) also reported that these symptoms were among the most 
burdensome in their sample. In general, mean burden scores in Zambroski et al.’s (2005) 
study were higher than were those reported in the current study. Variations in mean 
burden scores could result from the higher number of participants (77.4%) with either 
NYHA class III-IV HF in Zambroski et al.’s (2005) sample compared with the current 
study.  
The mean for the MUIS-C was 52.85 (SD = 14.24), indicating that participants 
reported moderate levels of uncertainty. Uncertainty levels were essentially consistent 
with uncertainty levels measured by the MUIS-C (M = 54.9, SD = 7.7) reported by 
Winters (1999) in an outpatient HF population and lower than uncertainty scores (M = 
71.4, SD = 9.56) reported by Jurgens (2006) in hospital inpatients with HF.  
In summary, this HF sample reported slight to moderate limitations in activity 
from their symptoms. Symptom prevalence and burden reports and levels of uncertainty 
were comparable to other outpatient HF populations. These results support a finding that 
negative factors thought to contribute to distress in HF were present to a small to 
moderate degree in this sample.  
Reports of Personal Growth 
In this study, participants reported a moderate degree of personal growth. The 
areas of greatest growth involved appreciation for life followed by relationships with 
others, spiritual change, and personal strength. These results are congruent with results of 
qualitative studies that either informed the development of the RUIT or used the RUIT as 
a guiding framework, which found that some individuals living with uncertainty in 
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chronic illness perceive positive outcomes (Baier, 1995; Bailey et al. 2007; Brashers et 
al., 1999; Fleury et al., 1995; Mishel & Murdaugh, 1987). Positive perceptions in these 
studies included hope or optimism for the future, lifestyle change, personal or spiritual 
growth, and finding joy in small accomplishments, but were typically described in 
conjunction with more pervasive negative thoughts or emotions. The PTGI, which was 
used to evaluate personal growth in the current study, did not account for concurrent 
negative perceptions or outcomes.  
Results from the current study also supplement the literature that has 
quantitatively examined uncertainty in relationship to growth in other illness populations, 
specifically in men with prostate cancer (Bailey et al. 2004) and breast cancer survivors 
(Gil et al., 2006, Mast 1998, Porter et. al, 2006), using Mishel and Fleury’s (1994) 
GTUS. A synthesis of these findings is discussed below.  
Correlates and Predictors of Personal Growth 
In the RUIT, Mishel (1990) suggests that disease severity and symptom status can 
contribute to greater levels of uncertainty, but that over time, individuals may be able to 
positively reappraise uncertainty and perceive growth. Time since diagnosis was 
examined in the current study to assess the influence of time on this process in HF. Time 
since diagnosis was not significantly associated with growth in the current study, 
consistent with findings demonstrated by Mast (1998), who measured growth via the 
GTUS in breast cancer survivors. However, both of these studies used cross-sectional 
data collection, which may have limited the ability to detect findings related to growth 
over time. In addition, although personal growth evolves over time, time in and of itself 
may not be sufficient to produce personal growth on its own. 
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Disease severity was also not significantly related to personal growth in this 
study; however, NYHA class did demonstrate significant relationships with age and 
uncertainty, indicating that individuals with more severe HF were older and had higher 
levels of uncertainty. This finding supports relationships outlined in Mishel’s (1988, 
1990) UIT and RUIT. In these theories, disease severity and symptom status are included 
as components of the stimuli frame, which is characterized as an antecedent of 
uncertainty. Consistent with findings from this study, Mishel (1988, 1990) proposes that 
greater illness severity increases uncertainty. The positive association between disease 
severity and uncertainty in this study is also consistent with the fact that with increased 
duration of chronic HF, the frequency of sudden, acute exacerbations tends to increase 
and intervening periods of stability may be shorter in duration (Hupcey et al., 2009; 
Jessup et al., 2009).  
Symptom burden showed a weak positive association with personal growth. 
However, in the regression model, symptom burden did not account for significant 
variance in personal growth after controlling for demographic and clinical factors and 
uncertainty. The overall negative finding indicates that variables that were not included in 
this analysis may account for personal growth in HF. Symptom burden did demonstrate a 
moderate, positive correlation with uncertainty, suggesting that higher symptom burden is 
associated with greater uncertainty. This finding also supports the relationship outlined 
by Mishel (1988, 1990) between symptoms and uncertainty and is congruent with the 
literature, which suggests that symptoms can contribute to uncertainty in HF (Aldred et 
al., 2005; Beckelman, Nowels, Retrum et al., 2011; Brännström et al., 2006; Brännström 
et al., 2007; Falk et al., 2007; Jurgens, 2006; Russell et al., 1998; Winters, 1999).  
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There was no significant association between uncertainty and personal growth in 
the current study. This finding contrasts with a previous study of uncertainty as a 
component of a negative cognitive state, which showed an association between 
uncertainty and less growth, a relationship that was mediated by higher symptom distress 
and less social support satisfaction in breast cancer survivors (Porter et al., 2006). Mishel 
(1990) proposed that reappraising uncertainty requires a cognitive restructuring of reality 
that occurs over time and that achieving growth through uncertainty is supported by self-
organization (integrating uncertainty into one’s life) and probabilistic thinking; in 
addition, the propensity for growth may be influenced by past life experience, 
physiologic states, social support, and interactions with health care providers. With the 
exception of disease severity and symptom burden as measures of physiologic state, these 
other factors were not assessed in the current study, which could have contributed to the 
nonsignificant findings.  
Other researchers who have studied symptoms and uncertainty as correlates or 
predictors of growth, as characterized within the RUIT, have included variables thought 
to facilitate psychosocial well-being or positive reappraisal (Bailey et al. 2004; Gil et al., 
2006; Mast, 1998; Porter et. al, 2006). For example, Porter et al. (2006) demonstrated that 
greater symptom prevalence, when combined with increased religious participation, 
higher levels of education, and younger age, was significantly associated with increased 
reports of growth in breast cancer survivors. In addition, cognitively reframing events in 
a positive way helped to explain growth in both African American and White breast 
cancer survivors and mediated the influence of social support and religious involvement 
on personal growth (Porter et al., 2006). Examining variables thought to facilitate 
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psychosocial health and cognitive reframing may be necessary to better understand 
personal growth in HF. 
In conclusion, this study found that community-residing adults with stable HF 
report on average moderate levels of personal growth that is not explained by age, sex, 
ethnicity, time since diagnosis, symptom burden, or uncertainty. Several factors could 
help to explain why reports of personal growth were not higher in this HF sample and 
why study variables did not help to explain variance in personal growth.  
The overall stability of this HF sample could suggest that participants did not 
experience adversity significant enough to challenge their fundamental worldviews, a 
prerequisite required for PTG as described by Tedeschi and Calhoun (2004). The long 
duration of time that most participants had been living with HF could have supported 
more traditional adjustment to their illness not characterized by personal transformations 
necessary for growth. In addition, growth may have been a more salient feature in earlier 
stages of HF that, for a majority of patients, would have occurred many years earlier.  
In addition, characteristics of the cardiology clinic and/or providers that were not 
accounted for in this study but observed by the researcher could have minimized potential 
adversity. Patients were routinely evaluated by consistent providers who had been 
affiliated with the clinic for several years. In addition, practitioners provided patients with 
ongoing education related to their HF diagnosis and management and comprehensive 
follow-up for changes in their clinical condition. On several occasions during research 
interviews, participants made unsolicited remarks about their satisfaction with and 
confidence in the care provided by the cardiology clinic. At the same time, providers 
predominantly focused on managing the physical consequences of HF, rather than on 
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providing psychosocial or cognitive support, which is consistent with national guidelines 
for the treatment of HF (Heart Failure Society of America, 2010a, 2010b; Jessup et al., 
2009). Therefore, variables not included in this analysis, such as psychological, social or 
spiritual support, or interventions that promote cognitive reappraisal may be more 
important in the development of personal growth. Bekelman, Nowels, Allen et al. (2011) 
found that individuals living with HF receiving outpatient palliative care services 
reported significant needs related to psychosocial support which was lacking in 
traditional HF management. Integrating supportive care into HF management programs 
might help to facilitate personal growth.  
Limitations 
 Several limitations need to be considered when interpreting results from this 
study. Most notably, convenience sampling of participants who could speak and 
understand English from one private practice cardiology clinic in San Antonio, TX, 
reduced the external validity of findings (Shadish et al., 2002). Participants were 
predominantly White, male, married or living with a partner, educated at or above a high 
school level, and older, limiting the ability to generalize findings to more diverse 
populations. The small number of female, Hispanic, and Class IV HF participants may 
have limited the ability to detect significant relationships between growth and sex, 
ethnicity, and disease severity in this study. In addition, the cardiology clinic has been 
well established in the community for many years and has a strong reputation for 
providing quality cardiac care. Characteristics of the clinic and its providers could have 
also influenced results, especially related to symptom burden and uncertainty reports. 
Results might differ in settings that do not provide the same level of comprehensive, 
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coordinated HF management, limiting the ability to generalize findings to more diverse 
settings.  
 Reliability of the MSAS-HF has been established for the total symptom 
prevalence score and the physical, psychological, and HF-specific subscales (Zambroski 
et al., 2005). Because the total symptom burden score on the MSAS-HF depends on 
unique combinations of symptoms for each respondent, an overall reliability coefficient 
cannot be estimated. This is a potential threat to statistical conclusion validity. However, 
reliability coefficients for the burden scores of individual symptoms could be estimated, 
and most were, satisfactory (especially in view of being based on just 2 or 3 items per 
symptom).   
Investigator expectancy (Shadish et al., 2002) is a plausible threat to construct 
validity in this study. Participants who chose to complete the survey via a researcher-
conducted interview in the clinic rather than independently may have been inclined to 
respond to items differently due to the presence of the researcher or clinic staff. In 
particular, participants may have been more inclined to provide favorable responses to 
items on the MUIS-C, which asked specific questions about their HF management.  
To minimize these risks, participants were given the option of completing the 
survey independently, either electronically or on paper. In addition, when the participant 
opted for a researcher-conducted interview, the researcher read the survey directions and 
questions exactly as they were written on the survey. Interviews were conducted in 
private rooms before or after patients were evaluated by their providers and participants 
were assured that their responses would not be shared with clinic staff. To assess for this 
threat, independent samples t tests were conducted to examine differences in PTGI, 
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MUIS-C, and MSAS-HF scores by survey administration methods. No significant 
differences in questionnaire scores between participants who completed the survey 
independently on paper and those who participated in a researcher-conducted interview 
were found. Only 2% of participants completed the survey electronically, so this group 
was excluded from this analysis. These findings suggest that threats to construct validity 
resulting from unintended researcher/staff expectancies were most likely limited.  
Although the aims of this descriptive, exploratory study were not to test causal 
relationships, threats to internal validity also need to be considered when interpreting 
results. As described above, convenience sampling was used to enroll participants, 
potentially contributing to selection bias (Shadish et al., 2002). Individuals who perceived 
their HF experience as more positive may have been more interested in participating. To 
ensure that all potentially eligible participants were informed of the study, recruitment 
letters were sent to individuals meeting diagnostic criteria for HF; recruitment flyers were 
also available in all patient rooms and the waiting room and were given to all HF patients 
by providers during scheduled visits.  
In addition to selection bias, threats to ambiguous temporal precedence could 
influence internal validity. Cross-sectional data collection limited inferences regarding 
both the onset of growth and its trajectory in HF over time (Shadish et al., 2002). 
Although the PTGI asked participants to rate the degree of positive change in response to 
their HF diagnosis in this study, other adverse life events not accounted for within this 
research may have influenced participants’ responses.   
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Implications for Future Research 
 This study provides the first known examination of personal growth exclusively 
in HF and specifically in relation to symptoms and uncertainty. Findings provide a 
beginning understanding of personal growth in HF by demonstrating that community-
residing adults living with stable HF report moderate levels of personal growth that is not 
explained by demographics, time since diagnosis, disease stage, uncertainty, or symptom 
burden. The results create a foundation for future research to build on in advancing our 
understanding of personal growth in HF. A more in-depth knowledge of personal growth 
in HF may be useful in informing supportive care models being developed to supplement 
traditional medical management of HF. Enhanced understanding of personal growth 
could help to clarify how nurses and other health care providers facilitate or hinder 
personal growth for patients with HF. 
To improve the ability to generalize findings, researchers should examine 
personal growth in more diverse HF populations that include a greater number of female 
participants and greater racial and ethnic diversity as well as greater variability in clinical 
condition (e.g., with more recently diagnosed or less stable patients). Reports of personal 
growth and correlates should also be examined in individuals living in rural and 
underserved regions and receiving care within public, academic, or hospital-based 
settings. Larger, more representative samples from multiple settings would also enhance 
the generalizability of findings.  
Incorporating a greater range of sociodemographic and psychosocial variables 
(e.g., income, social support, coping strategies, and personality dispositions) might 
provide a more comprehensive representation of personal growth in HF and help to 
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identify potential mediating/moderating factors and predictors of growth. A better 
understanding of growth through uncertainty in relation to adversity would most likely 
result from studies that assess personal growth using both the PTGI and GTUS. 
Longitudinal assessment of personal growth beginning at the time of diagnosis and at 
regular intervals thereafter would generate a better understanding of the onset and 
trajectory of growth within HF. In addition to replicating quantitative assessments of 
growth, qualitative approaches that garner a deeper understanding of participants’ 
experiences of growth would strengthen the science of personal growth in chronic illness. 
Finally, future research should include qualitative approaches and/or instruments that also 
assess cognitive processes, such as rumination, positive reappraisal, or probabilistic 
thinking to better understand how personal growth develops and to test relationships 
proposed by Tedeschi and Calhoun (2004) and Mishel (1990).    
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APPENDIX A 
RECONCEPTUALIZED UNCERTAINTY IN ILLNESS CONCEPTUAL MODEL 
 
 
Reprinted from Bailey, D. E., & Stewart, J. (2014). Uncertainty in illness. In M. R. 
Alligood (Ed.), Nursing theorists and their work (8
th
 ed., pp. 555-573). St. Louis, MO: 
Elsevier, Mosby. Copyright Merle Mishel, 1990. 
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APPENDIX B 
UNCERTAINTY IN ILLNESS CONCEPTUAL MODEL 
 
 
Reprinted with permission from: Mishel, M. H. (1988). Uncertainty in illness. 
Image: The Journal of Nursing Scholarship, 20(4), 225-232. 
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RECRUITMENT FLYER 
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RECRUITMENT LETTER 
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APPENDIX E 
COMBINED INFORMED CONSENT AND HIPAA AUTHORIZATION 
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APPENDIX F 
POSTTRAUMATIC GROWTH INVENTORY 
 
Indicate for each of the statements below the degree to which this change occurred in 
your life as a result of your heart failure diagnosis, using the following scale. 
0= I did not experience this change as a result of my crisis. 
1= I experienced this change to a very small degree as a result of my crisis. 
2= I experienced this change to a small degree as a result of my crisis. 
3= I experienced this change to a moderate degree as a result of my crisis. 
4= I experienced this change to a great degree as a result of my crisis. 
5= I experienced this change to a very great degree as a result of my crisis. 
1. I changed my priorities    0 1 2 3 4 5 
    about what is important in life.  
 
2. I have a greater appreciation   0 1 2 3 4 5 
    for the value of my own life.  
 
3. I developed new interests.    0  1  2 3 4 5 
 
4. I have a greater feeling of self-reliance.  0 1 2 3 4 5 
 
5. I have a better understanding   0 1 2 3 4 5 
    of spiritual matters. 
  
6. I more clearly see that I can count  0 1 2 3 4 5  
    on people in times of trouble.   
 
7. I established a new path for my life.   0 1 2 3 4 5 
 
8. I have a greater sense of closeness   0 1 2 3 4 5 
    with others.   
 
9. I am more willing to express   0 1 2 3 4 5 
    my emotions.   
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10. I know better that I can    0 1 2 3 4 5 
      handle difficulties.   
11. I am able to do better things    0 1 2 3 4 5 
      with my life.  
 
12. I am better able to accept    0 1 2 3 4 5 
      the way things work out.  
 
13. I can better appreciate each day.  0 1 2 3 4 5   
 
14. New opportunities are available  0 1 2 3 4 5 
      which wouldn't have been otherwise. 
  
15. I have more compassion for others.   0 1 2 3 4 5 
 
16. I put more effort into my   0 1 2 3 4 5 
      relationships.   
 
17. I am more likely to try to change  0 1 2 3 4 5 
      things which need changing.   
 
18. I have a stronger religious faith.  0 1 2 3 4 5 
 
19. I discovered that I'm stronger   0 1 2 3 4 5 
      than I thought I was.   
 
20. I learned a great deal about  0 1 2 3 4 5 
      how wonderful people are.  
  
21. I better accept needing others.   0 1 2 3 4 5 
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APPENDIX G 
MISHEL UNCERTAINTY IN ILLNESS SCALE–COMMUNITY FORM 
 
MISHEL UNCERTAINTY IN ILLNESS SCALE–
COMMUNITY FORM 
 
        INSTRUCTIONS: 
         Please read each statement. Take your time and think about what each 
 statement says. Then place an “X” under the column that most closely 
 measures how you are feeling TODAY.  
 
 If you agree with a statement, then you would mark under either “Strongly 
 Agree” or “Agree.” If you disagree with a statement, then mark under either 
 “Strongly Disagree” or “Disagree.” 
 
If you are undecided about how you feel, then mark under “Undecided” for 
that statement. Please respond to every statement.  
 
 
1. I don’t know what is wrong with me. 
 
Strongly Agree      Agree        Undecided         Disagree        Strongly Disagree 
     (5)                  (4)                 (3)                    (2)                        (1) 
 
_______           ______          ______            ______                 ______ 
 
2. I have a lot of questions without answers. 
  
Strongly Agree      Agree        Undecided         Disagree        Strongly Disagree 
     (5)                  (4)                 (3)                    (2)                        (1) 
 
_______           ______          ______            ______                 ______ 
 
3.   I am unsure if my illness is getting better or worse. 
  
Strongly Agree      Agree        Undecided         Disagree        Strongly Disagree 
     (5)                  (4)                 (3)                    (2)                        (1) 
 
_______           ______          ______            ______                 ______ 
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4.  It is unclear how bad my pain will be. 
 
Strongly Agree      Agree        Undecided         Disagree        Strongly Disagree 
     (5)                  (4)                 (3)                    (2)                        (1) 
 
_______            ______          ______            ______                 ______ 
 
5.  The explanations they give about my condition seem hazy to me. 
 
Strongly Agree      Agree        Undecided         Disagree        Strongly Disagree 
     (5)                  (4)                 (3)                    (2)                        (1) 
 
_______            ______          ______            ______                 ______ 
 
6. The purpose of each treatment is clear to me. 
 
Strongly Agree      Agree        Undecided         Disagree        Strongly Disagree 
     (5)                  (4)                 (3)                    (2)                        (1) 
 
_______            ______          ______            ______                 ______ 
 
7. My symptoms continue to change unpredictably. 
 
Strongly Agree      Agree        Undecided         Disagree        Strongly Disagree 
     (5)                  (4)                 (3)                    (2)                        (1) 
 
_______            ______          ______            ______                 ______ 
 
8. I understand everything explained to me. 
 
Strongly Agree      Agree        Undecided         Disagree        Strongly Disagree 
     (5)                  (4)                 (3)                    (2)                        (1) 
 
_______            ______          ______            ______                 ______ 
 
9. The doctors say things to me that could have many meanings. 
 
Strongly Agree      Agree        Undecided         Disagree        Strongly Disagree 
     (5)                  (4)                 (3)                    (2)                        (1) 
 
_______            ______          ______            ______                 ______ 
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10. My treatment is too complex to figure out. 
 
Strongly Agree      Agree        Undecided         Disagree        Strongly Disagree 
     (5)                  (4)                 (3)                    (2)                        (1) 
 
_______            ______          ______            ______                 ______ 
 
11. It is difficult to know if the treatments or medications I am getting are 
helping. 
 
Strongly Agree      Agree        Undecided         Disagree        Strongly Disagree 
     (5)                  (4)                 (3)                    (2)                        (1) 
 
_______            ______          ______            ______                 ______ 
 
12. Because of the unpredictability of my illness, I cannot plan for the future.  
 
Strongly Agree      Agree        Undecided         Disagree        Strongly Disagree 
     (5)                  (4)                 (3)                    (2)                        (1) 
 
_______            ______          ______            ______                 ______ 
 
13. The course of my illness keeps changing. I have good and bad days. 
 
Strongly Agree      Agree        Undecided         Disagree        Strongly Disagree 
    (5)                   (4)                 (3)                    (2)                        (1) 
 
_______            ______          ______            ______                 ______ 
 
14. I have been given many differing opinions about what is wrong with me. 
 
Strongly Agree      Agree        Undecided         Disagree        Strongly Disagree 
     (5)                  (4)                 (3)                    (2)                        (1) 
 
_______            ______          ______            ______                 ______ 
 
15. It is not clear what is going to happen to me. 
 
Strongly Agree      Agree        Undecided         Disagree        Strongly Disagree 
     (5)                  (4)                 (3)                    (2)                        (1) 
 
_______            ______          ______            ______                 ______ 
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16. The results of my tests are inconsistent. 
 
Strongly Agree      Agree        Undecided         Disagree        Strongly Disagree 
     (5)                  (4)                 (3)                    (2)                        (1) 
 
_______            ______          ______            ______                 ______ 
 
17. The effectiveness of the treatment is undetermined. 
 
Strongly Agree      Agree        Undecided         Disagree        Strongly Disagree 
     (5)                  (4)                 (3)                    (2)                        (1) 
 
_______            ______          ______            ______                 ______ 
 
18. Because of the treatment, what I can do and cannot do keeps changing. 
 
Strongly Agree      Agree        Undecided         Disagree        Strongly Disagree 
     (5)                  (4)                 (3)                    (2)                        (1) 
 
_______            ______          ______            ______                 ______ 
 
19. I’m certain they will not find anything else wrong with me. 
 
Strongly Agree      Agree        Undecided         Disagree        Strongly Disagree 
     (5)                  (4)                 (3)                    (2)                        (1) 
 
_______            ______          ______            ______                 ______ 
 
20. The treatment I am receiving has a known probability of success. 
 
Strongly Agree      Agree        Undecided         Disagree        Strongly Disagree 
     (5)                  (4)                 (3)                    (2)                        (1) 
 
_______            ______          ______            ______                 ______ 
 
21. They have not given me a specific diagnosis. 
 
Strongly Agree      Agree        Undecided         Disagree        Strongly Disagree 
     (5)                  (4)                 (3)                    (2)                        (1) 
 
_______            ______          ______            ______                 ______ 
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22. The seriousness of my illness has been determined. 
 
Strongly Agree      Agree        Undecided         Disagree        Strongly Disagree 
     (5)                  (4)                 (3)                    (2)                        (1) 
 
_______            ______          ______            ______                 ______ 
 
23. The doctors and nurses use everyday language so I can understand what they 
are saying. 
 
Strongly Agree      Agree        Undecided         Disagree        Strongly Disagree 
     (5)                  (4)                 (3)                    (2)                        (1) 
 
_______            ______          ______            ______                 ______  
168 
APPENDIX H 
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MEDICAL RECORD REVIEW FORM: ADDITIONAL CLINICAL DATA 
 
